

PCTWORLD INTELLECTUAL PROPERTY
International BureauExp Mail EV335610941US
USAN 09/780,669

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/21, 5/10, 15/12, 15/63, C12Q 1/00, 1/68, C07K 14/435, 14/47, 16/00, A61K 38/17, 48/00	A1	(11) International Publication Number: WO 98/12302 (43) International Publication Date: 26 March 1998 (26.03.98)
(21) International Application Number: PCT/US97/15627 (22) International Filing Date: 5 September 1997 (05.09.97) (30) Priority Data: 08/715,032 17 September 1996 (17.09.96) US 08/897,340 21 July 1997 (21.07.97) US (71) Applicant: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US). (72) Inventors: GIMENO, Carlos, J.; Apartment 23, 250 Com- monwealth Avenue, Boston, MA 02116 (US). ERRADA, Patrick, R.; 41 Lee Street, Cambridge, MA 02139 (US). (74) Agents: SILVERI, Jean, M. et al.; Lahive & Cockfield LLP, 28 State Street, Boston, MA 02109 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: WEIGHT CONTROL PATHWAY GENES AND USES THEREFOR		
(57) Abstract The present invention relates to the discovery of novel genes encoding Tub interactor (77) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WEIGHT CONTROL PATHWAY GENES AND USES THEREFOR

Background of the Invention

Obesity represents the most prevalent of body weight disorders, and it is the most important nutritional disorder in the western world, with estimates of its prevalence ranging from 30% to 50% within the middle-aged population. Other body weight disorders, such as anorexia nervosa and bulimia nervosa which together affect approximately 0.2% of the female population of the western world, also pose serious health threats. Further, such disorders as anorexia and cachexia (wasting) are also prominent features of other diseases such as cancer, cystic fibrosis, and AIDS.

Obesity, defined as an excess of body fat relative to lean body mass, also contributes to other diseases. For example, this disorder is responsible for increased incidences of diseases such as coronary artery disease, hypertension, stroke diabetes, hyperlipidemia and some cancers. (See, e.g., Nishina, P.M. et al. (1994) *Metab.* 43:554-558; Grundy, S.M. and Barnett, J.P. (1990) *Dis. Mon.* 36:641-731) Obesity is not merely a behavioral problem, i.e., the result of voluntary hyperphagia. Rather, the differential body composition observed between obese and normal subjects results from differences in both metabolism and neurologic/metabolic interactions. These differences seem to be, to some extent, due to differences in gene expression, and /or level of gene products or activity (Friedman, J.M. et al. (1991) *Mammalian Gene* 1:130-144).

The epidemiology of obesity strongly shows that the disorder exhibits inherited characteristics (Stunkard (1990) *N. Eng. J. Med.* 322:1483). Moll et al. have reported that, in many populations, obesity seems to be controlled by a few genetic loci (Moll et al. (1991) *Am. J. Hum. Gen.* 49:1243). In addition, human twin studies strongly suggest a substantial genetic basis in the control of body weight, with estimates of heritability of 80-90% (Simopoulos, A. P. and Childs B., eds., 1989, in "Genetic Variation and Nutrition in Obesity", *World Review of Nutrition and Diabetes* 63, S. Karger, Basel, Switzerland; Borjeson, M., 1976, *Acta. Paediatr. Scand.* 65:279-287).

Studies of non-obese persons who deliberately attempted to gain weight by systematically over-eating were found to be more resistant to such weight gain and able to maintain an elevated weight only by very high caloric intake. In contrast, spontaneously obese individuals are able to maintain their status with normal or only moderately elevated caloric intake. In addition, it is a commonplace experience in animal husbandry that different strains of swine, cattle, etc., have different predispositions to obesity. Studies of the genetics of human obesity and of models of animal obesity demonstrate that obesity results from complex defective regulation of

both food intake, food induced energy expenditure and of the balance between lipid and lean body anabolism.

There are a number of genetic diseases in man and other species which feature obesity among their more prominent symptoms, along with, frequently, dysmorphic features and mental retardation. For example, Prader-Willi syndrome (PWS; reviewed in Knoll, J.H. et al. (1993) *Am. J. Med. Genet.* 46:2-6) affects approximately 1 in 20,000 live births, and involves poor neonatal muscle tone, facial and genital deformities, and generally obesity.

In addition to PWS, many other pleiotropic syndromes which include obesity as a symptom have been characterized (e.g. Ahlstrom, Carpenter, Bardet-Biedl, Cohen, and Morgagni-Stewart-Monel Syndromes). These syndromes are more genetically straightforward and appear to involve autosomal recessive alleles.

A number of models exist for the study of obesity (see, e.g., Bray, G.A. (1992) *Prog. Brain Res.* 93:333-341, and Bray, G. A. (1989) *Amer. J. Clin. Nutr.* 5:891-902). For example, animals having mutations which lead to syndromes that include obesity symptoms have also been identified. Attempts have been made to utilize such animals as models for the study of obesity, and the best studied animal models, to date, for genetic obesity are mice. For reviews, see e.g., Friedman, J.M. et al. (1991) *Mamm. Gen.* 1:130-144; Friedman, J.M. and Liebel, R.L. (1992) *Cell* 69:217-220.

Studies utilizing mice have confirmed that obesity is a very complex trait with a high degree of heritability. Mutations at a number of loci have been identified which lead to obese phenotypes. These include the autosomal recessive mutations obese (*ob*), diabetes (*db*), fat (*fat*) and tubby (*tub*). In addition, the autosomal dominant mutations Yellow at the *agouti* locus and Adipose (*Ad*) have been shown to contribute to an obese phenotype.

The *ob* and *db* mutations are on chromosomes 6 and 4, respectively, but lead to clinically similar pictures of obesity, evident starting at about one month of age, which include hyperphagia, severe abnormalities in glucose and insulin metabolism, very poor thermoregulation and non-shivering thermogenesis, and extreme torpor and underdevelopment of the lean body mass.

The *ob* gene and its human homologue have recently been cloned (Zhang, Y. et al., (1994) *Nature* 372:425-432). The gene appears to produce a 4.5 kb adipose tissue messenger RNA which contains a 167 amino acid open reading frame. The predicted amino acid sequence of the *ob* gene product indicates that it is a secreted protein and may, therefore, play a role as part of a signaling pathway from adipose tissue which may serve to regulate some aspect of body fat deposition.

The *db* locus encodes a high affinity receptor for the *ob* gene product (Chen, H. et al. *Cell* 84:491-495). The *db* gene product is a single membrane-spanning receptor most closely related to the gp130 cytokine receptor signal transducing component (Tartaglia, L.A. et al. (1995) *Cell* 83:1263-1271).

5 Homozygous mutations at either the *fat* or *tub* loci cause obesity which develops more slowly than that observed in *ob* and *db* mice (Coleman, D.L., and Eicher, E.M. (1990) *J. Heredity* 81:424-427), with *tub* obesity developing slower than that observed in *fat* animals. This feature of the *tub* obese phenotype makes the development of *tub* obese phenotype closest in resemblance to the manner in which obesity develops in
10 humans. Even so, however, the obese phenotype within such animals can be characterized as massive in that animals eventually attain body weights which are nearly two times the average weight seen in normal mice. *tub/tub* mice develop insulin resistance with their weight gain but do not progress to overt diabetes.

In addition to obesity, retinal defects, hearing loss and infertility have all been
15 observed in *tub* mice (Heckenlively, 1988, in *Retinitis Pigmentosa*, Heckenlively, ed., Lippincott, Philadelphia, pp. 221-235; Coleman, D.L. & Eicher, E.M., 1990, *J. Hered.* 81:424-4a27; Ohlemiller, K.K. et al. (1995) *Neuroreport* 6:845-849). Several human syndromes exist in which such defects are found to co-exist with an obesity phenotype, including Bardet-Biedl syndrome, Ahlstrom syndrome, polycystic ovarian disease and
20 Usher's syndrome.

The *fat* mutation has been mapped to mouse chromosome 8, while the *tub* mutation has been mapped to mouse chromosome 7. According to Naggert et al., the *fat* mutation has recently been identified (Naggert, J.K., et al. (1995) *Nature Genetics* 10:135-141). Specifically, the *fat* mutation appears to be a mutation within the *Cpe* locus, which encodes the carboxypeptidase (*Cpe*) E protein. *Cpe* is an exopeptidase
25 involved in the processing of prohormones, including proinsulin.

The dominant Yellow mutation at the *agouti* locus, causes a pleiotropic syndrome which causes moderate adult onset obesity, a yellow coat color, and a high incidence of tumor formation (Herberg, L. and Coleman, D.L. (1977) *Metabolism*
30 26:59), and an abnormal anatomic distribution of body fat (Coleman, D.L. (1978) *Diabetologia* 14:141-148). This mutation may represent the only known example of a pleiotropic mutation that causes an increase, rather than a decrease, in body size. The mutation causes the widespread expression of a protein which is normally seen only in neonatal skin (Michaud, E.J. et al. (1994) *Genes Devel.* 8:1463-1472).

35 Other animal models include *fa/fa* (fatty) rats, which bear many similarities to the *ob/ob* and *db/db* mice, discussed above. One difference is that, while *fa/fa* rats are very sensitive to cold, their capacity for non-shivering thermogenesis is normal. Torpor

- 4 -

seems to play a larger part in the maintenance of obesity in *fa/fa* rats than in the mice mutants. In addition, inbred mouse strains such as NZO mice and Japanese KK mice are moderately obese. Certain hybrid mice, such as the Wellesley mouse, become spontaneously fat. Further, several desert rodents, such as the spiny mouse, do not
5 become obese in their natural habitats, but do become so when fed on standard laboratory feed.

Animals which have been used as models for obesity have also been developed via physical or pharmacological methods. For example, bilateral lesions in the ventromedial hypothalamus (VMH) and ventrolateral hypothalamus (VLH) in the rat are
10 associated, respectively, with hyperphagia and gross obesity and with aphagia, cachexia and anorexia. Further, it has been demonstrated that feeding monosodiumglutamate (MSG) or gold thioglucose to newborn mice also results in an obesity syndrome.

In summary, therefore, obesity, which poses a major, worldwide health problem, represents a highly heritable trait. Given the severity, prevalence and potential
15 heterogeneity of such disorders, there exists a great need for the identification genes involved in the control of body weight.

Summary of the Invention

The present invention is based on the discovery of novel molecules, referred to
20 herein as "Tub Interactor" ("TI") nucleic acid and polypeptide molecules. Exemplary novel TI molecules are contained in and encoded by: 1) *E. coli* plasmid ptyhq049, which was deposited with the American Type Culture Collection (ATCC) on August 6, 1996 and has been assigned ATCC designation number 98125; 2) *E. coli* plasmid ptyhq054, which was deposited with the American Type Culture Collection (ATCC) on August 6,
25 1996 and has been assigned ATCC designation number 98126; 3) *E. coli* plasmid ptyhq058, which was deposited with the American Type Culture Collection (ATCC) on August 6, 1996 and has been assigned ATCC designation number 98127; and 4) *E. coli* plasmid ptyhq036, which was deposited with the American Type Culture Collection (ATCC) on August 6, 1996 and has been assigned ATCC designation number 98128.

30 Six novel TI genes were cloned and identified based on their ability to interact with the C-terminus (i.e. the last 44 amino acids) of *htub* in a two hybrid assay as further described in the following Examples. hTI-1 (Figure 1 (SEQ ID NO:1)) is a 1386 base pair nucleic acid encoding a serine protease. hTI-2 (Figure 2 (SEQ ID NO:2)) is a 2103 base pair nucleic acid containing ANK (i.e. ankyrin) repeats. hTI-3 (Figure 3 (SEQ ID
35 NO:3)) is a 1048 base pair nucleic acid containing TPR repeats (i.e. tetratricopeptide repeats) and also DNAJ repeats. mTI-3 (Figure 4 (SEQ ID NO:4)) is a 1700 base pair nucleic acid that is the murine homologue of hTI-3. hTI-4 (Figure 5 (SEQ ID NO:5)) is

a 1421 base pair nucleic acid that contains RING finger repeats and also Zinc finger repeats. mTI-4 (Figure 6 (SEQ ID NO:6)) is a 2121 base pair nucleic acid that is the murine homologue of hTI-4. A final TI gene (hTI-5) was identified as encoding human serine palmitoyltransferase (GenBank Accession No. U15555).

5 In one aspect, the invention features isolated vertebrate *TI* nucleic acid molecules. The disclosed molecules can be non-coding, (e.g. probe, antisense or ribozyme molecules) or can encode a functional *TI* polypeptide (e.g. a polypeptide which specifically modulates, e.g., by acting as either an agonist or antagonist, at least one bioactivity of the human *TI* polypeptide). In one embodiment, the nucleic acid
10 molecules can hybridize to the *TI* gene contained in any of ATCC designation numbers 98125, 98126, 981257, or 98128 or to the complement of the *TI* gene contained in any of ATCC designation numbers 98125, 98126, 981257, or 98128. In another embodiment, the nucleic acids of the present invention can hybridize to a vertebrate *TI* gene or to the complement of a vertebrate *TI* gene. In a further embodiment, the
15 claimed nucleic acid can hybridize with the nucleic acid sequence, designated in SEQ ID NOs:1-6 or to the complement to the nucleic acid sequence designated in SEQ ID NOs:1-6. In a preferred embodiment, the hybridization is conducted under mildly stringent or stringent conditions.

In further embodiments, the nucleic acid molecule is a *TI* nucleic acid that is at
20 least 70%, preferably 80%, more preferably 85%, and even more preferably at least 90% or 95% homologous in sequence to any of the nucleic acids shown as SEQ ID NOs:1-6 or to the complement of the nucleic acid shown as SEQ ID NOs:1-6. In a further embodiment, the nucleic acid molecule is a *TI* nucleic acid that is at least 70%, preferably 80%, more preferably 85% and even more preferably at least 90% or 95%
25 similar in sequence to the *TI* gene contained in any of ATCC designation numbers 98125, 98126, 981257, or 98128 or to the complement of the *TI* gene contained in any of ATCC designation numbers 98125, 98126, 981257, or 98128.

The invention also provides probes and primers comprising substantially purified oligonucleotides, which correspond to a region of nucleotide sequence which hybridizes
30 to at least 6 consecutive nucleotides of any of the sequences set forth as SEQ ID NOs:1-6 or complements of any of the sequences set forth as SEQ ID NOs:1-6 or naturally occurring mutants thereof. In preferred embodiments, the probe/primer further includes a label group attached thereto, which is capable of being detected.

For expression, the subject nucleic acids can include a transcriptional regulatory
35 sequence, e.g. at least one of a transcriptional promoter (e.g., for constitutive expression or inducible expression) or transcriptional enhancer sequence, which regulatory sequence is operably linked to the gene sequence. Such regulatory sequences in

- 6 -

conjunction with a *Tl* nucleic acid molecule can provide a useful vector for gene expression. This invention also describes host cells transfected with said expression vector whether prokaryotic or eukaryotic and *in vitro* (e.g. cell culture) and *in vivo* (e.g. transgenic) methods for producing *Tl* proteins by employing said expression vectors.

5 In another aspect, the invention features isolated *Tl* polypeptides, preferably substantially pure preparations e.g. of plasma purified or recombinantly produced polypeptides. In preferred embodiments, the polypeptide is able to bind to the C-terminus (e.g. the last 44 amino acids) of the human tub protein. In particularly preferred embodiments, the subject polypeptides, whether agonists or antagonists, can
10 suppress the development and/or progression of a weight disorder (obesity, cachexia or anorexia nervosa) or a related disorder (e.g. diabetes).

In a preferred embodiment, the *Tl* polypeptide is encoded by a nucleic acid which hybridizes with any of the nucleic acid sequences represented in SEQ ID NOs:1-6 or with the gene or gene fragment contained in any of ATCC Designation Nos.
15 designation numbers 98125, 98126, 981257, or 98128. The subject *Tl* proteins also include modified protein, which are resistant to post-translational modification, as for example, due to mutations which alter modification sites (such as tyrosine, threonine, serine or asparagine residues), or which prevent glycosylation of the protein, or which prevent interaction of the protein with intracellular proteins involved in signal
20 transduction.

The *Tl* polypeptides can comprise a full length protein or it can comprise a fragment corresponding to one or more particular motifs/domains, or to arbitrary sizes, e.g., at least 5, 10, 25, 50, 100, 150 or 200 amino acids in length. In preferred
25 embodiments, the polypeptide includes a sufficient portion of the domain that interacts with the C-terminus (i.e. the last 44 amino acids) of normal human tub.

Another aspect of the invention features chimeric molecules (e.g. fusion proteins) comprised of a *Tl* protein. For instance, the *Tl* protein can be provided as a recombinant fusion protein which includes a second polypeptide portion, e.g., a second polypeptide having an amino acid sequence unrelated (heterologous) to the *Tl*
30 polypeptide, (e.g. the second polypeptide portion is glutathione-S-transferase, an enzymatic activity such as alkaline phosphatase or an epitope tag).

Yet another aspect of the present invention concerns an immunogen comprising a *Tl* polypeptide in an immunogenic preparation, the immunogen being capable of eliciting an immune response specific for a *Tl* polypeptide; e.g. a humoral response, an
35 antibody response and/or cellular response. In a preferred embodiment, the immunogen comprises an antigenic determinant, e.g. a unique determinant of a protein encoded by any of the nucleic acids SEQ ID NOs:1-6.

A still further aspect of the present invention features antibodies and antibody preparations specifically reactive with an epitope of a *TI* protein.

The invention also features transgenic non-human animals which include (and preferably express) a heterologous form of a *TI* gene described herein, or which
5 misexpress an endogenous *TI* gene (e.g., an animal in which expression of one or more of the subject *TI* proteins is disrupted). Such a transgenic animal can serve as an animal model for studying cellular and tissue disorders comprising mutated or mis-expressed *TI* alleles or for use in drug screening. Alternatively, such a transgenic animal can be useful for expressing recombinant *TI* polypeptides.

10 The invention also pertains to methods for identifying a compound or agent which interacts with (e.g., binds to) a *TI* polypeptide. These methods can include the steps of contacting the *TI* polypeptide with the compound or agent under conditions which allow binding of the compound to the *TI* polypeptide to form a complex and detecting the formation of a complex of the *TI* polypeptide and the compound in which
15 the ability of the compound to bind to the *TI* polypeptide is indicated by the presence of the compound in the complex.

In yet another aspect, the invention provides assays, e.g., for screening test compounds to identify modulators (e.g., inhibitors, or alternatively, potentiators) of an interaction between a *TI* protein and, for example, a tub polypeptide. An exemplary
20 method includes the steps of (i) combining a *TI* protein or bioactive fragment thereof, a *TI* protein target molecule (such as Tub), and a test compound, e.g., under conditions wherein, but for the test compound, the *TI* protein and target molecule are able to interact; and (ii) detecting the formation of a complex which includes the *TI* protein and the target polypeptide either by directly quantitating the complex, by measuring
25 inductive effects of the *TI* protein, or, in the instance of a substrate, measuring the conversion to product. A statistically significant change, such as a decrease, in the interaction of the *TI* protein and target molecule in the presence of a test compound (relative to what is detected in the absence of the test compound) is indicative of a modulation (e.g., inhibition or potentiation of the interaction between the *TI* protein and
30 the target molecule).

Yet another aspect of the present invention concerns a method for modulating apoptosis in a cell by modulating *TI* bioactivity, (e.g., by potentiating or disrupting certain protein-protein interactions). In general, whether carried out *in vivo*, *in vitro*, or *in situ*, the method comprises treating the cell with an effective amount of a *TI*
35 therapeutic so as to alter, relative to the cell in the absence of treatment, lipid uptake by the cell. Accordingly, the method can be carried out with *TI* modulating agents such as peptide and peptidomimetics or other molecules identified in the above-referenced drug

5 screens which agonize or antagonize the effects of signaling in a biochemical pathway involving a *TI* protein. Other modulating agents for use as therapeutics include antisense constructs for inhibiting expression of *TI* proteins, and dominant negative mutants of *TI* proteins which competitively inhibit ligand interactions upstream and signal transduction downstream of the wild-type *TI* protein.

10 A further aspect of the present invention provides a method of determining if a subject is at risk for a disorder characterized by inappropriate *TI* protein expression, such as, for example, a weight disorder (e.g. obesity, cachexia or anorexia nervosa) or a related disorder, such as diabetes. The method includes detecting, in a tissue of the subject, the presence or absence of a genetic lesion characterized by at least one of (i) a mutation of a gene encoding a *TI* protein, e.g. represented in any of SEQ ID NOs:1-6 or a homologue thereof; or (ii) the mis-expression of a *TI* gene. In preferred embodiments, detecting the genetic lesion includes ascertaining the existence of at least one of: a deletion of one or more nucleotides from a *TI* gene; an addition of one or more
15 nucleotides to the gene, a substitution of one or more nucleotides of the gene, a gross chromosomal rearrangement of the gene; an alteration in the level of a messenger RNA transcript of the gene; the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; a non-wild type level of the protein; and/or an aberrant level of soluble *TI* protein.

20 For example, detecting the genetic lesion can include (i) providing a probe/primer comprised of an oligonucleotide which hybridizes to a sense or antisense sequence of a *TI* gene or naturally occurring mutants thereof, or 5' or 3' flanking sequences naturally associated with the *TI* gene; (ii) contacting the probe/primer to an appropriate nucleic acid containing sample; and (iii) detecting, by hybridization of the probe/primer to the nucleic acid, the presence or absence of the genetic lesion; e.g.
25 wherein detecting the lesion comprises utilizing the probe/primer to determine the nucleotide sequence of the *TI* gene and, optionally, of the flanking nucleic acid sequences. For instance, the primer can be employed in a polymerase chain reaction (PCR) or in a ligation chain reaction (LCR). In alternate embodiments, the level of a *TI*
30 protein is detected in an immunoassay using an antibody which is specifically immunoreactive with the *TI* protein.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 shows the DNA sequence of a novel human *TI* gene, *E. coli* plasmid ptyhq049, ATCC designation no. 98125 (hTI-1) (SEQ ID NO:1) and a deduced amino acid sequence.

5 *Figure 2* shows the DNA sequence of a novel human *TI* gene, *E. coli* plasmid ptyhq058, ATCC designation no. 98127 (hTI-2) (SEQ ID NO:2) and a deduced amino acid sequence.

Figure 3 shows the DNA sequence of a novel human *TI* gene, *E. coli* plasmid ptyhq036, ATCC designation no. 98128 (hTI-3) (SEQ ID NO:3) and a deduced amino acid sequence.

10 *Figure 4* shows the DNA sequence of a novel murine *TI* gene, *E. coli* plasmid ptyht101 (mTI-3) (SEQ ID NO:4) and a deduced amino acid sequence.

Figure 5 shows the DNA sequence of a novel human *TI* gene, *E. coli* plasmid ptyhq054, ATCC designation no. 98126 (hTI-4) (SEQ ID NO:5) and a deduced amino acid sequence.

15 *Figure 6* shows the DNA sequence of a novel murine *TI* gene, *E. coli* plasmid ptyht102 (mTI-4) (SEQ ID NO:6) and a deduced amino acid sequence.

Detailed Description of the Invention

20 The present invention is based on the discovery of novel genes, referred to herein as the "Tub interactor" or "*TI*" genes, which function in biochemical pathways involved in weight control and/or related disorder, such as diabetes.

Six novel *TI* genes were cloned and identified based on their ability to interact with the C-terminus (i.e. the last 44 amino acids) of *hTub* in a two hybrid assay as further described in the following Examples. hTI-1 is a 1386 base pair nucleic acid, the sequence of which is presented in Figure 1 (SEQ ID NO:1). Based on sequence analysis, the polypeptide encoded by the gene is a putative serine protease.

hTI-2 is a 2103 base pair nucleic acid, the sequence of which is presented in Figure 2 (SEQ ID NO:2). The sequence contains ANK (i.e. ankyrin) repeats indicating that the protein encoded by the nucleic acid specifically recognize proteins and/or nucleic acid molecules (Michaely, P. and V. Bennett (1992) *Trends in Cell Biology* 2:127-129). Based on Northern analysis, a major band of 2.4kb and a minor band of 8kb corresponding to TI-2 was expressed in all human tissue and cell lines tested. However, the highest expression occurred in the testis, pancreas, liver, uterus and brain.

35 hTI-3 is a 1048 base pair nucleic acid, the sequence of which is presented in Figure 3 (SEQ ID NO:3). The sequence contains TPR repeats (i.e. tetratricopeptide repeats) and also DNAJ repeats, indicating that the protein encoded by the nucleic acid

is involved in protein-protein interactions. Based on Northern analysis, a major band of 2.2kb and a minor band of 1.2kb corresponding to hTI-3 was expressed in all human tissue and cell lines tested. However, the highest expression occurred in skeletal muscle, liver, heart and testis.

5 mTI-3 is a 1700 base pair nucleic acid, the sequence of which is presented in Figure 4 (SEQ ID NO:4). A sequence comparison of a 1035 base region indicates that the human and mouse genes are 86.8% identical. Like the human, the murine sequence contains TPR repeats (i.e. tetratricopeptide repeats) (Silkorski, R.J. et al., (January 26, 1990) *Cell* 60:307-317; Lee, T.G. et al. (April 1994) *Mol. Cell. Biol.* 14:2331-2342; 10 Barber, G.N et al. (May 1994) *Proc. Natl. Acad. Sci. USA* 91:4278-4282) and also DNAJ repeats (Silver, P.A. (July 16, 1993) *Cell* 74:5-6), indicating that the protein encoded by the nucleic acid is involved in protein-protein interactions. Based on Northern analysis, a major band of 1.4kb corresponding to mTI-3 was expressed in all murine tissue tested (both tub and B6). However, the highest expression occurred in 15 skeletal muscle, liver, heart and testis.

hTI-4 is a 1421 base pair nucleic acid, the sequence of which is presented in Figure 5 (SEQ ID NO:5). The sequence contains RING finger repeats (Saurin, A.J. et al. (June 1996) *TIBS* 21:) and also Zinc finger repeats (Lovering R. et al. (March 1993) *Proc. Natl. Acad. Sci. USA* 90:2112-2116) indicating that the protein encoded by the 20 nucleic acid is involved in nucleic acid (i.e. DNA or RNA) interactions. Based on Northern analysis, bands of 4 and 3 kb corresponding to hTI-4 was expressed in all human tissue and cell lines tested. In addition, a 1.4 kb band was strongly expressed in testis. Further, a band corresponding to 2.4 kb was expressed in the human SHEP, SHSY5Y, SKNMC and SKNSH cell lines.

25 mTI-4 is a 2121 base pair nucleic acid, the sequence of which is presented in Figure 6 (SEQ ID NO:6). A sequence comparison of a 959 base region indicates that the human and mouse genes are 86.8% identical. Like the human, the murine sequence contains RING finger repeats and also Zinc finger repeats indicating that the protein encoded by the nucleic acid is involved in nucleic acid (i.e. DNA or RNA) interactions. 30 Based on Northern analysis, major bands of 3.0 and 2.4kb corresponding to mTI-4 was expressed in all murine tissue tested. In addition, a 1.4 kb band was expressed in Tub and B6 mouse.

Another TI gene (hTI-5) was identified as encoding human serine palmitoyltransferase (GenBank Accession No. U15555), an enzyme that catalyzes the 35 committed step in sphingolipid and ceramide biosynthesis. Ceramide is a second messenger that regulates apoptosis via PP2A (Nickels, J.T. and J.R. Broach (1996) *Genes & Development* 10:382-394.

The cDNAs corresponding to *TI* gene transcripts were initially cloned from human breast tissue based on the ability of their encoded proteins to bind to the C-terminal domain (i.e. the last 44 amino acids) of the htub gene product in an assay that detects protein/protein interactions, placing the *TI* gene products in the same
5 biochemical pathway as tub. The tub protein is described in U.S. patent application serial number 08/631,200 filed on April 12, 1996.

Accordingly, certain aspects of the present invention relate to nucleic acid molecules encoding *TI* proteins, the *TI* proteins, antibodies immunoreactive with *TI* proteins, and preparations of such compositions. In addition, drug discovery assays are
10 provided for identifying agents which can modulate the biological function of *TI* proteins, such as by altering the interaction of *TI* molecules with either downstream or upstream elements in the tub signal transduction pathway. Such agents can be useful therapeutically, for example, to modulate weight control and/or diabetes. Moreover, the present invention provides diagnostic and therapeutic assays and reagents for detecting
15 and treating disorders involving, for example, aberrant expression (or loss thereof) of *TI* genes. Other aspects of the invention are described below or will be apparent to those skilled in the art in light of the present disclosure.

For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.

20 "Cells," "host cells" or "recombinant host cells" are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within
25 the scope of the term as used herein.

A "chimeric protein" or "fusion protein" is a fusion of a first amino acid sequence encoding one of the subject *TI* polypeptides with a second amino acid sequence defining a domain (e.g. polypeptide portion) foreign to and not substantially homologous with any domain of one of the *TI* polypeptides. A chimeric protein may
30 present a foreign domain which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an "interspecies", "intergenic", etc. fusion of protein structures expressed by different kinds of organisms. In general, a fusion protein can be represented by the general formula X-*TI*-Y, wherein *TI* represents a portion of the protein which is derived from one of the *TI* proteins, and X and Y are
35 independently absent or represent amino acid sequences which are not related to one of the *TI* amino acid sequences in an organism, including naturally occurring mutants.

- 12 -

"Complementary" sequences as used herein refer to sequences which have sufficient complementarity to be able to hybridize, forming a stable duplex.

A "delivery complex" shall mean a targeting means (e.g. a molecule that results in higher affinity binding of a gene, protein, polypeptide or peptide to a target cell surface and/or increased cellular uptake by a target cell). Examples of targeting means include: sterols (e.g. cholesterol), lipids (e.g. a cationic lipid, virosome or liposome), viruses (e.g. adenovirus, adeno-associated virus, and retrovirus) or target cell specific binding agents (e.g. ligands recognized by target cell specific receptors). Preferred complexes are sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization by the target cell. However, the complex is cleavable under appropriate conditions within the cell so that the gene, protein, polypeptide or peptide is released in a functional form.

As is well known, genes for a particular polypeptide may exist in single or multiple copies within the genome of an individual. Such duplicate genes may be identical or may have certain modifications, including nucleotide substitutions, additions or deletions, which all still code for polypeptides having substantially the same activity. The term "DNA sequence encoding a *T1* polypeptide" may thus refer to one or more genes within a particular individual. Moreover, certain differences in nucleotide sequences may exist between individual organisms, which are called alleles. Such allelic differences may or may not result in differences in amino acid sequence of the encoded polypeptide yet still encode a protein with the same biological activity.

As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid molecule comprising an open reading frame encoding one of the *T1* polypeptides of the present invention, including both exon and (optionally) intron sequences. A "recombinant gene" refers to nucleic acid molecule encoding a *T1* polypeptide and comprising *T1* protein-encoding exon sequences, though it may optionally include intron sequences which are either derived from a chromosomal *T1* gene or from an unrelated chromosomal gene. Exemplary recombinant genes encoding the subject *T1* polypeptides are represented in the appended Sequence Listing. The term "intron" refers to a DNA sequence present in a given gene which is not translated into protein and is generally found between exons.

"Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions

shared by the sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, though preferably less than 25% identity, with one of the *Tl* sequences of the present invention.

5 The term "interact" as used herein is meant to include detectable interactions between molecules, such as can be detected using, for example, a yeast two hybrid assay. The term interact is also meant to include "binding" interactions between molecules. Interactions may be protein-protein or protein-nucleic acid in nature.

10 The term "isolated" as used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source of the macromolecule. For example, an isolated nucleic acid encoding one of the subject *Tl* polypeptides preferably includes no more than 10 kilobases (kb) of nucleic acid sequence which naturally immediately flanks the *Tl* gene in genomic DNA, more preferably no more than 5kb of such naturally occurring flanking sequences, and most preferably less than 1.5kb of such naturally occurring
15 flanking sequence. The term isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an "isolated nucleic acid" is meant to include nucleic acid fragments which are not naturally occurring as fragments and
20 would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides.

The term "modulation" as used herein refers to both upregulation, i.e., stimulation, and downregulation, i.e. suppression, of a response.

25 The "non-human animals" of the invention include mammals such as rodents, non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc. Preferred non-human animals are selected from the rodent family including rat and mouse, most preferably mouse. The term "chimeric animal" is used herein to refer to animals in which the recombinant gene is found, or in which the recombinant is expressed in some
30 but not all cells of the animal. The term "tissue-specific chimeric animal" indicates that one of the recombinant *Tl* genes is present and/or expressed or disrupted in some tissues but not others.

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The
35 term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

As used herein, the term "promoter" means a DNA sequence that regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in cells. The term encompasses "tissue specific" promoters, i.e. promoters, which effect expression of the selected DNA sequence only in specific cells (e.g. cells of a specific tissue). The term also covers so-called "leaky" promoters, which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well. The term also encompasses non-tissue specific promoters and promoters that constitutively express or that are inducible (i.e. expression levels can be controlled).

10 The terms "protein", "polypeptide" and "peptide" are used interchangeably herein when referring to a gene product.

The term "recombinant protein" refers to a polypeptide of the present invention which is produced by recombinant DNA techniques, wherein generally, DNA encoding a *Tl* polypeptide is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein. Moreover, the phrase "derived from", with respect to a recombinant *Tl* gene, is meant to include within the meaning of "recombinant protein" those proteins having an amino acid sequence of a native *Tl* protein, or an amino acid sequence similar thereto which is generated by mutations including substitutions and deletions (including truncation) of a naturally occurring form of the protein.

As used herein, the term "specifically hybridizes" or "specifically detects" refers to the ability of a nucleic acid molecule of the invention to hybridize to at least approximately 6, 12, 20, 30, 50, 100, 150, 200, 300, 350, 400 or 425 consecutive nucleotides of a vertebrate, preferably mammalian, *Tl* gene, such as the *Tl* sequence designated in one of SEQ ID NOs:1-6, or a sequence complementary thereto, or naturally occurring mutants thereof, such that it shows more than 10 times more hybridization, preferably more than 100 times more hybridization, and even more preferably more than 100 times more hybridization than it does to a cellular nucleic acid (e.g., mRNA or genomic DNA) encoding a protein other than a vertebrate, preferably mammalian, *Tl* protein as defined herein.

"Transcriptional regulatory sequence" is a generic term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In preferred embodiments, transcription of one of the recombinant *Tl* genes is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the

recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally-occurring forms of *TI* proteins.

As used herein, the term "transfection" means the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer. "Transformation", as used herein, refers to a process in which a cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA, and, for example, the transformed cell expresses a recombinant form of a *TI* polypeptide or, in the case of anti-sense expression from the transferred gene, the expression of a naturally-occurring form of the *TI* protein is disrupted.

As used herein, the term "transgene" means a nucleic acid sequence encoding, e.g., one of the *TI* polypeptides, or an antisense transcript thereto, which is partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene or its insertion results in a knockout). A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, (e.g. as intron), that may be necessary for optimal expression of a selected nucleic acid.

A "transgenic animal" refers to any animal, preferably a non-human mammal, bird or an amphibian, in which one or more of the cells of the animal contain heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA. In the typical transgenic animals described herein, the transgene causes cells to express a recombinant form of one of the *TI* proteins, e.g. either agonistic or antagonistic forms. However, transgenic animals in which the recombinant *TI* gene is silent are also contemplated, as for example, the FLP or CRE recombinase dependent constructs described below. Moreover, "transgenic animal" also includes those recombinant animals in which gene disruption of one or more *TI* genes is caused by human intervention, including both recombination and antisense techniques.

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

15 Nucleic Acids

As described below, one aspect of the invention pertains to isolated nucleic acids comprising nucleotide sequences encoding Tub interactor or *TI* polypeptides, and/or equivalents of such nucleic acids. The term equivalent is understood to include nucleotide sequences encoding functionally equivalent *TI* polypeptides or functionally equivalent peptides having an activity of a *TI* protein such as described herein. Equivalent nucleotide sequences will include sequences that differ by one or more nucleotide substitution, addition or deletion, such as allelic variants; and will, therefore, include sequences that differ from the nucleotide sequence of the *TI* gene shown in SEQ ID NOs:1-6 due to the degeneracy of the genetic code.

25 Preferred nucleic acids are vertebrate *TI* nucleic acids. Particularly preferred vertebrate *TI* nucleic acids are mammalian. Regardless of species, particularly preferred *TI* nucleic acids encode polypeptides that are at least 80% similar to an amino acid sequence of a vertebrate *TI* protein. In one embodiment, the nucleic acid is a cDNA encoding a polypeptide having at least one bioactivity of the subject *TI* polypeptide. Preferably, the nucleic acid includes all or a portion of the nucleotide sequence corresponding to the nucleic acid of SEQ ID NOs:1, 3, 5, 7, or 9.

Still other preferred nucleic acids of the present invention encode a *TI* polypeptide which is comprised of at least 2, 5, 10, 25, 50, 100, 150 or 200 amino acid residues. For example, preferred nucleic acid molecules for use as probes/primer or antisense molecules (i.e. noncoding nucleic acid molecules) can comprise at least about 35 6, 12, 20, 30, 50, 100, 125, 150 or 200 base pairs in length, whereas coding nucleic acid

molecules can comprise about 300, 400, 500, 600, 700, 800, 900, 950, 975, 1000, 1005, 1010 or 1015 base pairs.

Another aspect of the invention provides a nucleic acid which hybridizes under stringent conditions to a nucleic acid represented by one of SEQ ID NOs:1-6.

- 5 Appropriate stringency conditions which promote DNA hybridization, for example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C, are known to those skilled in the art or can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50°C to a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C. Both temperature and salt may be varied, or temperature of salt concentration may be held constant while the other variable is changed. In a preferred embodiment, a *TI* nucleic acid of the present invention will bind to one of SEQ ID NOs:1-6 under moderately stringent conditions, for example at about 2.0 x SSC and about 40°C. In a particularly preferred embodiment, a *TI* nucleic acid of the present invention will bind to one of SEQ ID NOs:1-6 under high stringency conditions.

- 20 Preferred nucleic acids have a sequence at least 75% homologous and more preferably 80% and even more preferably at least 85% homologous with an amino acid sequence of a *TI* gene, e.g., such as a sequence shown in one of SEQ ID NOs:1-6. Nucleic acids at least 90%, more preferably 95%, and most preferably at least about 98-99% homologous with a nucleic sequence represented in one of SEQ ID NOs:1-6 are of course also within the scope of the invention. In preferred embodiments, the nucleic acid is mammalian and in particularly preferred embodiments, includes all or a portion of the nucleotide sequence corresponding to the coding region of one of SEQ ID NOs:1-6.

- 30 Nucleic acids having a sequence that differs from the nucleotide sequences shown in one of SEQ ID NOs:1-6 due to degeneracy in the genetic code are also within the scope of the invention. Such nucleic acids encode functionally equivalent peptides (i.e., a peptide having a biological activity of a *TI* polypeptide) but differ in sequence from the sequence shown in the sequence listing due to degeneracy in the genetic code. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC each encode histidine) may result in "silent" mutations which do not affect the amino acid sequence of a *TI* polypeptide. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject *TI*
- 35

- 18 -

polypeptides will exist among mammals. One skilled in the art will appreciate that these variations in one or more nucleotides (e.g., up to about 3-5% of the nucleotides) of the nucleic acids encoding polypeptides having an activity of a *TI* polypeptide may exist among individuals of a given species due to natural allelic variation.

5 As indicated by the examples set out below, *TI* protein-encoding nucleic acids can be obtained from mRNA present in any of a number of eukaryotic cells. It should also be possible to obtain nucleic acids encoding *TI* polypeptides of the present invention from genomic DNA from both adults and embryos. For example, a gene encoding a *TI* protein can be cloned from either a cDNA or a genomic library in
10 accordance with protocols described herein, as well as those generally known to persons skilled in the art. Examples of tissues and/or libraries suitable for isolation of the subject nucleic acids include breast, among others. A cDNA encoding a *TI* protein can be obtained by isolating total mRNA from a cell, e.g. a vertebrate cell, a mammalian cell, or a human cell, including embryonic cells. Double stranded cDNAs can then be
15 prepared from the total mRNA, and subsequently inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques. The gene encoding a *TI* protein can also be cloned using established polymerase chain reaction techniques in accordance with the nucleotide sequence information provided by the invention. The nucleic acid of the invention can be DNA or RNA or analogs thereof. A
20 preferred nucleic acid is a cDNA represented by a sequence selected from the group consisting of SEQ ID NOs:1-6.

Vectors.

This invention also provides expression vectors containing a nucleic acid
25 encoding a *TI* polypeptide, operably linked to at least one transcriptional regulatory sequence. "Operably linked" is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence. Regulatory sequences are art-recognized and are selected to direct expression of the subject *TI* proteins. Accordingly, the term "transcriptional regulatory sequence"
30 includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). In one embodiment, the expression vector includes a recombinant gene encoding a peptide having an agonistic activity of a subject *TI* polypeptide, or alternatively, encoding a peptide which is an
35 antagonistic form of the *TI* protein. Such expression vectors can be used to transfect cells and thereby produce polypeptides, including fusion proteins, encoded by nucleic acids as described herein. Moreover, the gene constructs of the present invention can

also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of one of the subject *TI* proteins. Thus, another aspect of the invention features expression vectors for *in vivo* or *in vitro* transfection and expression of a *TI* polypeptide in particular cell types so as to reconstitute the function of, or alternatively, abrogate the function of *TI*-induced signaling in a tissue. This could be desirable, for example, when the naturally-occurring form of the protein is misexpressed; or to deliver a form of the protein which alters differentiation of tissue. Expression vectors may also be employed to inhibit neoplastic transformation.

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a subject *TI* polypeptide in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral targeting means of the present invention rely on endocytic pathways for the uptake of the subject *TI* polypeptide gene by the targeted cell. Exemplary targeting means of this type include liposomal derived systems, polylysine conjugates, and artificial viral envelopes.

Probes and Primers

Moreover, the nucleotide sequences determined from the cloning of *TI* genes from mammalian organisms will further allow for the generation of probes and primers designed for use in identifying and/or cloning *TI* homologues in other cell types, e.g. from other tissues, as well as *TI* homologues from other mammalian organisms. For instance, the present invention also provides a probe/primer comprising a substantially purified oligonucleotide, which oligonucleotide comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least approximately 12, preferably 25, more preferably 40, 50 or 75 consecutive nucleotides of sense or anti-sense sequence selected from the group consisting of SEQ ID NOs:1-6 or naturally occurring mutants thereof. For instance, primers based on the nucleic acid represented in SEQ ID NOs:1, 3, 5, 7 or 9 can be used in PCR reactions to clone *TI* homologues. Preferred primers for hTI-4 are set forth as SEQ ID NOs:9 and 10. Preferred primers for mTI-3 are set forth as SEQ ID NOs:13 and 14. Preferred primers for hTI-3 are set forth in SEQ ID NOs:17 and 18. Preferred primers for hTI-1 are set forth in SEQ ID NOs:21 and 22. Preferred primers for mTI-4 are set forth in SEQ ID NOs:25 and 26. Preferred primers for hTI-2 are set forth in SEQ ID NOs:29 and 30.

Likewise, probes based on the subject *TI* sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto and

able to be detected, e.g. the label group is a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.

As discussed in more detail below, such probes can also be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a *TI* protein, such as by measuring a level of a *TI*-encoding nucleic acid in a sample of cells from a patient; e.g. detecting *TI* mRNA levels or determining whether a genomic *TI* gene has been mutated or deleted. Briefly, nucleotide probes can be generated from the subject *TI* genes which facilitate histological screening of intact tissue and tissue samples for the presence (or absence) of *TI*-encoding transcripts. Similar to the diagnostic uses of anti-*TI* antibodies, the use of probes directed to *TI* messages, or to genomic *TI* sequences, can be used for both predictive and therapeutic evaluation of allelic mutations which might be manifest in, for example, a predisposition to diabetes. Used in conjunction with immunoassays as described herein, the oligonucleotide probes can help facilitate the determination of the molecular basis for a disorder which may involve some abnormality associated with expression (or lack thereof) of a *TI* protein. For instance, variation in polypeptide synthesis can be differentiated from a mutation in a coding sequence.

Antisense, Ribozyme and Triplex techniques

Another aspect of the invention relates to the use of the isolated nucleic acid in "antisense" therapy. As used herein, "antisense" therapy refers to administration or *in situ* generation of oligonucleotide molecules or their derivatives which specifically hybridize (e.g. bind) under cellular conditions, with the cellular mRNA and/or genomic DNA encoding one or more of the subject *TI* proteins so as to inhibit expression of that protein, e.g. by inhibiting transcription and/or translation. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" therapy refers to the range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.

An antisense construct of the present invention can be delivered, for example, as an expression plasmid which, when transcribed in the cell, produces RNA which is complementary to at least a unique portion of the cellular mRNA which encodes a *TI* protein. Alternatively, the antisense construct is an oligonucleotide probe which is generated *ex vivo* and which, when introduced into the cell causes inhibition of expression by hybridizing with the mRNA and/or genomic sequences of a *TI* gene. Such oligonucleotide probes are preferably modified oligonucleotides which are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and are

therefore stable *in vivo*. Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S. Patents 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy have been reviewed, for example, by Van der Krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668. With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, *e.g.*, between the -10 and +10 regions of the *Tl* nucleotide sequence of interest, are preferred. Particularly preferred antisense molecules are set forth in SEQ ID NOs:11, 15, 19, 23 and 27.

Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are complementary to *Tl* mRNA. The antisense oligonucleotides will bind to the *Tl* mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation of mRNAs as well. (Wagner, R. (1994) *Nature* 372:333). Therefore, oligonucleotides complementary to either the 5' or 3' untranslated, non-coding regions of a *Tl* gene could be used in an antisense approach to inhibit translation of endogenous *Tl* mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5', 3' or coding region of *Tl* mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50, 25, 17 or 10 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W0 88/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W0 89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, *e.g.*, Krol et al. (1988) *BioTechniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxyethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,

5-methyluracil, uracil-5- oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

5 The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

10 In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

15 In yet a further embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier et al. (1987) *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al. (1987) *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

20 Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988) *Nucl. Acids Res.* 16:3209). methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al. (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:7448-7451), etc.

25 While antisense nucleotides complementary to the *TI* coding region sequence can be used, those complementary to the transcribed untranslated region are most preferred. For example, an antisense oligonucleotide as set forth in SEQ ID NOs:11, 15, 19, 23 and 27 can be utilized in accordance with the invention.

30 The antisense molecules should be delivered to cells which express *TI* *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systematically.

35 However, it is often difficult to achieve intracellular concentrations of the antisense sufficient to suppress translation on endogenous mRNAs. Therefore a

preferred approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form

5 complementary base pairs with the endogenous *Tl* transcripts and thereby prevent translation of the *Tl* mRNA. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by

10 recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon (1981) *Nature* 290:304-310), the promoter contained in

15 the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al. (1980) *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al. (1981) *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al. (1982) *Nature* 296:39-42), etc. Any type of plasmid, cosmid, YAC or viral vector

20 can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site; *e.g.*, the choroid plexus or hypothalamus. Alternatively, viral vectors can be used which selectively infect the desired tissue; (*e.g.*, for brain, herpesvirus vectors may be used), in which case administration may be accomplished by another route (*e.g.*, systematically).

25 Ribozyne molecules designed to catalytically cleave *Tl* mRNA transcripts can also be used to prevent translation of *Tl* mRNA and expression of *Tl* (See, *e.g.*, PCT Publication No. WO 90/11364, published October 4, 1990; Sarver et al. (1990) *Science* 247:1222-1225 and U.S. Patent No. 5,093,246). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy *Tl* mRNAs, the use of

30 hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach

35 (1988) *Nature* 334:585-591. There are hundreds of potential hammerhead ribozyme cleavage sites within the nucleotide sequence of human *Tl* cDNA (Fig. 1). Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end

of the *TI* mRNA; *i.e.*, to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in
5 *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al. (1984) *Science* 224:574-578; Zaug and Cech (1986) *Science* 231:470-475; Zaug, et al. (1986) *Nature* 324:429-433; published PCT Publication No. WO 88/04300 by University Patents Inc.; Been and Cech, (1986) *Cell* 47:207-216). The Cech-type ribozymes have an eight base
10 pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences that are present in a *TI* gene. Particularly preferred ribozymes are set forth in SEQ ID NOs:8, 12, 16, 20, 24 and 28.

As in the antisense approach, the ribozymes can be composed of modified
15 oligonucleotides (*e.g.* for improved stability, targeting, etc.) and should be delivered to cells which express the *TI* gene *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous *TI* messages and inhibit translation. Because
20 ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Endogenous *TI* gene expression can also be reduced by inactivating or "knocking out" the *TI* gene or its promoter using targeted homologous recombination. (*see, e.g.*, Smithies et al. (1985) *Nature* 317:230-234; Thomas and Capecchi (1987) *Cell* 51:503-
25 512; Thompson et al. (1989) *Cell* 5:313-321; each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional *TI* (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous *TI* gene (either the coding regions or regulatory regions of the *TI* gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that
30 express *TI* *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the *TI* gene. Such approaches are particularly suited in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive *TI* (*e.g.*, *see* Thomas and Capecchi, 1987, and Thompson, 1989, *supra*). However this approach can be adapted for use in
35 humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors, *e.g.*, herpes virus vectors for delivery to brain tissue; *e.g.*, the hypothalamus and/or choroid plexus.

Alternatively, endogenous *TI* gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the *TI* gene (*i.e.*, the *TI* promoter and/or enhancers) to form triple helical structures that prevent transcription of the *TI* gene in target cells in the body. (See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C., et al. (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15).

Likewise, the antisense constructs of the present invention, by antagonizing the normal biological activity of one of the *TI* proteins, can be used in the manipulation of issue, e.g. lipid metabolism, both *in vivo* and for *ex vivo* tissue cultures.

Furthermore, like the antisense techniques (e.g. microinjection of antisense molecules, or transfection with plasmids whose transcripts are antisense with regard to a *TI* mRNA or gene sequence) antagonizing the normal biological activity of one of the *TI* proteins can be used to investigate role of *TI* in lipid metabolism. Such techniques can be utilized in cell culture, but can also be used in the creation of transgenic animals, as detailed below.

Nucleic acid molecules to be used in triple helix formation for the inhibition of transcription are preferably single stranded and composed of deoxyribonucleotides. The base composition of these oligonucleotides should promote triple helix formation via Hoogsteen base pairing rules, which generally require sizable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, containing a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in CGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizable stretch of either purines or pyrimidines to be present on one strand of a duplex.

Antisense RNA and DNA, ribozyme, and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA molecules. These include techniques for chemically synthesizing

oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

Moreover, various well-known modifications to nucleic acid molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

Polypeptides of the Invention

The present invention also makes available isolated *Tf* polypeptides which are isolated from, or otherwise substantially free of other cellular proteins, especially other signal transduction factors and/or transcription factors which may normally be associated with the *Tf* polypeptide. The term "substantially free of other cellular proteins" (also referred to herein as "contaminating proteins") or "substantially pure or purified preparations" are defined as encompassing preparations of *Tf* polypeptides having less than about 20% (by dry weight) contaminating protein, and preferably having less than about 5% contaminating protein. Functional forms of the subject polypeptides can be prepared, for the first time, as purified preparations by using a cloned gene as described herein. By "purified", it is meant, when referring to a peptide or DNA or RNA sequence, that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other proteins. The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above. "Isolated" and "purified" do not encompass either natural materials in their native state or natural materials that have been separated into components (e.g., in an acrylamide gel) but not obtained either as pure (e.g. lacking contaminating proteins, or chromatography reagents such as denaturing agents and polymers, e.g.

acrylamide or agarose) substances or solutions. In preferred embodiments, purified *TI* preparations will lack any contaminating proteins from the same animal from which *TI* is normally produced, as can be accomplished by recombinant expression of, for example, a human *TI* protein in a non-human cell.

5 Full length proteins or fragments corresponding to one or more particular motifs and/or domains or to arbitrary sizes, for example, at least 5, 10, 25, 50, 75, 100, 125, 150 amino acids in length are within the scope of the present invention.

For example, isolated *TI* polypeptides can be encoded by all or a portion of a nucleic acid sequence shown in any of SEQ ID NOs:1-6. Isolated peptidyl portions of
10 *TI* proteins can be obtained by screening peptides recombinantly produced from the corresponding fragment of the nucleic acid encoding such peptides. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, a *TI* polypeptide of the present invention may be arbitrarily divided into fragments of desired
15 length with no overlap of the fragments, or preferably divided into overlapping fragments of a desired length. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments which can function as either agonists or antagonists of a wild-type (e.g., "authentic") *TI* protein.

Another aspect of the present invention concerns recombinant forms of the *TI*
20 proteins. Recombinant polypeptides preferred by the present invention, in addition to native *TI* proteins, are encoded by a nucleic acid, which is at least 85% homologous and more preferably 90% homologous and most preferably 95 % homologous with a nucleic acid sequence represented by SEQ ID NOs:1-6. Polypeptides which are encoded by a nucleic acid that is at least about 98-99% homologous with the sequence of SEQ ID
25 NOs: 1-6 are also within the scope of the invention. In a preferred embodiment, a *TI* protein of the present invention is a mammalian *TI* protein. In a particularly preferred embodiment a *TI* protein is encoded by one of the nucleic acids set forth as SEQ ID NOs:1-6. In particularly preferred embodiment, a *TI* protein has a *TI* bioactivity. It will be understood that certain post-translational modifications, e.g., phosphorylation and the
30 like, can increase the apparent molecular weight of the *TI* protein relative to the unmodified polypeptide chain.

The present invention further pertains to recombinant forms of one of the subject *TI* polypeptides. Such recombinant *TI* polypeptides preferably are capable of functioning in one of either role of an agonist or antagonist of at least one biological
35 activity of a wild-type ("authentic") *TI* protein of the appended sequence listing. The term "evolutionarily related to", with respect to amino acid sequences of *TI* proteins, refers to both polypeptides having amino acid sequences which have arisen naturally,

and also to mutational variants of human *TI* polypeptides which are derived, for example, by combinatorial mutagenesis.

In general, polypeptides referred to herein as having an activity (e.g., are "bioactive") of a *TI* protein are defined as polypeptides which include an amino acid sequence encoded by all or a portion of the nucleic acid sequences shown in one of SEQ ID NOs:1-6 and which mimic or antagonize all or a portion of the biological/biochemical activities of a naturally occurring *TI* protein. In preferred embodiments a *TI* protein of the present invention specifically interacts with a the carboxy terminus (i.e. last 44 amino acids) of the human tub polypeptide. Examples of such biological activity include the ability to modulate weight control and/or diabetes. Other biological activities of the subject *TI* proteins are described herein or will be reasonably apparent to those skilled in the art. According to the present invention, a polypeptide has biological activity if it is a specific agonist or antagonist of a naturally-occurring form of a *TI* protein.

The present invention further pertains to methods of producing the subject *TI* polypeptides. For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding the subject polypeptides can be cultured under appropriate conditions to allow expression of the peptide to occur. The cells may be harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The recombinant *TI* polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such peptide. In a preferred embodiment, the recombinant *TI* polypeptide is a fusion protein containing a domain which facilitates its purification, such as GST fusion protein.

Moreover, it will be generally appreciated that, under certain circumstances, it may be advantageous to provide homologues of one of the subject *TI* polypeptides which function in a limited capacity as one of either a *TI* agonist (mimetic) or a *TI* antagonist, in order to promote or inhibit only a subset of the biological activities of the naturally-occurring form of the protein. Thus, specific biological effects can be elicited by treatment with a homologue of limited function, and with fewer side effects relative to treatment with agonists or antagonists which are directed to all of the biological activities of naturally occurring forms of *TI* proteins.

Homologues of each of the subject *TI* proteins can be generated by mutagenesis, such as by discrete point mutation(s), or by truncation. For instance, mutation can give rise to homologues which retain substantially the same, or merely a subset, of the

biological activity of the *TI* polypeptide from which it was derived. Alternatively, antagonistic forms of the protein can be generated which are able to inhibit the function of the naturally occurring form of the protein, such as by competitively binding to a downstream or upstream member of the *TI* cascade which includes the *TI* protein. In addition, agonistic forms of the protein may be generated which are constitutively active. Thus, the *TI* protein and homologues thereof provided by the subject invention may be either positive or negative regulators of weight control and/or diabetes.

The recombinant *TI* polypeptides of the present invention also include homologues of the wild-type *TI* proteins, such as versions of those protein which are resistant to proteolytic cleavage, as for example, due to mutations which alter ubiquitination or other enzymatic targeting associated with the protein.

TI polypeptides may also be chemically modified to create *TI* derivatives by forming covalent or aggregate conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like. Covalent derivatives of *TI* proteins can be prepared by linking the chemical moieties to functional groups on amino acid sidechains of the protein or at the N-terminus or at the C-terminus of the polypeptide.

Modification of the structure of the subject *TI* polypeptides can be for such purposes as enhancing therapeutic or prophylactic efficacy, stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*), or post-translational modifications (e.g., to alter phosphorylation pattern of protein). Such modified peptides, when designed to retain at least one activity of the naturally-occurring form of the protein, or to produce specific antagonists thereof, are considered functional equivalents of the *TI* polypeptides described in more detail herein. Such modified peptides can be produced, for instance, by amino acid substitution, deletion, or addition.

For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (i.e. isosteric and/or isoelectric mutations) will not have a major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids can be divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. In similar fashion, the amino acid repertoire can be grouped as (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine, (3) aliphatic = glycine, alanine, valine, leucine, isoleucine, serine, threonine, with serine and threonine optionally be grouped separately as aliphatic-hydroxyl; (4)

aromatic = phenylalanine, tyrosine, tryptophan; (5) amide = asparagine, glutamine; and (6) sulfur -containing = cysteine and methionine. (see, for example, *Biochemistry*, 2nd ed., Ed. by L. Stryer, W.H. Freeman and Co., 1981). Whether a change in the amino acid sequence of a peptide results in a functional *TI* homologue (e.g. functional in the sense that the resulting polypeptide mimics or antagonizes the wild-type form) can be readily determined by assessing the ability of the variant peptide to produce a response in cells in a fashion similar to the wild-type protein, or competitively inhibit such a response. Polypeptides in which more than one replacement has taken place can readily be tested in the same manner.

10 This invention further contemplates a method for generating sets of combinatorial mutants of the subject *TI* proteins as well as truncation mutants, and is especially useful for identifying potential variant sequences (e.g. homologues) that are functional in modulating signal transduction from a lipid receptor. The purpose of screening such combinatorial libraries is to generate, for example, novel *TI* homologues
15 which can act as either agonists or antagonist, or alternatively, possess novel activities all together. To illustrate, *TI* homologues can be engineered by the present method to provide selective, constitutive activation of a tub signaling pathway. Thus, combinatorially-derived homologues can be generated to have an increased potency relative to a naturally occurring form of the protein.

20 Likewise, *TI* homologues can be generated by the present combinatorial approach to selectively inhibit (antagonize) induction by a lipid. For instance, mutagenesis can provide *TI* homologues which are able to bind other signal pathway proteins (or DNA) yet prevent propagation of the signal, e.g. the homologues can be dominant negative mutants. Moreover, manipulation of certain domains of *TI* by the
25 present method can provide domains more suitable for use in fusion proteins.

In one embodiment, the variegated library of *TI* variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential *TI* sequences are
30 expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g. for phage display) containing the set of *TI* sequences therein.

There are many ways by which such libraries of potential *TI* homologues can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the
35 synthetic genes then ligated into an appropriate expression vector. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential *TI* sequences. The synthesis of degenerate oligonucleotides is

well known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules*, ed. AG Walton, Amsterdam: Elsevier pp 273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *Proc. Natl. Acad. Sci. USA* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

10 Likewise, a library of coding sequence fragments can be provided for a *TI* clone in order to generate a variegated population of *TI* fragments for screening and subsequent selection of bioactive fragments. A variety of techniques are known in the art for generating such libraries, including chemical synthesis. In one embodiment, a library of coding sequence fragments can be generated by (i) treating a double stranded
15 PCR fragment of a *TI* coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule; (ii) denaturing the double stranded DNA; (iii) renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products; (iv) removing single stranded portions from reformed duplexes by treatment with S1 nuclease; and (v) ligating the resulting fragment
20 library into an expression vector. By this exemplary method, an expression library can be derived which codes for N-terminal, C-terminal and internal fragments of various sizes.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA
25 libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of *TI* homologues. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and
30 expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of degenerate *TI* sequences created by combinatorial mutagenesis techniques.

35 In one embodiment, cell based assays can be exploited to analyze the variegated *TI* library. For instance, the library of expression vectors can be transfected into a cell line ordinarily responsive to insulin. The transfected cells are then contacted with the

insulin and the effect of the *TI* mutant on signaling by a Y5 receptor can be detected. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of lipid receptor induction, and the individual clones further characterized.

- 5 Combinatorial mutagenesis has a potential to generate very large libraries of mutant proteins, e.g., in the order of 10^{26} molecules. Combinatorial libraries of this size may be technically challenging to screen even with high throughput screening assays. To overcome this problem, a new technique has been developed recently, recursive ensemble mutagenesis (REM), which allows one to avoid the very high proportion of
- 10 non-functional proteins in a random library and simply enhances the frequency of functional proteins, thus decreasing the complexity required to achieve a useful sampling of sequence space. REM is an algorithm which enhances the frequency of functional mutants in a library when an appropriate selection or screening method is employed (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815;
- 15 Yourvan et al. (1992) *Parallel Problem Solving from Nature*, 2., In Maenner and Manderick, eds., Elsevier Publishing Co., Amsterdam, pp. 401-410; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

- The invention also provides for reduction of the *TI* proteins to generate mimetics, e.g. peptide or non-peptide agents, which are able to disrupt binding of a *TI* polypeptide
- 20 of the present invention with either upstream or downstream components of a lipid uptake signaling cascade, such as binding proteins or interactors. Thus, such mutagenic techniques as described above are also useful to map the determinants of the *TI* proteins which participate in protein-protein interactions involved in, for example, binding of the subject *TI* polypeptide to proteins which may function upstream (including both
- 25 activators and repressors of its activity) or to proteins or nucleic acids which may function downstream of the *TI* polypeptide, whether they are positively or negatively regulated by it, for example. To illustrate, the critical residues of a subject *TI* polypeptide which are involved in molecular recognition of, for example, tub or other components upstream or downstream of a *TI* can be determined and used to generate *TI*-
- 30 derived peptidomimetics which competitively inhibit binding of the authentic *TI* protein with that moiety. By employing, for example, scanning mutagenesis to map the amino acid residues of each of the subject *TI* proteins which are involved in binding other extracellular proteins, peptidomimetic compounds can be generated which mimic those residues of the *TI* protein which facilitate the interaction. Such mimetics may then be
- 35 used to interfere with the normal function of a *TI* protein. For instance, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (c.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed.,

ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J. Med. Chem.* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), b-turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J. Chem. Soc. Perkin. Trans.* 1:1231), and b-aminoalcohols (Gordon et al. (1985) *Biochem. Biophys. Res. Commun.* 126:419; and Dann et al. (1986) *Biochem. Biophys. Res. Commun.* 134:71).

Cells Expressing Recombinant TI polypeptides.

This invention also pertains to host cells transfected to express a recombinant form of the subject TI polypeptides. The host cell may be any prokaryotic or eukaryotic cell. Thus, a nucleotide sequence derived from the cloning of mammalian TI proteins, encoding all or a selected portion of the full-length protein, can be used to produce a recombinant form of a TI polypeptide via microbial or eukaryotic cellular processes. Ligating the polynucleotide sequence into a gene construct, such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures used in producing other well-known proteins, e.g. MAP kinase, p53, WT1, PTP phosphatases, SRC, and the like. Similar procedures, or modifications thereof, can be employed to prepare recombinant TI polypeptides by microbial means or tissue-culture technology in accord with the subject invention.

The recombinant TI genes can be produced by ligating a nucleic acid encoding a TI protein, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Expression vectors for production of recombinant forms of the subject TI polypeptides include plasmids and other vectors. For instance, suitable vectors for the expression of a TI polypeptide include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

A number of vectors exist for the expression of recombinant proteins in yeast. For instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae* (see, for example, Broach et al. (1983) in *Experimental Manipulation of Gene Expression*, ed. M. Inouye Academic Press, p. 83, incorporated by reference herein).

These vectors can replicate in *E. coli* due the presence of the pBR322 ori, and in *S. cerevisiae* due to the replication determinant of the yeast 2 micron plasmid. In addition, drug resistance markers such as ampicillin can be used. In an illustrative embodiment, a *Tl* polypeptide is produced recombinantly utilizing an expression vector generated by sub-cloning the coding sequence of one of the *Tl* genes represented in SEQ ID NOs: 1, 3, 5, 7, or 9.

The preferred mammalian expression vectors contain both prokaryotic sequences, to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, PKO-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papillomavirus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. The various methods employed in the preparation of the plasmids and transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989) Chapters 16 and 17.

In some instances, it may be desirable to express the recombinant *Tl* polypeptide by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

When it is desirable to express only a portion of a *Tl* protein, such as a form lacking a portion of the N-terminus, i.e. a truncation mutant which lacks the signal peptide, it may be necessary to add a start codon (ATG) to the oligonucleotide fragment containing the desired sequence to be expressed. It is well known in the art that a methionine at the N-terminal position can be enzymatically cleaved by the use of the enzyme methionine aminopeptidase (MAP). MAP has been cloned from *E. coli* (Ben-Bassat et al. (1987) *J. Bacteriol.* 169:751-757) and *Salmonella typhimurium* and its *in vitro* activity has been demonstrated on recombinant proteins (Miller et al. (1987) *Proc. Natl. Acad. Sci.* 84:2718-1722). Therefore, removal of an N-terminal methionine, if desired, can be achieved either *in vivo* by expressing *Tl*-derived polypeptides in a host

- 36 -

which produces MAP (e.g., *E. coli* or CM89 or *S. cerevisiae*), or *in vitro* by use of purified MAP (e.g., procedure of Miller et al., *supra*).

In other embodiments transgenic animals, described in more detail below could be used to produce recombinant proteins.

5

Fusion Proteins and Immunogens.

In another embodiment, the coding sequences for the polypeptide can be incorporated as a part of a fusion gene including a nucleotide sequence encoding a different polypeptide. This type of expression system can be useful under conditions
10 where it is desirable to produce an immunogenic fragment of a *TI* protein. For example, the VP6 capsid protein of rotavirus can be used as an immunologic carrier protein for portions of the *TI* polypeptide, either in the monomeric form or in the form of a viral particle. The nucleic acid sequences corresponding to the portion of a subject *TI* protein to which antibodies are to be raised can be incorporated into a fusion gene construct
15 which includes coding sequences for a late vaccinia virus structural protein to produce a set of recombinant viruses expressing fusion proteins comprising *TI* epitopes as part of the virion. It has been demonstrated with the use of immunogenic fusion proteins utilizing the hepatitis b surface antigen fusion proteins that recombinant hepatitis b virions can be utilized in this role as well. Similarly, chimeric constructs coding for
20 fusion proteins containing a portion of a *TI* protein and the poliovirus capsid protein can be created to enhance immunogenicity of the set of polypeptide antigens (see, for example, EP Publication No: 0259149; and Evans et al. (1989) *Nature* 339:385; Huang et al. (1988) *J. Virol.* 62:3855; and Schlienger et al. (1992) *J. Virol.* 66:2).

The Multiple Antigen Peptide system for peptide-based immunization can also
25 be utilized to generate an immunogen, wherein a desired portion of a *TI* polypeptide is obtained directly from organo-chemical synthesis of the peptide onto an oligomeric branching lysine core (see, for example, Posnett et al. (1988) *J. Biol. Chem.* 263:1719 and Nardelli et al. (1992) *J. Immunol.* 148:914). Antigenic determinants of *TI* proteins can also be expressed and presented by bacterial cells.

30 In addition to utilizing fusion proteins to enhance immunogenicity, it is widely appreciated that fusion proteins can also facilitate the expression of proteins, and accordingly, can be used in the expression of the *TI* polypeptides of the present invention. For example, *TI* polypeptides can be generated as glutathione-S-transferase (GST-fusion) proteins. Such GST-fusion proteins can enable easy purification of the
35 polypeptide, as for example by the use of glutathione-derivatized matrices (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. (John Wiley & Sons, NY 1991)).

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant protein, can allow purification of the expressed fusion protein by affinity chromatography using a Ni²⁺ metal resin. The purification leader sequence
5 can then be subsequently removed by treatment with enterokinase to provide the purified protein (e.g., see Hochuli et al. (1987) *J. Chromatography* 411:177; and Janknecht et al. *PNAS* 88:8972).

Techniques for making fusion genes are known to those skilled in the art. Essentially, the joining of various DNA fragments coding for different polypeptide
10 sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated
15 DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. John Wiley & Sons: 1992).

20

Antibodies

Another aspect of the invention pertains to an antibody specifically reactive with a mammalian *TI* protein. For example, by using immunogens derived from a *TI* protein, e.g. based on the cDNA sequences, anti-protein/anti-peptide antisera or monoclonal
25 antibodies can be made by standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide (e.g., a mammalian *TI* polypeptide or an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein as described above).
30 Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a *TI* protein can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of
35 antibodies. In a preferred embodiment, the subject antibodies are immunospecific for antigenic determinants of a *TI* protein of a mammal, e.g. antigenic determinants of a

- 38 -

protein encoded by SEQ ID NOs:1-6 or closely related homologues (e.g. at least 90% homologous, and more preferably at least 94% homologous).

Following immunization of an animal with an antigenic preparation of a *TI* polypeptide, anti-*TI* antisera can be obtained and, if desired, polyclonal anti-*TI* antibodies isolated from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma technique (originally developed by Kohler and Milstein, (1975) *Nature* 256: 495-497), the human B cell hybridoma technique (Kozbar et al. (1983) *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. pp. 77-96). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a mammalian *TI* polypeptide of the present invention and monoclonal antibodies isolated from a culture comprising such hybridoma cells. In one embodiment anti-human *TI* antibodies specifically react with any of the proteins encoded by the DNA of ATCC deposit Nos. 98125- 98128.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with one of the subject mammalian *TI* polypeptides. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab)₂ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain and chimeric molecules having affinity for a *TI* protein conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able to be detected, (e.g. the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

Antibodies which specifically bind *TI* epitopes can also be used in immunohistochemical staining of tissue samples in order to evaluate the abundance and pattern of expression of each of the subject *TI* polypeptides. Anti-*TI* antibodies can be used diagnostically in immuno-precipitation and immuno-blotting to detect and evaluate *TI* protein levels in tissue as part of a clinical testing procedure. For instance, such measurements can be useful in predictive valuations of the onset or progression of proliferative disorders. Likewise, the ability to monitor *TI* protein levels in an individual can allow determination of the efficacy of a given treatment regimen for an individual

afflicted with such a disorder. The level of *TI* polypeptides may be measured from cells in bodily fluid, such as in samples of cerebral spinal fluid, such as produced by biopsy. Diagnostic assays using anti-*TI* antibodies can include, for example, immunoassays designed to aid in early diagnosis of a degenerative disorder. Diagnostic assays using anti-*TI* polypeptide antibodies can also include immunoassays designed to aid in early diagnosis and phenotyping neoplastic or hyperplastic disorders.

Another application of anti-*TI* antibodies of the present invention is in the immunological screening of cDNA libraries constructed in expression vectors such as λ gt11, λ gt18-23, λ ZAP, and λ ORF8. Messenger libraries of this type, having coding sequences inserted in the correct reading frame and orientation, can produce fusion proteins. For instance, λ gt11 will produce fusion proteins whose amino termini consist of β -galactosidase amino acid sequences and whose carboxy termini consist of a foreign polypeptide. Antigenic epitopes of a *TI* protein, e.g. other orthologues of a particular *TI* protein or other paralogues from the same species, can then be detected with antibodies, as, for example, reacting nitrocellulose filters lifted from infected plates with anti-*TI* antibodies. Positive phage detected by this assay can then be isolated from the infected plate. Thus, the presence of *TI* homologues can be detected and cloned from other animals, as can alternate isoforms (including splicing variants) from humans.

20 Methods of Treating Disease

There are a wide variety of disorders for which *TI* molecules of the present invention can be used in treatment. As discussed herein *TI* molecule can increase the transcription or activity of *TI* molecules in a cell. A *TI* molecule therapeutic can be, as appropriate, any of the preparations described above, including isolated polypeptides, gene therapy constructs, antisense molecules, peptidomimetics or agents identified in the drug assays provided herein.

In preferred embodiments the subject *TI* molecules are modulated to control weight in a subject. Hypothalamic neuropeptide Y (NPY) is a member of the pancreatic polypeptide family and is a potent feeding signal. NPY levels in the paraventricular nucleus (PVN) of the brain have been shown to increase with food deprivation and return to normal after insulin injections (Sahu et al. (1995) *Endocrinology* 136:5718). In one embodiment the subject *TI* molecules are modulated to control weight in a subject by modulation of a biochemical pathway involving NPY. NPY is thought to signal via the Y5 receptor (Gerald et al. (1996) *Nature* 382:168). The distribution of Y5 mRNA shows that the Y5 receptor is also involved in regulating the emotional aspect of appetitive behaviors. In another embodiment the subject *TI* molecules are modulated to control weight by modulation of a biochemical pathway involving the Y5 receptor.

Insulin regulates food intake by altering NPY expression in the hypothalamus of the brain (Schwartz et al. (1992) *Endocr Rev.* 13:387). Insulin deficiency, which can be caused, for example, by diabetes, is thought to lead to increased NPY expression in the hypothalamus and to the hyperphagia characteristic of uncontrolled type I diabetes
5 (Sipols et al. (1995) *Diabetes* 44:147). In one embodiment the subject *TI* molecules are modulated to control weight in a subject by modulation of a biochemical pathway involving insulin. In another embodiment, obesity is controlled by modulation of a biochemical pathway involving insulin-like growth factor II (IGF-II).

In other embodiments, the subject *TI* molecules are modulated to affect a
10 bioactivity of tub in order to effect a treatment for weight control. In a preferred embodiment the subject *TI* molecules are modulated to control obesity, diabetes, or cachexia.

In still other embodiments, the subject *TI* molecules are modulated to control apoptosis in a cell. Apoptosis, or programmed cell death, is characterized by distinct
15 morphological changes and can be triggered by a variety of mechanisms. Certain apoptosis-inducing agents stimulate sphingomyelinases, which act on sphingolipids resulting in the generation of phosphocholine and ceramide, a key regulator of cell cycle control and apoptosis (Pushkareva et al. (1995) *Immunology Today* 16:295). Ceramide is thought to act as a second messenger since a soluble analog of ceramide mimics the
20 affects of agents that induce ceramide production (Law and Rossie (1995) *J. Biol. Chem.* 270:12808). Ceramide is thought to control apoptosis via its interaction with the protein phosphatase 2A (PP2A) family of serine/threonine protein phosphatases (Hannun (1994) *J. Biol. Chem.* 269:3125). The catalytic subunit of PP-2A has been shown to be
activated by Ceramide (Law and Rossie, *supra*).

25 In a preferred embodiment the subject *TI* molecules are modulated to control apoptosis in a cell of the PVN of the brain. In one embodiment modulation of the molecules to control apoptosis in the PVN of the brain leads to one or more of weight control and diabetes in a subject.

In one embodiment apoptosis is modulated by modulating the activity of *TI-1* in
30 a cell. In yet another embodiment apoptosis is modulated by modulating the activity of *TI-2* in a cell. In still another embodiment apoptosis is modulated by modulating the activity of *TI-3* in a cell. In another embodiment apoptosis is modulated by modulating *TI-4* activity in a cell. In addition, therapy may involve modulation of any combination of the disclosed *TI* molecules.

35 The present invention will also be useful in treating neurodegenerative diseases which are characterized by apoptosis, including Alzheimer's disease, Parkinson's

disease, Huntington's chorea, amyotrophic lateral sclerosis and the like, as well as spinocerebellar degenerations.

In another embodiment the present invention can be used to modulate a pathway involving integrin-mediated signaling.

5 In another embodiment the subject *TI* molecules are modulated to control cell cycle progression. Entry of cells into mitosis characteristically involves coordinated and simultaneous events, which include, for example, cytoskeletal rearrangements, disassembly of the nuclear envelope and of the nucleoli, and condensation of chromatin into chromosomes. Cell-cycle events are thought to be regulated by a series of
10 interdependent biochemical steps, with the initiation of late events requiring the successful completion of those proceeding them. In eukaryotic cells mitosis does not normally take place until the G1, S and G2 phases of the cell-cycle are completed. For instance, at least two stages in the cell cycle are regulated in response to DNA damage, the G1/S and the G2/M transitions. These transitions serve as checkpoints to which cells
15 delay cell-cycle progress to allow repair of damage before entering either S phase, when damage would be perpetuated, or M phase, when breaks would result in loss of genomic material. Both the G1/S and G2/M checkpoints are known to be under genetic control as there are mutants that abolish arrest or delay which ordinarily occur in wild-type cells in response to DNA damage.

20 Tumor suppressors have also been linked to cell cycle control. For example, both p53 (Green (1989) *Cell* 56:1-3; Mowat et al (1985) *Nature* 314:633-636) and the retinoblastoma gene product (Rb) have been linked to cell cycle control. The first firm evidence for a specific biochemical link between p53 and the cell cycle comes a finding that p53 apparently regulates expression of a second protein, p21, which inhibits cyclin-
25 dependent kinases (cdks) needed to drive cells through the cell cycle, e.g. from G1 into S phase (Xiong et al. (1993) *Nature* 366:701-704). C6 ceramide has been shown to cause dephosphorylation of Rb and Rb deficient cells are more resistant to ceramide-induced growth suppression (Pushkareva et al. supra).

In one embodiment cell cycle progression is modulated by modulating the
30 activity of TI-1 in a cell. In yet another embodiment cell cycle progression is modulated by modulating the activity of TI-2 in a cell. In still another embodiment cell cycle progression is modulated by modulating the activity of TI-3 in a cell. In another embodiment cell cycle progression is modulated by modulating TI-4 in a cell. In addition, therapy may involve modulation of any combination of the disclosed *TI*
35 molecules.

Since, in some cases, genes may be upregulated in a disease state and in other cases may be suppressed, it will be desirable to activate and/or potentiate or suppress

and/or downmodulate *TI* bioactivity depending on the condition to be treated using the techniques compounds and methods described herein.

Among the approaches which may be used to ameliorate disease symptoms involving the misexpression of a *TI* gene are, for example, antisense, ribozyme, and triple helix molecules described above. Compounds that compete with an *TI* protein for binding to upstream or downstream elements in a lipid uptake signaling cascade will antagonize a *TI* protein, thereby inducing a therapeutic effect. Examples of suitable compounds include the antagonists or homologues described in detail above. In other instances, the increased expression or bioactivity of a *TI* protein may be desirable and may be accomplished by, for example the use of the *TI* agonists or mimetics or by gene replacement therapy, as described herein.

Compounds identified as increasing or decreasing *TI* gene expression or protein activity can be administered to a subject at therapeutically effective dose to treat the diseases described herein. A therapeutically effective dose refers to that amount of the compound sufficient to effect a change in a *TI*-associated disorder, such as abnormal weight control and/or diabetes.

Effective Dose

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining The LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine

useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

Formulation and Use

5 Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by, for example, injection, inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal
10 administration.

 For such therapy, the oligomers of the invention can be formulated for a variety of loads of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in *Remington's Pharmaceutical Sciences*, Meade Publishing Co., Easton, PA. For systemic administration, injection is
15 preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the oligomers of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the oligomers may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.

20 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium
25 stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations
30 may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, ationd oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also
35 contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

 Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from
5 pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder
10 mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.* in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or
15 emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.* sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as
20 suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular
25 injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Systemic administration can also be by transmucosal or transdermal means. For
30 transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays or using suppositories. For topical
35 administration, the oligomers of the invention are formulated into ointments, salves, gels, or creams as generally known in the art.

In clinical settings, the gene delivery systems for the therapeutic *TI* gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). A *TI* gene, such as any one of the sequences represented in the group consisting of SEQ ID NOs:1-6 or a sequence homologous thereto can be delivered in a gene therapy construct by electroporation using techniques described, for example, by Dev et al. ((1994) *Cancer Treat. Rev.* 20:105-115).

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

Diagnostic and Prognostic Assays

In the diagnostic and prognostic assays described herein, in addition to the *TI* nucleic acid molecules and polypeptides described above, the present invention provides for the use of a nucleic acid comprising at least a portion of a *TI* nucleic acid molecule, for example, at least a portion of a nucleic acid sequence shown in SEQ ID NOs:1-6 or polypeptides encoded by at least a portion of the nucleic acid sequence shown in SEQ ID NOs:1-6.

The present method provides a method for determining if a subject is at risk for a disorder characterized by apoptosis or aberrant cell proliferation. In preferred embodiments, the methods can be characterized as comprising detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at

least one of (i) an alteration affecting the integrity of a gene encoding a *TI*-protein, or (ii) the mis-expression of the *TI* gene. To illustrate, such genetic lesions can be detected by ascertaining the existence of at least one of (i) a deletion of one or more nucleotides from a *TI* gene, (ii) an addition of one or more nucleotides to a *TI* gene, (iii) a
5 substitution of one or more nucleotides of a *TI* gene, (iv) a gross chromosomal rearrangement of a *TI* gene, (v) a gross alteration in the level of a messenger RNA transcript of a *TI* gene, (vi) aberrant modification of a *TI* gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a *TI* gene, (viii) a non-wild type level of a *TI*-
10 protein, (ix) allelic loss of a *TI* gene, and (x) inappropriate post-translational modification of a *TI*-protein. As set out below, the present invention provides a large number of assay techniques for detecting lesions in a *TI* gene, and importantly, provides the ability to discern between different molecular causes underlying *TI*-dependent aberrant cell growth, proliferation and/or differentiation.

15 In an exemplary embodiment, there is provided a nucleic acid composition comprising a (purified) oligonucleotide probe including a region of nucleotide sequence which is capable of hybridizing to a sense or antisense sequence of a *TI* gene, such as represented by any of SEQ ID NOs:1-6, or naturally occurring mutants thereof, or 5' or 3' flanking sequences or intronic sequences naturally associated with the subject *TI*
20 genes or naturally occurring mutants thereof. The nucleic acid of a cell is rendered accessible for hybridization, the probe is exposed to nucleic acid of the sample, and the hybridization of the probe to the sample nucleic acid is detected. Such techniques can be used to detect lesions at either the genomic or mRNA level, including deletions, substitutions, etc., as well as to determine mRNA transcript levels.

25 As set out above, one aspect of the present invention relates to diagnostic assays for determining, in the context of cells isolated from a patient, if mutations have arisen in one or more *TI* of the sample cells. The present method provides a method for determining if a subject is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In preferred embodiments, the method can be
30 generally characterized as comprising detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by an alteration affecting the integrity of a gene encoding a *TI*. To illustrate, such genetic lesions can be detected by ascertaining the existence of at least one of (i) a deletion of one or more nucleotides from a *TI*-gene, (ii) an addition of one or more nucleotides to a *TI*-gene, (iii) a
35 substitution of one or more nucleotides of a *TI*-gene, and (iv) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a *TI*-gene. As set out below, the

present invention provides a large number of assay techniques for detecting lesions in *TI* genes.

In certain embodiments, detection of the lesion comprises utilizing the probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the *TI*-gene (see Abravaya et al. (1995) *Nuc Acid Res* 23:675-682). In a merely illustrative embodiment, the method includes the steps of (i) collecting a sample of cells from a patient, (ii) isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, (iii) contacting the nucleic acid sample with one or more primers which specifically hybridize to a *TI* gene under conditions such that hybridization and amplification of the *TI*-gene (if present) occurs, and (iv) detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Another embodiment of the invention provides for a nucleic acid composition comprising a (purified) oligonucleotide probe including a region of nucleotide sequence which is capable of hybridizing to a sense or antisense sequence of a *TI*-gene, or naturally occurring mutants thereof, or 5' or 3' flanking sequences or intronic sequences naturally associated with the subject *TI*-genes or naturally occurring mutants thereof. The nucleic acid of a cell is rendered accessible for hybridization, the probe is exposed to nucleic acid of the sample, and the hybridization of the probe to the sample nucleic acid is detected. Such techniques can be used to detect lesions at either the genomic or mRNA level, including deletions, substitutions, etc., as well as to determine mRNA transcript levels. Such oligonucleotide probes can be used for both predictive and therapeutic evaluation of allelic mutations which might be manifest in, for example, apoptosis or aberrant cell growth.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a *TI* gene.

Antibodies directed against wild type or mutant *TI* proteins, which are discussed, above, may also be used in disease diagnostics and prognostics. Such diagnostic methods, may be used to detect abnormalities in the level of *TI* protein expression, or

abnormalities in the structure and/or tissue, cellular, or subcellular location of *TI* protein. Structural differences may include, for example, differences in the size, electronegativity, or antigenicity of the mutant *TI* protein relative to the normal *TI* protein. Protein from the tissue or cell type to be analyzed may easily be detected or isolated using techniques which are well known to one of skill in the art, including but not limited to western blot analysis. For a detailed explanation of methods for carrying out western blot analysis, see Sambrook et al, 1989, supra, at Chapter 18. The protein detection and isolation methods employed herein may also be such as those described in Harlow and Lane, for example, (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety.

This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorimetric detection. The antibodies (or fragments thereof) useful in the present invention may, additionally, be employed histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of *TI* proteins. *In situ* detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody of the present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the *TI* protein, but also its distribution in the examined tissue. Using the present invention, one of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

Often a solid phase support or carrier is used as a support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

One means for labeling an anti-*TI* protein specific antibody is via linkage to an enzyme and use in an enzyme immunoassay (EIA) (Voller, "The Enzyme Linked Immunosorbent Assay (ELISA)", *Diagnostic Horizons* 2:1-7, 1978, Microbiological Associates Quarterly Publication, Walkersville, MD; Voller, et al., J. Clin. Pathol. 31:507-520 (1978); Butler, Meth. Enzymol. 73:482-523 (1981); Maggio, (ed.) *Enzyme Immunoassay*, CRC Press, Boca Raton, FL, 1980; Ishikawa, et al., (eds.) *Enzyme Immunoassay*, Kaku Shoin, Tokyo, 1981). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect fingerprint gene wild type or mutant peptides through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., *Principles of Radioimmunoassays*, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

The antibody can also be detectably labeled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are
5 luminol, isoluminol, therrromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent
10 reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Moreover, it will be understood that any of the above methods for detecting alterations in a *TI* gene or gene product can be used to monitor the course of treatment or
15 therapy.

Drug Screening Assays

In drug screening assays described herein, in addition to the *TI* nucleic acid molecules and polypeptides described above, the present invention also provides for the
20 use of nucleic acid molecules comprising at least a portion of a *TI* nucleic acid molecule, for example, at least a portion of a sequence shown in SEQ ID NOs:1-6 or polypeptides encoded by at least a portion of the nucleic acid sequence shown in any of SEQ ID NOs:1-6.

Furthermore, by making available purified and recombinant *TI* polypeptides, the
25 present invention facilitates the development of assays which can be used to screen for drugs, including homologues, which are either agonists or antagonists of the normal cellular function of the subject polypeptides. In one embodiment, the assay evaluates the ability of a compound to modulate binding between a *TI* polypeptide and a molecule, be it protein or DNA, that interacts either upstream or downstream of the *TI* polypeptide
30 in a lipid transfer pathway. A variety of assay formats will suffice and, in light of the present inventions, will be comprehended by a skilled artisan.

Cell-Free Assays

In many drug screening programs which test libraries of compounds and natural
35 extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins. are often

preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the *in vitro* system, the assay instead being
5 focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with upstream or downstream elements. Accordingly, in an exemplary screening assay of the present invention, the compound of interest is contacted with proteins which may function upstream (including both activators and repressors of its activity) or to proteins or nucleic acids which may function downstream
10 of the *TI* polypeptide, whether they are positively or negatively regulated by it. To the mixture of the compound and the upstream or downstream element is then added a composition containing a *TI* polypeptide. Detection and quantification of complexes of *TI* with its upstream or downstream elements provide a means for determining a compound's efficacy at inhibiting (or potentiating) complex formation between *TI* and
15 the *TI*-binding elements. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, isolated and purified *TI* polypeptide is added to a composition containing the *TI*-binding element, and the formation of a complex is
20 quantitated in the absence of the test compound.

Complex formation between the *TI* polypeptide and a binding element (e.g., Tub) may be detected by a variety of techniques. Modulation of the formation of complexes can be quantitated using, for example, detectably labeled proteins such as radiolabeled, fluorescently labeled, or enzymatically labeled *TI* polypeptides, by immunoassay, or by
25 chromatographic detection.

Typically, it will be desirable to immobilize either *TI* or its binding protein to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of *TI* to an upstream or downstream element, in the presence and absence of a candidate agent, can
30 be accomplished in any vessel suitable for containing the reactants. Examples include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase/*TI* (GST/*TI*) fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or
35 glutathione derivatized microtitre plates, which are then combined with the cell lysates, e.g. an ³⁵S-labeled, and the test compound, and the mixture incubated under conditions conducive to complex formation, e.g. at physiological conditions for salt and pH, though

- 52 -

slightly more stringent conditions may be desired. Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly (e.g. beads placed in scintillant), or in the supernatant after the complexes are subsequently dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of *TI*-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques such as described in the appended examples.

Other techniques for immobilizing proteins on matrices are also available for use in the subject assay. For instance, either *TI* or its cognate binding protein can be immobilized utilizing conjugation of biotin and streptavidin. For instance, biotinylated *TI* molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with *TI* but which do not interfere with binding of upstream or downstream elements can be derivatized to the wells of the plate, and *TI* trapped in the wells by antibody conjugation. As above, preparations of a *TI*-binding protein and a test compound are incubated in the *TI*-presenting wells of the plate, and the amount of complex trapped in the well can be quantitated. Exemplary methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the *TI* binding element, or which are reactive with *TI* protein and compete with the binding element; as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the binding element, either intrinsic or extrinsic activity. In the instance of the latter, the enzyme can be chemically conjugated or provided as a fusion protein with the *TI* binding protein. To illustrate, the *TI* binding protein can be chemically cross-linked or genetically fused with horseradish peroxidase, and the amount of polypeptide trapped in the complex can be assessed with a chromogenic substrate of the enzyme, e.g. 3,3'-diamino-benzadine tetrahydrochloride or 4-chloro-1-naphthol. Likewise, a fusion protein comprising the polypeptide and glutathione-S-transferase can be provided, and complex formation quantitated by detecting the GST activity using 1-chloro-2,4-dinitrobenzene (Habig et al (1974) *J. Biol. Chem.* 249:7130).

For processes which rely on immunodetection for quantitating one of the proteins trapped in the complex, antibodies against the protein, such as anti-*TI* antibodies, can be used. Alternatively, the protein to be detected in the complex can be "epitope tagged" in the form of a fusion protein which includes, in addition to the *TI* sequence, a second polypeptide for which antibodies are readily available (e.g. from

commercial sources). For instance, the GST fusion proteins described above can also be used for quantification of binding using antibodies against the GST moiety. Other useful epitope tags include myc-epitopes (e.g., see Ellison et al. (1991) *J. Biol. Chem.* 266:21150-21157) which includes a 10-residue sequence from c-myc, as well as the pFLAG system (International Biotechnologies, Inc.) or the pEZZ-protein A system (Pharmacia, NJ).

Cell Based Assays

In addition to cell-free assays, such as described above, the readily available *TI* proteins provided by the present invention also facilitates the generation of cell-based assays for identifying small molecule agonists/antagonists and the like. For example, cells which are sensitive to apoptosis can be caused to overexpress a recombinant *TI* protein in the presence and absence of a test agent of interest, with the assay scoring for modulation in *TI* responses by the target cell mediated by the test agent. As with the cell-free assays, agents which produce a statistically significant change in *TI*-dependent responses (either inhibition or potentiation) can be identified. In an illustrative embodiment, the expression or activity of a *TI* is modulated in embryos or cells and the effects of compounds of interest on the readout of interest (such as apoptosis) are measured. For example, the expression of genes which are up- or down-regulated in response to a *TI*-dependent signal cascade can be assayed. In preferred embodiments, the regulatory regions of such genes, e.g., the 5' flanking promoter and enhancer regions, are operably linked to a detectable marker (such as luciferase) which encodes a gene product that can be readily detected.

Further, the transgenic animals described herein may be used to generate cell lines, containing one or more cell types involved in a weight disorder, that can be used as cell culture models for diseases or disorders described herein. While primary cultures derived from transgenic animals of the invention may be utilized, the generation of continuous cell lines is preferred. For examples of techniques which may be used to derive a continuous cell line from the transgenic animals, see Small et al. (1985) *Mol. Cell Biol.* 5:642-648.

In the event that the *TI* proteins themselves, or in complexes with other proteins, are capable of binding DNA and modifying transcription of a gene, a transcriptional based assay could be used, for example, in which a *TI* - responsive regulatory sequence is operably linked to a detectable marker gene.

Monitoring the influence of compounds on cells may be applied not only in basic drug screening, but also in clinical trials. In such clinical trials, the expression of a panel of genes may be used as a "read out" of a particular drug's therapeutic effect.

In yet another aspect of the invention, the subject *TI* polypeptides can be used to generate a "two hybrid" assay (see, for example, U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and PCT Publication No. WO 94/10300), for isolating coding sequences for other cellular proteins which bind to or interact with *TI*, such as the C-terminus of tub, and the like. Briefly, the two hybrid assay relies on reconstituting *in vivo* a functional transcriptional activator protein from two separate fusion proteins. In particular, the method makes use of chimeric genes which express hybrid proteins. To illustrate, a first hybrid gene comprises the coding sequence for a DNA-binding domain of a transcriptional activator fused in frame to the coding sequence for a *TI* polypeptide. The second hybrid protein encodes a transcriptional activation domain fused in frame to a sample gene from a cDNA library. If the bait and sample hybrid proteins are able to interact, e.g., form a *TI*-dependent complex, they bring into close proximity the two domains of the transcriptional activator. This proximity is sufficient to cause transcription of a reporter gene which is operably linked to a transcriptional regulatory site responsive to the transcriptional activator, and expression of the reporter gene can be detected and used to score for the interaction of the *TI* and sample proteins. The use of the subject *TI* molecules in a three hybrid assay which allows for phosphorylation of the assay components, such as for example by the inclusion of src, or the PDGF cytoplasmic domain is also provided for.

Transgenic Animals

These systems may be used in a variety of applications. For example, the cell- and animal-based model systems may be used to further characterize *TI* genes and proteins. In addition, such assays may be utilized as part of screening strategies designed to identify compounds which are capable of ameliorating disease symptoms. Thus, the animal- and cell-based models may be used to identify drugs, pharmaceuticals, therapies and interventions which may be effective in treating disease.

Animal-Based Systems

One aspect of the present invention concerns transgenic animals which are comprised of cells (of that animal) which contain a transgene of the present invention and which preferably (though optionally) express an exogenous *TI* protein in one or more cells in the animal. A *TI* transgene can encode the wild-type form of the protein, or can encode homologues thereof, including both agonists and antagonists, as well as antisense constructs. In preferred embodiments, the expression of the transgene is

restricted to specific subsets of cells, tissues or developmental stages utilizing, for example, cis-acting sequences that control expression in the desired pattern. In the present invention, such mosaic expression of a *Tf* protein can be essential for many forms of lineage analysis and can additionally provide a means to assess the effects of, for example, lack of *Tf* expression which might grossly alter development in small patches of tissue within an otherwise normal embryo. Toward this end, tissue-specific regulatory sequences and conditional regulatory sequences can be used to control expression of the transgene in certain spatial patterns. Moreover, temporal patterns of expression can be provided by, for example, conditional recombination systems or prokaryotic transcriptional regulatory sequences.

Genetic techniques which allow for the expression of transgenes can be regulated via site-specific genetic manipulation *in vivo* are known to those skilled in the art. For instance, genetic systems are available which allow for the regulated expression of a recombinase that catalyzes the genetic recombination a target sequence. As used herein, the phrase "target sequence" refers to a nucleotide sequence that is genetically recombined by a recombinase. The target sequence is flanked by recombinase recognition sequences and is generally either excised or inverted in cells expressing recombinase activity. Recombinase catalyzed recombination events can be designed such that recombination of the target sequence results in either the activation or repression of expression of one of the subject *Tf* proteins. For example, excision of a target sequence which interferes with the expression of a recombinant *Tf* gene, such as one which encodes an antagonistic homologue or an antisense transcript, can be designed to activate expression of that gene. This interference with expression of the protein can result from a variety of mechanisms, such as spatial separation of the *Tf* gene from the promoter element or an internal stop codon. Moreover, the transgene can be made wherein the coding sequence of the gene is flanked by recombinase recognition sequences and is initially transfected into cells in a 3' to 5' orientation with respect to the promoter element. In such an instance, inversion of the target sequence will reorient the subject gene by placing the 5' end of the coding sequence in an orientation with respect to the promoter element which allow for promoter driven transcriptional activation.

The transgenic animals of the present invention all include within a plurality of their cells a transgene of the present invention, which transgene alters the phenotype of the "host cell" with respect to regulation of cell growth, death and/or differentiation. Since it is possible to produce transgenic organisms of the invention utilizing one or more of the transgene constructs described herein, a general description will be given of the production of transgenic organisms by referring generally to exogenous genetic material. This general description can be adapted by those skilled in the art in order to

incorporate specific transgene sequences into organisms utilizing the methods and materials described below.

In an illustrative embodiment, either the *cre/loxP* recombinase system of bacteriophage P1 (Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236; Orban et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6861-6865) or the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355; PCT Publication No. WO 92/15694) can be used to generate *in vivo* site-specific genetic recombination systems. Cre recombinase catalyzes the site-specific recombination of an intervening target sequence located between *loxP* sequences. *loxP* sequences are 34
10 base pair nucleotide repeat sequences to which the Cre recombinase binds and are required for Cre recombinase mediated genetic recombination. The orientation of *loxP* sequences determines whether the intervening target sequence is excised or inverted when Cre recombinase is present (Abremski et al. (1984) *J. Biol. Chem.* 259:1509-1514); catalyzing the excision of the target sequence when the *loxP* sequences are
15 oriented as direct repeats and catalyzes inversion of the target sequence when *loxP* sequences are oriented as inverted repeats.

Accordingly, genetic recombination of the target sequence is dependent on expression of the Cre recombinase. Expression of the recombinase can be regulated by promoter elements which are subject to regulatory control, e.g., tissue-specific,
20 developmental stage-specific, inducible or repressible by externally added agents. This regulated control will result in genetic recombination of the target sequence only in cells where recombinase expression is mediated by the promoter element. Thus, the activation expression of a recombinant *Tl* protein can be regulated via control of recombinase expression.

25 Use of the *cre/loxP* recombinase system to regulate expression of a recombinant *Tl* protein requires the construction of a transgenic animal containing transgenes encoding both the Cre recombinase and the subject protein. Animals containing both the Cre recombinase and a recombinant *Tl* gene can be provided through the construction of "double" transgenic animals. A convenient method for providing such animals is to
30 mate two transgenic animals each containing a transgene, e.g., a *Tl* gene and recombinase gene.

One advantage derived from initially constructing transgenic animals containing a *Tl* transgene in a recombinase-mediated expressible format derives from the likelihood that the subject protein, whether agonistic or antagonistic, can be deleterious upon
35 expression in the transgenic animal. In such an instance, a founder population, in which the subject transgene is silent in all tissues, can be propagated and maintained. Individuals of this founder population can be crossed with animals expressing the

recombinase in, for example, one or more tissues and/or a desired temporal pattern. Thus, the creation of a founder population in which, for example, an antagonistic *Tl* transgene is silent will allow the study of progeny from that founder in which disruption of *Tl* mediated induction in a particular tissue or at certain developmental stages would result in, for example, a lethal phenotype.

Similar conditional transgenes can be provided using prokaryotic promoter sequences which require prokaryotic proteins to be simultaneously expressed in order to facilitate expression of the *Tl* transgene. Exemplary promoters and the corresponding trans-activating prokaryotic proteins are given in U.S. Patent No. 4,833,080.

Moreover, expression of the conditional transgenes can be induced by gene therapy-like methods wherein a gene encoding the trans-activating protein, e.g. a recombinase or a prokaryotic protein, is delivered to the tissue and caused to be expressed, such as in a cell-type specific manner. By this method, a *Tl* transgene could remain silent into adulthood until "turned on" by the introduction of the trans-activator.

In an exemplary embodiment, the "transgenic non-human animals" of the invention are produced by introducing transgenes into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The specific line(s) of any animal used to practice this invention are selected for general good health, good embryo yields, good pronuclear visibility in the embryo, and good reproductive fitness. In addition, the haplotype is a significant factor. For example, when transgenic mice are to be produced, strains such as C57BL/6 or FVB lines are often used (Jackson Laboratory, Bar Harbor, ME). Preferred strains are those with H-2^b, H-2^d or H-2^q haplotypes such as C57BL/6 or DBA/1. The line(s) used to practice this invention may themselves be transgenics, and/or may be knockouts (i.e., obtained from animals which have one or more genes partially or completely suppressed).

In one embodiment, the transgene construct is introduced into a single stage embryo. The zygote is the best target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1-2 pl of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host genome before the first cleavage (Brinster et al. (1985) *Proc. Natl. Acad. Sci. USA* 82:4438-4442). As a consequence, all cells of the transgenic animal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene.

Normally, fertilized embryos are incubated in suitable media until the pronuclei appear. At about this time, the nucleotide sequence comprising the transgene is introduced into the female or male pronucleus as described below. In some species such as mice, the male pronucleus is preferred. It is most preferred that the exogenous genetic material be added to the male DNA complement of the zygote prior to its being processed by the ovum nucleus or the zygote female pronucleus. It is thought that the ovum nucleus or female pronucleus release molecules which affect the male DNA complement, perhaps by replacing the protamines of the male DNA with histones, thereby facilitating the combination of the female and male DNA complements to form the diploid zygote.

Thus, it is preferred that the exogenous genetic material be added to the male complement of DNA or any other complement of DNA prior to its being affected by the female pronucleus. For example, the exogenous genetic material is added to the early male pronucleus, as soon as possible after the formation of the male pronucleus, which is when the male and female pronuclei are well separated and both are located close to the cell membrane. Alternatively, the exogenous genetic material could be added to the nucleus of the sperm after it has been induced to undergo decondensation. Sperm containing the exogenous genetic material can then be added to the ovum or the decondensed sperm could be added to the ovum with the transgene constructs being added as soon as possible thereafter.

Introduction of the transgene nucleotide sequence into the embryo may be accomplished by any means known in the art such as, for example, microinjection, electroporation, or lipofection. Following introduction of the transgene nucleotide sequence into the embryo, the embryo may be incubated *in vitro* for varying amounts of time, or reimplanted into the surrogate host, or both. In vitro incubation to maturity is within the scope of this invention. One common method is to incubate the embryos in vitro for about 1-7 days, depending on the species, and then reimplant them into the surrogate host.

For the purposes of this invention a zygote is essentially the formation of a diploid cell which is capable of developing into a complete organism. Generally, the zygote will be comprised of an egg containing a nucleus formed, either naturally or artificially, by the fusion of two haploid nuclei from a gamete or gametes. Thus, the gamete nuclei must be ones which are naturally compatible, i.e., ones which result in a viable zygote capable of undergoing differentiation and developing into a functioning organism. Generally, a euploid zygote is preferred. If an aneuploid zygote is obtained, then the number of chromosomes should not vary by more than one with respect to the euploid number of the organism from which either gamete originated.

In addition to similar biological considerations, physical ones also govern the amount (e.g., volume) of exogenous genetic material which can be added to the nucleus of the zygote or to the genetic material which forms a part of the zygote nucleus. If no genetic material is removed, then the amount of exogenous genetic material which can be added is limited by the amount which will be absorbed without being physically disruptive. Generally, the volume of exogenous genetic material inserted will not exceed about 10 picoliters. The physical effects of addition must not be so great as to physically destroy the viability of the zygote. The biological limit of the number and variety of DNA sequences will vary depending upon the particular zygote and functions of the exogenous genetic material and will be readily apparent to one skilled in the art, because the genetic material, including the exogenous genetic material, of the resulting zygote must be biologically capable of initiating and maintaining the differentiation and development of the zygote into a functional organism.

The number of copies of the transgene constructs which are added to the zygote is dependent upon the total amount of exogenous genetic material added and will be the amount which enables the genetic transformation to occur. Theoretically only one copy is required; however, generally, numerous copies are utilized, for example, 1,000-20,000 copies of the transgene construct, in order to insure that one copy is functional. As regards the present invention, there will often be an advantage to having more than one functioning copy of each of the inserted exogenous DNA sequences to enhance the phenotypic expression of the exogenous DNA sequences.

Any technique which allows for the addition of the exogenous genetic material into nucleic genetic material can be utilized so long as it is not destructive to the cell, nuclear membrane or other existing cellular or genetic structures. The exogenous genetic material is preferentially inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is known and is used in the art.

Reimplantation is accomplished using standard methods. Usually, the surrogate host is anesthetized, and the embryos are inserted into the oviduct. The number of embryos implanted into a particular host will vary by species, but will usually be comparable to the number of off spring the species naturally produces.

Transgenic offspring of the surrogate host may be screened for the presence and/or expression of the transgene by any suitable method. Screening is often accomplished by Southern blot or Northern blot analysis, using a probe that is complementary to at least a portion of the transgene. Western blot analysis using an antibody against the protein encoded by the transgene may be employed as an alternative or additional method for screening for the presence of the transgene product. Typically, DNA is prepared from tail tissue and analyzed by Southern analysis or PCR for the

transgene. Alternatively, the tissues or cells believed to express the transgene at the highest levels are tested for the presence and expression of the transgene using Southern analysis or PCR, although any tissues or cell types may be used for this analysis.

Alternative or additional methods for evaluating the presence of the transgene
5 include, without limitation, suitable biochemical assays such as enzyme and/or
immunological assays, histological stains for particular marker or enzyme activities,
flow cytometric analysis, and the like. Analysis of the blood may also be useful to
detect the presence of the transgene product in the blood, as well as to evaluate the effect
of the transgene on the levels of various types of blood cells and other blood
10 constituents.

Progeny of the transgenic animals may be obtained by mating the transgenic
animal with a suitable partner, or by *in vitro* fertilization of eggs and/or sperm obtained
from the transgenic animal. Where mating with a partner is to be performed, the partner
may or may not be transgenic and/or a knockout; where it is transgenic, it may contain
15 the same or a different transgene, or both. Alternatively, the partner may be a parental
line. Where *in vitro* fertilization is used, the fertilized embryo may be implanted into a
surrogate host or incubated *in vitro*, or both. Using either method, the progeny may be
evaluated for the presence of the transgene using methods described above, or other
appropriate methods.

20 The transgenic animals produced in accordance with the present invention will
include exogenous genetic material. As set out above, the exogenous genetic material
will, in certain embodiments, be a DNA sequence which results in the production of a *Tf*
protein (either agonistic or antagonistic), and antisense transcript, or a *Tf* mutant.
Further, in such embodiments the sequence will be attached to a transcriptional control
25 element, e.g., a promoter, which preferably allows the expression of the transgene
product in a specific type of cell.

Retroviral infection can also be used to introduce transgene into a non-human
animal. The developing non-human embryo can be cultured *in vitro* to the blastocyst
stage. During this time, the blastomeres can be targets for retroviral infection (Jaenich,
30 R. (1976) *Proc. Natl. Acad. Sci. USA* 73:1260-1264). Efficient infection of the
blastomeres is obtained by enzymatic treatment to remove the zona pellucida
(*Manipulating the Mouse Embryo*, Hogan eds. (Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, 1986). The viral vector system used to introduce the transgene is
typically a replication-defective retrovirus carrying the transgene (Jahner et al. (1985)
35 *Proc. Natl. Acad. Sci.* 82:6927-6931; Van der Putten et al. (1985) *Proc. Natl. Acad. Sci.*
USA 82:6148-6152). Transfection is easily and efficiently obtained by culturing the
blastomeres on a monolayer of virus-producing cells (Van der Putten, *supra*; Stewart et

al. (1987) *EMBO J.* 6:383-388). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (Jahner et al. (1982) *Nature* 298:623-628). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic non-human animal. Further, the founder may contain various retroviral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line by intrauterine retroviral infection of the midgestation embryo (Jahner et al., *supra*).

5 A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured *in vitro* and fused with embryos (Evans et al. (1981) *Nature* 292:154-156; Bradley et al. (1984) *Nature* 309:255-258; Gossler et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:9065-9069; and Robertson et al. (1986) *Nature* 322:445-448). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. For review see Jaenisch, R. (1988) *Science* 240:1468-1474.

10 In one embodiment, gene targeting, which is a method of using homologous recombination to modify an animal's genome, can be used to introduce changes into cultured embryonic stem cells. By targeting a *Tf* gene of interest in ES cells, these changes can be introduced into the germlines of animals to generate chimeras. The gene targeting procedure is accomplished by introducing into tissue culture cells a DNA targeting construct that includes a segment homologous to a target *Tf* locus, and which also includes an intended sequence modification to the *Tf* genomic sequence (e.g., insertion, deletion, point mutation). The treated cells are then screened for accurate targeting to identify and isolate those which have been properly targeted.

25 Gene targeting in embryonic stem cells is in fact a scheme contemplated by the present invention as a means for disrupting a *Tf* gene function through the use of a targeting transgene construct designed to undergo homologous recombination with one or more *Tf* genomic sequences. The targeting construct can be arranged so that, upon recombination with an element of a *Tf* gene, a positive selection marker is inserted into (or replaces) coding sequences of the targeted gene. The inserted sequence functionally disrupts the *Tf* gene, while also providing a positive selection trait. Exemplary *Tf* targeting constructs are described in more detail below.

30 Generally, the embryonic stem cells (ES cells) used to produce the knockout animals will be of the same species as the knockout animal to be generated. Thus for

example, mouse embryonic stem cells will usually be used for generation of knockout mice.

Embryonic stem cells are generated and maintained using methods well known to the skilled artisan such as those described by Doetschman et al. (1985) *J. Embryol. Exp. Morphol.* 87:27-45). Any line of ES cells can be used, however, the line chosen is typically selected for the ability of the cells to integrate into and become part of the germ line of a developing embryo so as to create germ line transmission of the knockout construct. Thus, any ES cell line that is believed to have this capability is suitable for use herein. One mouse strain that is typically used for production of ES cells, is the 129J strain. Another ES cell line is murine cell line D3 (American Type Culture Collection, catalog no. CKL 1934) Still another preferred ES cell line is the WW6 cell line (Ioffe et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:7357-7361). The cells are cultured and prepared for knockout construct insertion using methods well known to the skilled artisan, such as those set forth by Robertson in: *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. IRL Press, Washington, D.C., 1987); by Bradley et al. (1986) *Current Topics in Devel. Biol.* 20:357-371); and by Hogan et al. (Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1986) .

Insertion of the knockout construct into the ES cells can be accomplished using a variety of methods well known in the art including for example, electroporation, microinjection, and calcium phosphate treatment. A preferred method of insertion is electroporation .

Each knockout construct to be inserted into the cell must first be in the linear form. Therefore, if the knockout construct has been inserted into a vector (described *infra*), linearization is accomplished by digesting the DNA with a suitable restriction endonuclease selected to cut only within the vector sequence and not within the knockout construct sequence.

For insertion, the knockout construct is added to the ES cells under appropriate conditions for the insertion method chosen, as is known to the skilled artisan. Where more than one construct is to be introduced into the ES cell, each knockout construct can be introduced simultaneously or one at a time.

If the ES cells are to be electroporated, the ES cells and knockout construct DNA are exposed to an electric pulse using an electroporation machine and following the manufacturer's guidelines for use. After electroporation, the ES cells are typically allowed to recover under suitable incubation conditions. The cells are then screened for the presence of the knockout construct .

Screening can be accomplished using a variety of methods. Where the marker gene is an antibiotic resistance gene, for example, the ES cells may be cultured in the presence of an otherwise lethal concentration of antibiotic. Those ES cells that survive have presumably integrated the knockout construct. If the marker gene is other than an antibiotic resistance gene, a Southern blot of the ES cell genomic DNA can be probed with a sequence of DNA designed to hybridize only to the marker sequence. Alternatively, PCR can be used. Finally, if the marker gene is a gene that encodes an enzyme whose activity can be detected (e.g., β -galactosidase), the enzyme substrate can be added to the cells under suitable conditions, and the enzymatic activity can be analyzed. One skilled in the art will be familiar with other useful markers and the means for detecting their presence in a given cell. All such markers are contemplated as being included within the scope of the teaching of this invention.

The knockout construct may integrate into several locations in the ES cell genome, and may integrate into a different location in each ES cell's genome due to the occurrence of random insertion events. The desired location of insertion is in a complementary position to the DNA sequence to be knocked out, e.g., the *Tf* coding sequence, transcriptional regulatory sequence, etc. Typically, less than about 1-5 % of the ES cells that take up the knockout construct will actually integrate the knockout construct in the desired location. To identify those ES cells with proper integration of the knockout construct, total DNA can be extracted from the ES cells using standard methods. The DNA can then be probed on a Southern blot with a probe or probes designed to hybridize in a specific pattern to genomic DNA digested with particular restriction enzyme(s). Alternatively, or additionally, the genomic DNA can be amplified by PCR with probes specifically designed to amplify DNA fragments of a particular size and sequence (i.e., only those cells containing the knockout construct in the proper position will generate DNA fragments of the proper size).

After suitable ES cells containing the knockout construct in the proper location have been identified, the cells can be inserted into an embryo. Insertion may be accomplished in a variety of ways known to the skilled artisan, however a preferred method is by microinjection. For microinjection, about 10-30 cells are collected into a micropipette and injected into embryos that are at the proper stage of development to permit integration of the foreign ES cell containing the knockout construct into the developing embryo. For instance, as the appended Examples describe, the transformed ES cells can be microinjected into blastocysts.

The suitable stage of development for the embryo used for insertion of ES cells is very species dependent, however for mice it is about 3.5 days. The embryos are obtained by perfusing the uterus of pregnant females. Suitable methods for

accomplishing this are known to the skilled artisan, and are set forth by, e.g., Bradley et al. (*supra*).

While any embryo of the right stage of development is suitable for use, preferred embryos are male. In mice, the preferred embryos also have genes coding for a coat color that is different from the coat color encoded by the ES cell genes. In this way, the offspring can be screened easily for the presence of the knockout construct by looking for mosaic coat color (indicating that the ES cell was incorporated into the developing embryo). Thus, for example, if the ES cell line carries the genes for white fur, the embryo selected will carry genes for black or brown fur.

After the ES cell has been introduced into the embryo, the embryo may be implanted into the uterus of a pseudopregnant foster mother for gestation. While any foster mother may be used, the foster mother is typically selected for her ability to breed and reproduce well, and for her ability to care for the young. Such foster mothers are typically prepared by mating with vasectomized males of the same species. The stage of the pseudopregnant foster mother is important for successful implantation, and it is species dependent. For mice, this stage is about 2-3 days pseudopregnant.

Offspring that are born to the foster mother may be screened initially for mosaic coat color where the coat color selection strategy (as described above, and in the appended examples) has been employed. In addition, or as an alternative, DNA from tail tissue of the offspring may be screened for the presence of the knockout construct using Southern blots and/or PCR as described above. Offspring that appear to be mosaics may then be crossed to each other, if they are believed to carry the knockout construct in their germ line, in order to generate homozygous knockout animals. Homozygotes may be identified by Southern blotting of equivalent amounts of genomic DNA from mice that are the product of this cross, as well as mice that are known heterozygotes and wild type mice.

Other means of identifying and characterizing the knockout offspring are available. For example, Northern blots can be used to probe the mRNA for the presence or absence of transcripts encoding either the gene knocked out, the marker gene, or both. In addition, Western blots can be used to assess the level of expression of the *Tl* gene knocked out in various tissues of the offspring by probing the Western blot with an antibody against the particular *Tl* protein, or an antibody against the marker gene product, where this gene is expressed. Finally, *in situ* analysis (such as fixing the cells and labeling with antibody) and/or FACS (fluorescence activated cell sorting) analysis of various cells from the offspring can be conducted using suitable antibodies to look for the presence or absence of the knockout construct gene product.

Yet other methods of making knock-out or disruption transgenic animals are also generally known. See, for example, *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Recombinase dependent knockouts can also be generated, e.g. by homologous recombination to insert target sequences, such that tissue specific and/or temporal control of inactivation of a *Tf*-gene can be controlled by recombinase sequences (described infra).

Animals containing more than one knockout construct and/or more than one transgene expression construct are prepared in any of several ways. The preferred manner of preparation is to generate a series of mammals, each containing one of the desired transgenic phenotypes. Such animals are bred together through a series of crosses, backcrosses and selections, to ultimately generate a single animal containing all desired knockout constructs and/or expression constructs, where the animal is otherwise congenic (genetically identical) to the wild type except for the presence of the knockout construct(s) and/or transgene(s).

The present invention is further illustrated by the following examples which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application are hereby expressly incorporated by reference.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); *DNA Cloning*, Volumes I and II (D. N. Glover ed., 1985); *Oligonucleotide Synthesis* (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; *Nucleic Acid Hybridization* (B. D. Hames and S. J. Higgins eds.; *Transcription And Translation* (B. D. Hames & S. J. Higgins eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLES

Identification of Tub Interactors

The following materials and methods were used in the Examples:

5 *Yeast strains, Media, and Microbiological Techniques*

Standard yeast media including synthetic complete medium lacking L-leucine, L-tryptophan, and L-histidine were prepared and yeast genetic manipulations were performed as described (Sherman (1991) *Meth. Enzymol.* 194:3-21). Yeast transformations were performed using standard protocols (Gietz et al. (1992) *Nucl. Acids*
10 *Res.* 20:1425. Ito et al, (1983) *J. Bacteriol.* 153:163-168). Plasmid DNAs were isolated from yeast strains by a standard method (Hoffman and Winston (1987) *Gene* 57:267-272).

Western Blotting

15 A total protein extract of TB14 and TB20 was subjected to Western blotting analysis to confirm and qualitatively evaluate expression of the GAL4 DNA-binding domain TUB fusion proteins. The protein extract were prepared by growing TB14 and TB20 in synthetic complete medium lacking L-tryptophan (Sherman (1991) *Meth. Enzymol.* 194:3) to an OD₆₀₀ of 1. The yeast cells from 4.5 ml of culture were
20 collected by centrifugation and the cell pellet was resuspended in 1 ml of 0.25 M NaOH 1% beta-mercaptoethanol and incubated at 4°C for 10 minutes. 160 ml of 50% TCA were then added to the cell suspension and after mixing the suspension was incubated at 4°C for 10 minutes. The suspension was then microfuged at 4°C for 10 minutes, the supernatant fraction was discarded, and the pellet was washed with cold acetone, air
25 dried, and then resuspended in 120 ml of 2X tris-glycine SDS sample buffer (Novex, San Diego, CA) diluted to 1X strength with deionized water.

15µl of the sample was boiled for 2 minutes and then electrophoresed on a 14% tris glycine SDS polyacrylamide gel (Novex) and then transferred to an immobilon PVDF membrane (Millipore; San Francisco, CA). The primary antibody utilized was a
30 rabbit anti-yeast GAL4 DNA-binding domain polyclonal antibody (Upstate Biotechnology Inc., Lake Placid, NY) and the secondary antibody was a donkey anti-rabbit Ig, peroxidase linked species-specific whole antibody (Amersham Life Sciences, Cleveland, OH). Western blotting procedures were essentially as described (Sambrook et al. *Molecular Cloning* 2nd edition. Cold Spring Harbor Laboratory Press. 1989) and
35 proteins interacting with the antibodies were visualized using the ECL detection system (Amersham Life Sciences, Cleveland, OH), essentially as described by the manufacturer.

Expression of the GAL4 DNA-binding domain TUB cytoplasmic domain fusion proteins were detected.

Beta Galactosidase Assays

5 The filter disk beta-galactosidase (beta-gal) assay was performed essentially as previously described (Brill et al. (1994) *Mol. Biol. Cell.* 5:297-312). Briefly, strains to be tested were grown as patches of cells on appropriate medium dictated by the experiment at 30°C overnight. The patches or colonies of cells were replica plated to Whatman #50 paper disks (Schleicher & Schuell, #576; Keene, NH) that had been
10 placed on the test medium in petri dishes. After growth overnight at 30°C, the paper disks were removed from the plates and the cells on them were permeabilized by immediately immersing them in liquid nitrogen for 30 seconds. After this treatment, the paper disks were thawed at room temperature for 20 seconds and then placed in petri dishes that contained a disk of Whatman #3 paper (Schleicher & Schuell, #593, Keene,
15 NH) saturated with 2.5 ml of Z buffer containing 37µl of 2% weight per volume of the chromogenic beta-gal substrate X-gal. The permeabilized strains on the paper disks were incubated at 30°C and inspected at timed intervals for the blue color diagnostic of beta-gal activity in this assay. The assay was stopped by removing the paper disk containing the patches of cells and air drying it.

20

Two Hybrid Screening and Identification of Tub Interactors

Human TUB 184-506 and human TUB 1-506 were cloned into pGBT9 (Clontech, Palo Alto, CA). The human TUB 184-506 was called pGBhTUB and the human TUB 1-506 clone was called pMB71. pGBhTUB and pMB71 were transformed
25 into two-hybrid screening strain HF7c. A pGBhTUB transformant was called TB14 and a pMB71 transformant was called TB20. It was verified that neither human TUB 184-506 nor human TUB 1-506 activated the HIS3 or lacZ reporter genes present in HF7c. Protein extracts from TB14 and TB20 were subjected to Western blot analysis. Human TUB 184-506 was expressed at a high level and human TUB 1-506 was expressed at a
30 very low level.

In one experiment, TB14 was transformed with a human prostate two-hybrid library and 20 million transformants were obtained and in another experiment TB14 was transformed with a mouse T-cell library and 10 million transformants were obtained. TB20 was transformed with a human prostate two-hybrid library and 1.5 million
35 transformants were obtained. By PCR with TUB-specific primers, it was determined that the TUB cDNA was present in these libraries. Transformants were plated on synthetic complete medium lacking leucine, tryptophan, and histidine to select for

- 68 -

transformants expressing cDNA library plasmids encoding TUB-interacting proteins. All colonies that grew on the selective plates were analyzed for beta-galactosidase expression using the filter beta-galactosidase assay and the strongest beta-galactosidase expressing plasmids from each screen were analyzed.

- 5 In the screen where TB14 was transformed with a human prostate two-hybrid library, *E. coli* plasmid ptyhq058; *E. coli* plasmid ptyhq054 and *E. coli* plasmid ptyhq036 were identified. In the screen where TB14 was transformed with a mouse T-cell library, *E. coli* plasmid ptyht101 and *E. coli* plasmid ptyht102, the mouse homologues of *E. coli* plasmid ptyhq036 and *E. coli* plasmid ptyhq054 were identified.
- 10 In the screen where TB20 was transformed with the human prostate library, *E. coli* plasmid ptyhq049 and human serine palmitoyl transferase (GenBank Accession No. U15555) were identified. Human serine palmitoyl transferase is a weak interactor because it activates the HIS3 reporter gene but not the lacZ gene, at least not enough to be detected in the assays. *E. coli* plasmid ptyhq058 appeared to be the strongest
- 15 interactor. All seven of these interactors bind to full length human and mouse TUB and the carboxyl-terminus of human and mouse TUB. In addition, none of these interactors bind to the carboxyl-terminus of human and mouse TUB missing the final 44 amino acids, amino acids lacking in the mutated mouse TUB gene. These seven interactors were found to not bind to several test proteins showing that they bind specifically to
- 20 TUB.

Northern Analysis

Methods

- 25 Total RNA was isolated from various mouse (C57BL/6 wild type and tub/tub) tissues using RNazol B (Tel-Test, Inc., Friendswood, Texas). Poly A+ RNA was isolated from a variety of human and mouse cell lines using the FastTrack system (Invitrogen, San Diego, CA). Extracted RNA was electrophoresed through a formaldehyde gel, transferred to Genescreen nylon membrane (NEN Research Products, Boston, MA) and cross-linked using a Stratalinker apparatus (Stratagene, La Jolla, CA).
- 30 For probing northern blots, 50 ng of the following probes were labelled using Prime-It (Stratagene, La Jolla, CA): human ank; human tpr; human ring; mouse tpr; or mouse ring. Blots were hybridized at 65°C in Church Buffer overnight and washed in 0.2X SSC/0.1% SDS also at 65°C. Filters were exposed to film (X-omat AR, Kodak) for 18-36 hours.

35

Human Tissue Results

Human multiple tissue northern blots (Clontech, Palo Alto, CA) were probed. The human tissues tested included: spleen, thymus, prostate, testes, uterus, small intestine, colon, peripheral blood leukocytes, heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas and retina.

Bands of approximately 2.4 kb and 10 kb were found to be ubiquitously expressed in all tissues tested using the human ank probe. The 2.4 kb band in retinal tissue gave an increased signal. Using the human ring probe, bands of 1.3kb and 2 kb were expressed in all tissues tested. The 2 kb band gave an increased signal in retinal tissue. Hybridization with the human ring probe yielded bands of 3kb and 4kb in all tissues tested. An additional band of 1.4 kb was detected in testes.

Mouse Tissue Results

Mouse tissues were obtained from C57BL/6 and tub/tub animals. Tissues used were: brain, hypothalamus, liver, heart, spleen, stomach, kidney, muscle, fat, and testes. Neither the human ring probe nor the human ank probe yielded any signal in any tissue tested. the mouse tpr probe hybridized with a 1.4 kb band in C57BL/6 testes and a 1.4 kb band in tub/tub brain and testes. The mouse ring probe hybridized with a 2.4 kb and a 3.0 kb band in all tissues tested from both strains of mice and also hybridized with a 1.4 kb band from testes tissue from C57BL/6 and tub/tub mice.

Cell Line Results

Poly A+ RNA was isolated from a variety of ATCC cell lines (including human cell lines SHEP; SHSY5Y; SKNMC (neuroblastoma); SKNSH; Neuro 2A (neuroblastoma), NB412A/8; the human breast carcinoma cell line MCF7 and the mouse fibroblast cell line NIH 3T3). The human ank probe hybridized with a 2.3 kb band in the SHEP, SHSY5Y, SKNMC, SKNSH, and MCF7 cell lines. The same human ank probe lit up a 2 kb band in Neuro 2A and NB412A/8 cells. No signal was detected in the 3T3 cell line. The human tpr probe hybridized with a 2 kb band in all cell lines tested. An additional band of 4.4 kb was detected using this probe in the neuro 2A cells. The human ring probe detected a 2.4 kb band in the SHEP, SHSY5Y, SKNMC, and SKNSH cell lines. No signal was detected in any other of the cell lines using the ring probe.

Deposit of Microorganisms

E. coli plasmid ptyhq049 was deposited with the American Type Culture Collection Rockville, MD, on August 6 1996 under the terms of the Budapest Treaty and assigned Accession Number 98125 (hTI-1).

- 5 *E. coli* plasmid ptyhq058 was deposited with the American Type Culture Collection Rockville, MD, on August 6 1996 under the terms of the Budapest Treaty and assigned Accession Number 98127 (hTI-2).

- 10 *E. coli* plasmid ptyhq036 was deposited with the American Type Culture Collection Rockville, MD, on August 6 1996 under the terms of the Budapest Treaty and assigned Accession Number 98128 (hTI-3).

E. coli plasmid ptyhq054 was deposited with the American Type Culture Collection Rockville, MD, on August 6 1996 under the terms of the Budapest Treaty and assigned Accession Number 98126 (hTI-4).

- 71 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: MILLENNIUM PHARMACEUTICALS, INC.
(B) STREET: 640 MEMORIAL DRIVE
(C) CITY: CAMBRIDGE
(D) STATE: MASSACHUSETTS
(E) COUNTRY: US
(F) POSTAL CODE (ZIP): 02139
(G) TELEPHONE:
(H) TELEFAX:

(ii) TITLE OF INVENTION: WEIGHT CONTROL PATHWAY GENES AND USES
THEREFOR

(iii) NUMBER OF SEQUENCES: 36

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LAHIVE & COCKFIELD, LLP
(B) STREET: 28 STATE STREET
(C) CITY: BOSTON
(D) STATE: MASSACHUSETTS
(E) COUNTRY: US
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/US97/
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/897,340
(B) FILING DATE: 21 JULY 1997
(C) APPLICATION NUMBER: US 08/715,032
(D) FILING DATE: 17 SEPTEMBER 1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: SILVERI, JEAN M.
(B) REGISTRATION NUMBER: 39,030
(C) REFERENCE/DOCKET NUMBER: MNI-005CPPC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617)227-7400
(B) TELEFAX: (617)742-4214

- 72 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1386 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15 GAATTCGGCA CGAGCGCACT CGCAGCCCTG GCAGGCGGCA CTGGTCATGG AAAACGAATT 60
GTTCTGCTCG GGCCTCCTGG TGCATCCGCA GTGGGTGCTG TCAGCCGCAC ACTGTTTCCA 120
GAAGTGAGTG CAGAGCTCCT ACACCATCGG GCTGGGCTTG CACAGTCTTG AGGCCGACCA 180
20 AGAGCCAGGG AGCCAGATGG TGGAGGCCAG CCTCTCCGTA CGGCACCCAG AGTACAACAG 240
ACCCTTGCTC GCTAACGACC TCATGCTCAT CAAGTTGGAC GAATCCGTGT CCGAGTCTGA 300
25 CACCATCCGG AGCATCAGCA TTGCTTCGCA GTGCCCTACC GCGGGGAACT CTTGCCTCGT 360
TTCTGGCTGG GGTCTGCTGG CGAACGGCAG AATGCCTACC GTGCTGCAGT GCGTGAACGT 420
GTGCGTGGTG TCTGAGGAGG TCTGCAGTAA GCTCTATGAC CCGCTGTACC ACCCCAGCAT 480
30 GTTCTGCGCC GCGGAGGGC AAGACCAGAA GGA CTCTGC AACGGTGACT CTGGGGGGCC 540
CCTGATCTGC AACGGGTACT TGCAGGGCCT TGTGTCTTTC GGAAAAGCCC CGTGTGGCCA 600
35 AGTTGGCGTG CCAGGTGTCT ACACCAACCT CTGCAAATTC ACTGAGTGGA TAGAGAAAAC 660
CGTACCAGGC CAGTTAACTC TGGGGACTGG GAACCCATGA AATTGACCCC CAAATACATC 720
CTGCGGAAGG AATTCAGGAA TATCTGTTCC CAGCCCCTCC TCCCTCAGGC YCAGGAGTCC 780
40 AGGCCCCCAG CCCCTCCTCC CTCAAACCAA GGTACAGAT CCCAGCCCC TCCTCCCTCA 840
GACCCAGGAG TCCAGACCCC CCAGCCCCCTC CTCCCTCAGA CCCAGGAGTC CAGCCCCCTC 900
45 TCCCTCAGAC CCAGGAGTCC AGACCCCCCA GCCCCTCCTC CCTCAGACCC AGGGGTCCAG 960
CCTCTCCTCC CTCAGACCCA GGAGTCCAGA CCCCCAGCC CCTCCTCCCT CAGACCCAGG 1020
AGTCCAGCCC CTCCTCCCTC AGACCCAGGA GTCCAGATCC CCCAGCCCCT CCTCCCTCAG 1080
50 ACCCAGGGGT CCAGGCCCCC AACCCCTCCT CCCTCAGACT CAGAGGTCCA AGCCCCAAC 1140
CCCTCCTTCC CCAGACCCAG AGGTCCAGGT ACCAGCCCCT CCTCCCTCAG ACCCAGCGGT 1200
55 CCAATGCCAC CTATACTCTC CCTGTACANA TTGCCNCCTT GTGGCACGTT GACCCAACCT 1260

- 73 -

TACCAGTTGG TTTTTCATT TTTGTCCCTT TCCCCTAGAT CCAGAAATAA AGTTTAAGRG 1320
RAGSGCCAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAACYCG 1380
5 AGAANT 1386

(2) INFORMATION FOR SEQ ID NO:2:

- 10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2103 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
GGATCCGAAT TCGGCACGAG GCGGAGGGAA GTAGGTCCGT TGGTCGGTCG GGAACGAGGC 60
TCAGGCGGCC AGGCCCCGCG GGAGCCGTTG CCATGGCAGC CGCCGCCGGG GACGCGGACG 120
25 ACGAGCCGCG CTCAGGCCAC TCGAGCTCGG AGGGCGAGTG CGCGGTGGCG CCGGAGCCGC 180
TGACTGACGC TGAGGGCCTC TTCTCCTTCG CTGACTTCGG GTCTGCGCTG GGCGGCGGCG 240
30 GCGCGGGCCT CTCGGGCCGG GCGTCCGGCG GGGCCCAGTC GCCGCTGCGC TACTTGACAG 300
TCCTGTGGCA GCAGGATGCG GAGCCGCGCG ACGAGCTGCG CTGCAAGATA CCCGCTGGCC 360
GGCTGAGGCG CGCTGCCAGG CCCACCCGGC GGCTCGGGCC CACGGGCAAG GAGGTGCACG 420
35 CTCTGAAGAG ACTGAGGGAC TCGGCCAATG CCAATGATGT GGAAACAGTG CAGCAGCTGC 480
TGGAAGATGG CGCGGATCCC TGTGCAGCTG ATGACAAGGG CCGCACAGCT CTACACTTTG 540
40 CCTCATGCAA TGGCAATGAC CAGATTGCTG CTCCTGGACC ATGGTGCTGA TCCTAACCAG 600
CGAGATGGGC TGGGGAACAC GCCACTGCAC CTGGCGGCCT GCACCAACCA CGTTCCTGTC 660
ATCACCACAC TGCTACGAGG AGGGGCCCCG GTAGATGCCC TGGACCGAGC TGGTCGCACA 720
45 CCCCTGCACC TGGCCAAGTC AAAGCTGAAT ATCCTGCAGG AGGGCCATGC CCAGTGCCTA 780
GAGGCTGTGC GTCTGGAGGT GAAGCAGATC ATCCATATGC TGAGGGAGTA TCTGGAGCGC 840
50 CTAGGGCAAC ATGAGCAGCG AGAACGCCTG GATGACCTCT GCACCCGCCT GCAGATGACC 900
AGTACCAAAG AGCAGGTGGA TGAAGTGAAT GACCTCCTGG CCAGCTTCAC CTCCCTCAGT 960
55 CTGCAGATGC AGAGCATGGA GAAGAGGTAG CAAGAGAGGC TCCCTGCCTT CCTGCCACTG 1020

- 74 -

CCCCACCCTG CCCCCTGCT GTCTCAGTAC CAAGAAAAAG CCCAACATCT GGGACTTGGA 1080
 GCTGCACTTG TCTGGTGAGG ACCTTGCCCT CACCCGCACA TGCCGTGGGG CAGAGATGCT 1140
 5 CTCTCTCCAC GGCCTCAGAG CCACTCCCAG CCACAGTTTC CAGCATCTCT GTGGACAGGG 1200
 ACCACAGCTC CCAGCTTCTT CCAGTTCTCG CAGCACCAGA CCAGCCTCTG CAGCTGCACT 1260
 10 TCAGCTCCGC AGACCTGCGC TATCTCAGCA GACCTCACTT GCCCCATGGC CTTTCATGGCG 1320
 CGCTCCAGGC CTCAGACCCT TCTCTGTGTT CCGTCCTGGC CATGGGCTTG TTGCAGTCAG 1380
 CAGGTGTGGG CTTAGGCGGG CACCCTGTGG CCAGGGGTAC TGCGTGAGGC CCTCAGTTGG 1440
 15 TCCTGTGCCT CTCACCAGCA CTTAGACAGA CACGTCACCA GACTTTCAAG GAGATACTGC 1500
 AGTGAGTTTC TCTGGTTGGA AGGGGAGGGT TGGTGAGTCC CAGACCTTAA AAATACAAGG 1560
 TTAAGAGGGA CCCCAAAGCA AAAAATTCCA ACCCTTTTCC TCCCAGTCAT TGAAACACCA 1620
 20 AAATATTAT ACCGGAGGGT GTAATAGTTT TGCTGCCAG TTGTGGTAGG CCAGTAGTGG 1680
 CCTCCCAAGA TGCCCATGTC CTAATCCCAG GAACCTGTCA AAATTACCTT GTATGGCCAA 1740
 25 AGGGGCTTTG CAGATGTAAT GAAGTTAAGG ATCTTTGCGC AGGAAGATTA TCCCAGCTTG 1800
 TTCAGGAGGG CTTGATGTCC TCACCCGGGT CTGTATAACA GAAGAGCAGG TGACGGGAGA 1860
 GGAGGTTGGA GGTGTAGCGA TGGAGCAGGA AACTGGAGTT GAGGAGGGCA GCTCAAGCCA 1920
 30 CAGAGTCCAG GCCACCTCAG AGCCAGGAAA TGCATCCTCC CACAGAGCCC TGGAAGGCCC 1980
 CAGCCCTGCT CCCACCTGGA CTGGCTCAGT GAGGCTAATT TTATAATTCT GGCTGATTTT 2040
 35 AGAACTCTAA GGAATAAAT TTGTGTTGTT TTAAGTCAAA AAAAAAAAAA AAAAAAATC 2100
 GAG 2103

(2) INFORMATION FOR SEQ ID NO:3:

40

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1048 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 45 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATTCGGCAC GAGAAAAATG CTAGCTATTA TGGTAATCGA GCAGCCACCT TGATGATGCT 60
 55 TGGAAGGTTT CGGGAAGCTC TTGGAGATGC ACAACAGTCA GTGAGGTTGG ATGACAGTTT 120

- 75 -

TGTCCGGGGA CATCTACGAG AGGGCAAGTG CCACCTCTCT CTGGGGAATG CCATGGCAGC 180
 5 ATGTCGCAGC TTCCAGAGAG CCCTAGAACT GGATCATAAA AATGCTCAGG CACAACAAGA 240
 GTTCAAGAAT GCTAATGCAG TCATGGAATA TGAGAAAATA GCAGAAACAG ATTTTGAGAA 300
 GCGAGATTTT CGGAAGGTTG TTTTCTGCAT GGACCGTGCC CTAGAATTG CCCCTGCCTG 360
 10 CCATCGCTTC AAAATCCTCA AGGCAGAATG TTTAGCAATG CTGGGTCGTT ATCCAGAAGC 420
 ACAGTCTGTG GCTAGTGACA TTCTACGAAT GGATTCCACC AATGCAGATG CTCTGTATGT 480
 ACGAGGTCTT TGCCTTTATT ACGAAGATTG TATTGAGAAG GCAGTTCAGT TTTTCGTACA 540
 15 GGCTCTCAGG ATGGCTCCTG ACCACGAGAA GGCCTGCATT GCCTGCAGAA ATGCCAAAGC 600
 ACTCAAAGCA AAGAAAGAAG ATGGGAATAA AGCATTTAAG GAAGGAAATT ACAAACTAGC 660
 20 ATATGAACTG TACACAGAAG CCCTGGGGAT AGACCCCAAC AATATAAAAA CAAATGCTAA 720
 ACTCTACTGT AATCGGGGTA CGGTTAATTC CAAGCTTAGG AAAGTAGATG ATGCAATAGA 780
 AACTGCACA AATGCAGTGA AGCTTGATGA CACTTACATA AAAGCCTACT TGAGAAGAGC 840
 25 TCAGTGTTAC ATGGACACAG AACAGTATGA AGAAGCAGTA CGAGACTATG AAAAAGTATA 900
 CCAGACAGAG AAAACAAAAG AACACAAACA GTCCTAAAAA AATGCGCAAC TTAAGTTTAG 960
 30 AAATTACAAG TTTCAGTAAT AGCTGAACCT GTTCAAAATG TTAATAAAGG TTTCGTTGCA 1020
 TGGTAGCATA AAAAAAAAAA AAAAAAAAAA 1048

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1700 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCGAGATTTA CCCATAGATA TGTGTCCTAA CAATGCCAGC TATTACGGTA ATCGAGCGGC 60
 50 CACACTGATG ATGCTTGGAC GGTTCGGGGA AGCTCTTGGA GATGCGCAGC AGTCTGTGAG 120
 GTTGGATGAC AGTTTGTGCC GGGGACACCT CCGAGAAGGC AAGTGCCACC TCTCACTTGG 180
 55 GAATGCAATG GCGGCATGTC GTAGTTTCCA AAGAGCCCTA GAACTGGATC ATAAAAATGC 240

- 76 -

CCAGGCACAG CAGGAGTTCA AGAACGCCAA TGCCGTCATG GAGTATGAGA AAATAGCAGA 300
 AGTGGATTTT GAAAAGCGAG ATTTCCGGAA GGTTGTTTTT TGCATGGACC GTGCCCTAGA 360
 5 ATTTGCCCTT GCCTGCCATC GATTCAAAAT TCTCAAAGCA GAATGTTTAG CAATGCTTGG 420
 TCGATACCCA GAAGCACAGT TTGTGGCCAG TGACATTTTA CGAATGGATT CCACCAATGC 480
 10 TGATGCTCTG TATGTCCGGG GTCTTTGCCT TTATTACGAA GATTGTATTG AGAAGGCAGT 540
 GCAGTTTTTT GTACAGGCTC TCAGGATGGC TCCTGACCAC GAGAAGGCTT GTGTCGCTTG 600
 TAGAAATGCC AAAGCCCTTA AAGCCAAGAA GGAAGATGGG AATAAAGCCT TTAAGGAAGG 660
 15 AAATTACAAG CTAGCATATG AACTGTACAC AGAAGCCTTG GGGATAGATC CCAACAACAT 720
 AAAAACAAAT GCTAACTCT ACTGTAATCG GGGTACGGT AATTCCAAGC TTAGGCAACT 780
 20 GGAAGATGCC ATAGAAGACT GTACAAATGC GGTGAAGCTC GATGACACTT ACATCAAAGC 840
 CTACCTGAGA AGAGCTCAGT GTTACATGGA CACAGAGCAG TTTGAAGAAG CCGTGC GGGA 900
 CTATGAAAAA GTGTATCAGA CGGAGAAAAC AAAAGAACAC AAACAGCTCC TTAAGAATGC 960
 25 ACAGCTGGAA CTGAAGAAGA GCAAGAGGAA AGATTACTAC AAGATCCTGG GAGTGGACAA 1020
 GAATGCCTCT GAGGACGAGA TCAAGAAAGC TTACCGGAAA CGGGCCTTGA TGCACCATCC 1080
 30 AGATCGGCAC AGTGGGGCCA GTGCCGAAGT TCAGAAGGAG GAGGAGAAGA AGTTTAAGGA 1140
 AGTGGGAGAG GCCTTTACCA TCCTCTCTGA TCCCAAGAAA AAGACTCGTT ATGACAGTGG 1200
 ACAGGACTTG GATGAGGAGG GCATGAATAT GGGCGATTTT GATGCAAACA ACATCTTCAA 1260
 35 GGCATTCTTC GGTGGTCCTG GGGGCTTCAG CTTTGAAGCA TCTGGCCCAG GGAATTTCTA 1320
 CTTTCAGTTT GGCTAATGAA GGCCAACCTAC TTAAAACCCA GAAAATGCAG ACTTGCTTGG 1380
 40 TTAAACCATG AGTGTGGACA GTTCACTTCC TCCATCATGT CCCTGTGTAC TTATAGCAGT 1440
 NTCGTTTTCT CAGTCGGGTG CCCTGTGTCT GTATGAGGGG TGAAGAAAAG GGGGCCAGTG 1500
 CTGAGGACTA GGGAGGGATG GAAGCCANGG GTAKACAGGG AAGCAGGCAG CTTGTGAATT 1560
 45 TTTGTTGTAT TGTTTAACTT TATTAAAAAA GAAAAACAAT ACTGTAAAWT WTAAAAAGGA 1620
 AAAGRATTAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1680
 AAAAAAAAAA AAAGGTAAAT 1700
 50

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1248 base pairs

(B) TYPE: nucleic acid

55

- 77 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

10	ACGAGCGGTG ACGGCCGGGT AGGCTGTAGG CAGCGCAATG CCAAGACAGA GCTGCTGGCG	60
	GCGGCGGGCG AATCTCCCTG CACCATGAGC CTCGGCTCCG GCCCCGTTAG GGGCCGATAA	120
	GCACAGCGCA CGCCGCCCTC CATTTGCCCC GGGGCTCGG CTGCGAAGAT AGCGGCGGCC	180
15	GGACAGGAAG CTCGAGGAAA GCGCTGGGCC GGGTCTCTAC GAACACGTGA AGGAAAAGCA	240
	GCTCCGTCCA CAACGCCGCT TCGGGGCTCC TAGGGAGTCG GGGCCGGGC CGCCACCGTC	300
20	ACCTCCGGCC GCTGCCGCTG TCGCCATCGC CTTGTTTCCC CATCCCCGC CATGGCCGAG	360
	GACCTCTCTG CGGCCACGTC CTACACCGAA GATGATTCT ACTGCCCCGT CTGTCAGGAG	420
	GTGCTCAAAA CGCCCGTGCG GACCACGGCC TGTCAGCACG TTTTCTGTAG AAAATGTTTC	480
25	CTGACTGCAA TGAGGGAAAG CGGAGCACAT TGTCCCCTAT GTCGTGAAA TGTGACTAGA	540
	AGAGAGAGAG CATGTCCTGA ACGGGCCTTA GACCTTGAAA ATATAATGAG GAAGTTTCT	600
30	GGTAGCTGCA GATGCTGTGC AAAACAGATT AAATTCTATC GCATGAGACA TCATTACAAA	660
	TCTTGTAAGA AGTATCAGGA TGAATATGGT GTTCTTCTA TCATTCCAAA CTTTCAGATC	720
	TCTCAAGATT CAGTAGGGAA CAGCAATAGG AGTGAAACAT CCACATCTGA TAACACAGAA	780
35	ACTTACCAAG AGAATACAAG TTCTTCTGGT CATCCTACTT TTAAGTGTC CCTGTGTCAA	840
	GAATCAAATT TTACCAGACA GCGTTTACTG GATCACTGTA ACAGTAATCA CCTATTTTCTAG	900
40	ATAGTTCCTG TGACATGTCC TATTTGTGTG TCTCTTCCTT GGGGAGATCC TAGCCAGATT	960
	ACCAGAAATT TCGTTAGTCA TCTAAATCAG AGACATCAAT TTGATTATGG AGAATTTGTG	1020
	AATCTTCAGC TAGATGAAGA AACCAATAC CAACTGCTG TTGAAGAATT TTTTCAAGTA	1080
45	AACATTTGAA GGCTGTAGAC ATTTTTCAT TTTTGTACCT GCAAGTGCCA TCTTTAAGGG	1140
	GGAAAMTACA TGAAGTCACC GTTACAGTAA CTTGATGTGT ATATTAATAA AAGTAATTCA	1200
50	GTCTMAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1248

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

55

(A) LENGTH: 2121 base pairs

- 78 -

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

10 AGTTCACCTA CCACCACCAC CTCGGCTCCT GCCGGCGCCG TCGCCTCTCC CGCCCACCCC 60
TCGCCATGTC CGAGGAACTT TCGGCGGCCA CGTCCTACAC GGAAGATGAT TTCTACTGCC 120
15 CTGTCTGTCA GGAGGTGCTC AAGACGCCGG TCGGACCGC GGCCTGTCAG CACGTTTCT 180
GTAGAAAATG TTTCTGACT GCAATGAGAG AAAGTGAAT ACATTGTCCC CTATGTCGTG 240
GAAGTGTGAC TAGAAGAGAA AGAGCATGTC CGGAACGGC CTTAGATCTT GAAAATATCA 300
20 TGAGGAGGTT TTCTGGTAGC TGCAGATGCT GTTCAAAAAA GATTAAATTC TATCGCATGA 360
GACATCATTA CAAATCTTGT AAGAAGTATC AGGATGAATA TGGTGTTTCT TCTGTCATTC 420
25 CAACTTTAA GATTCTCAA GATTCAGTAA GGAGCAGTAA TAGGAGTGAA ACATCTGCAT 480
CTGATAACAC AGAACTTAT CAAGAGGATA CAAGTTCTTC TGGGCATCCT ACCTTTAAGT 540
GTCCCTTATG TCAAGAGTCA AATTCACCA GACAACGTTT ATTGGATCAC TGTAATAGTA 600
30 ACCACCTATT TCAGATAGTT CCTGTGACAT GTCCTATTTG TGTGTCTCTT CCTTGGGGAG 660
ATCCTAGCCA GATTACTAGA AATTCGTTA GTCATCTAAA TCAAAGACAT CAGTTTGATT 720
35 ATGGAGAATT TGTGAATCTT CAGCTAGATG AGGAAACCCA ATATCAAAC GCTGTGGAAG 780
AGTCTTTTCA AGTAAACATG TGACATGTAT AGACATCTCT GCCTCCTGC AACCTACAAG 840
TGCCATCTTT AAGGAGAAGA CATGAAGTCA CCATTTTCAG TAATTGCTG TGCATATTAA 900
40 TAAAAATAAT AATTCAGTCT ACTGTATTAG GTTTTAAAT GAAAATAAAG GTGGGCCACC 960
CTAATACCAT TCTCTAGACA GTTACTTTAA CAGCATGGAA AGGGTTGTAT TTCACTTGTG 1020
45 TGGTGAAAAG AGAATCTCTG TTGTCTTTT CTTCCTTGTA TTACATATTC TCAATGTTTC 1080
ATTAAGTTGT TTTTGGTATT TGATATAGTT CCTTCTGTTT AGTACAGAGA TAACAGCAAA 1140
TTCTGAACGA TGTGATTCTT AAAAAGCTAA TAAACCTGAG CCATTTGTCA GAGCTGTAGA 1200
50 ATGGAACTT GAAGTGTGAA GTGGGATAAT CCAAAGGGAT TTTTTTTTAA AGTATAGATT 1260
CTAGCTGAGG AATTCAACAA TAAGAAAGTT GTATTTATGT AATGTTTAGT ATTTTGAAG 1320
55 ACTAGTGAGA TTTCTTTAAT AATTTTACT TTGAAAGCAT ATTGTACAAA TGTTTCTTCT 1380

- 79 -

TTTGCTATTA GAAGAACATC AAGAGAAGTT TCCTTTGGTG GTTAGTTTGT TATTTCAATC 1440
 5 TAGGTTGAAT AATTTGTAAG CCTAAATGTT ATATACCACA GTTCTTTGTA GTCAGTATTT 1500
 CTCACTGGGT GATGAAACTT TTCAGCCAGT GAATGATACA TTCAATTAGT TTTTAAAAA 1560
 TCCAAAGTTG CAGATGTATG TGGATATGTA CATAGACTTT TGCATGTATA TATACACATA 1620
 10 TATATCTTTG CCTAGAGTTT GTCAGGTTAT GTATAGAATT TCTATTAAAA AGTTTAAATA 1680
 ATGGACAAGC AATATAGGAT TGAAGTATTT ATCTCCTTTG TTTAAAATTT TGTATGTTAC 1740
 CAAGTTTTTA AAACAGTAAG CCAAATACTA TGTGGTACAG TTGGCTGTTA TTACACCTGA 1800
 15 AAAATGTAA ATGGTGCTCA CTTGTTACGT TTGAAAATGA TGCATAACTG ACGTGTGGTG 1860
 AGAGATTTTA CCAGCTACTG TTTCACTACA TTTTAGTCAA AACAAAGTTT GTTCTTAATC 1920
 20 TTTGGTATAA AGTGTGTAG AGAAGGCCAA GTCACAAAGT AAAGGGTGAA GGGGGAATTC 1980
 TGACATTCCA CACTAACATA ACACTGTTAT GCTTTCTTTA AAATAACTAA CCGCAAAAGA 2040
 AAATCTCTGA AGTAGTTTGC TGCTAATATA TACATATATT GTAAAAAAA AAGGTATATT 2100
 25 TTGATTTTCT GGTAATCTC G 2121

30

(2) INFORMATION FOR SEQ ID NO:7:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCTCGAGCTT CCTGTCC

17

(2) INFORMATION FOR SEQ ID NO:8:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 55 (D) TOPOLOGY: linear

- 80 -

(ii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AUGGCGACUG AUGAGCUCAC UAGAGCGAAA GCGGCA

36

10 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGTGAAGGAA AAGCAGC

17

25 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
30 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTAGAAATCA TCTTCGG

17

40

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
45 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

55 TGGAAACTAC GACATGCC

18

- 81 -

(2) INFORMATION FOR SEQ ID NO:12:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

15 CCUUCCGCUG AUGAGCUCAC UAGAGCGAAA AAUCUC

36

(2) INFORMATION FOR SEQ ID NO:13:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 25 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

30 GTAGTTTCCA AAGAGCCC

18

(2) INFORMATION FOR SEQ ID NO:14:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 40 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

45 CATACTCCAT GACGGCA

17

(2) INFORMATION FOR SEQ ID NO:15:

- 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
55 (C) STRANDEDNESS: single

- 82 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TATGATCCAG TTCTAGGG

18

10

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

25 CAAAUUCCUG AUGAGCUCAC UAGAGCGAAA GGGCAC

36

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

40

CAAGAATGCT AATGCAG

17

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

45

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

- 83 -

GCTTCTGGAT AACGACCC

18

(2) INFORMATION FOR SEQ ID NO:19:

5

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGTACGGAGA GGCTGG

16

20 (2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GCACUGCCUG AUGAGCUCAC UAGAGCGAAA AGCAAU

35

36

(2) INFORMATION FOR SEQ ID NO:21:

40

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: cDNA

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GAGCTCCTAC ACCATCGG

18

55 (2) INFORMATION FOR SEQ ID NO:22:

- 84 -

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 16 base pairs
 (B) TYPE: nucleic acid
5 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

15 TCAGACTCGG ACACGG 16

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
20 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

30 GGCGTCTTGA GCACCTCC 18

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
35 (A) LENGTH: 36 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

45 GACAAUGCUG AUGAGCUCAC UAGAGCGAAA UCCAC 36

(2) INFORMATION FOR SEQ ID NO:25:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
55 (D) TOPOLOGY: linear

- 85 -

(ii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CCTGTCAGCA CGTTTTC

17

10 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CCCGTTCCGG ACATGCTC

18

25

(2) INFORMATION FOR SEQ ID NO:27:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CCCTCAGCGT CAGTCAGC

18

45

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

55

- 86 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CAGCGCACUG AUGAGCUCAC UAGAGCGAAA CCCGAA

36

5 (2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GCGGAGCCGT TGCCATGG

18

20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

25 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

35 TCAGCGAAGG AGAAGAGG

18

40 2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 232 amino acids

45 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

50 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

55 Asn Ser Ala Arg Ala His Ser Gln Pro Trp Gln Ala Ala Leu Val Met

Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val
 20 25 30

Leu Ser Ala Ala His Cys Phe Gln Lys Xaa Val Gln Ser Ser Tyr Thr
 35 40 45

Ile Gly Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser
 50 55 60

Gln Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg
65 70 75 80

Pro Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val
 85 90 95

Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro
 100 105 110

Thr Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn
 115 120 125

Gly Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser
 130 135 140

Glu Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met
145 150 155 160

Phe Cys Ala Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp
 165 170 175

Ser Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser
 180 185 190

Phe Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr
 195 200 205

Asn Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Pro Gly Gln
 210 215 220

Leu Thr Leu Gly Thr Gly Asn Pro
225 230

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 300 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

- 88 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

5	Met	Ala	Ala	Ala	Ala	Gly	Asp	Ala	Asp	Asp	Glu	Pro	Arg	Ser	Gly	His	1	5	10	15
10	Ser	Ser	Ser	Glu	Gly	Glu	Cys	Ala	Val	Ala	Pro	Glu	Pro	Leu	Thr	Asp	20	25	30	
	Ala	Glu	Gly	Leu	Phe	Ser	Phe	Ala	Asp	Phe	Gly	Ser	Ala	Leu	Gly	Gly	35	40	45	
15	Gly	Gly	Ala	Gly	Leu	Ser	Gly	Arg	Ala	Ser	Gly	Gly	Ala	Gln	Ser	Pro	50	55	60	
	Leu	Arg	Tyr	Leu	His	Val	Leu	Trp	Gln	Gln	Asp	Ala	Glu	Pro	Arg	Asp	65	70	75	80
20	Glu	Leu	Arg	Cys	Lys	Ile	Pro	Ala	Gly	Arg	Leu	Arg	Arg	Ala	Ala	Arg	85	90	95	
	Pro	His	Arg	Arg	Leu	Gly	Pro	Thr	Gly	Lys	Glu	Val	His	Ala	Leu	Lys	100	105	110	
	Arg	Leu	Arg	Asp	Ser	Ala	Asn	Ala	Asn	Asp	Val	Glu	Thr	Val	Gln	Gln	115	120	125	
30	Leu	Leu	Glu	Asp	Gly	Ala	Asp	Pro	Cys	Ala	Ala	Asp	Asp	Lys	Gly	Arg	130	135	140	
	Thr	Ala	Leu	His	Phe	Ala	Ser	Cys	Asn	Gly	Asn	Asp	Gln	Ile	Val	Gln	145	150	155	160
35	Leu	Leu	Leu	Asp	His	Gly	Ala	Asp	Pro	Asn	Gln	Arg	Asp	Gly	Leu	Gly	165	170	175	
	Asn	Thr	Pro	Leu	His	Leu	Ala	Ala	Cys	Thr	Asn	His	Val	Pro	Val	Ile	180	185	190	
40	Thr	Thr	Leu	Leu	Arg	Gly	Gly	Ala	Arg	Val	Asp	Ala	Leu	Asp	Arg	Ala	195	200	205	
	Gly	Arg	Thr	Pro	Leu	His	Leu	Ala	Lys	Ser	Lys	Leu	Asn	Ile	Leu	Gln	210	215	220	
	Glu	Gly	His	Ala	Gln	Cys	Leu	Glu	Ala	Val	Arg	Leu	Glu	Val	Lys	Gln	225	230	235	240
50	Ile	Ile	His	Met	Leu	Arg	Glu	Tyr	Leu	Glu	Arg	Leu	Gly	Gln	His	Glu	245	250	255	
	Gln	Arg	Glu	Arg	Leu	Asp	Asp	Leu	Cys	Thr	Arg	Leu	Gln	Met	Thr	Ser	260	265	270	

- 89 -

Thr Lys Glu Gln Val Asp Glu Val Thr Asp Leu Leu Ala Ser Phe Thr
 275 280 285

5 Ser Leu Ser Leu Gln Met Gln Ser Met Glu Lys Arg
 290 295 300

(2) INFORMATION FOR SEQ ID NO:33:

10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 308 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide
 (v) FRAGMENT TYPE: internal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Met Leu Gly Arg Phe Arg Glu Ala Leu Gly Asp Ala Gln Gln Ser
 1 5 10 15
 25 Val Arg Leu Asp Asp Ser Phe Val Arg Gly His Leu Arg Glu Gly Lys
 20 25 30
 30 Cys His Leu Ser Leu Gly Asn Ala Met Ala Ala Cys Arg Ser Phe Gln
 35 40 45
 Arg Ala Leu Glu Leu Asp His Lys Asn Ala Gln Ala Gln Gln Glu Phe
 50 55 60
 35 Lys Asn Ala Asn Ala Val Met Glu Tyr Glu Lys Ile Ala Glu Thr Asp
 65 70 75 80
 Phe Glu Lys Arg Asp Phe Arg Lys Val Val Phe Cys Met Asp Arg Ala
 85 90 95
 40 Leu Glu Phe Ala Pro Ala Cys His Arg Phe Lys Ile Leu Lys Ala Glu
 100 105 110
 45 Cys Leu Ala Met Leu Gly Arg Tyr Pro Glu Ala Gln Ser Val Ala Ser
 115 120 125
 Asp Ile Leu Arg Met Asp Ser Thr Asn Ala Asp Ala Leu Tyr Val Arg
 130 135 140
 50 Gly Leu Cys Leu Tyr Tyr Glu Asp Cys Ile Glu Lys Ala Val Gln Phe
 145 150 155 160
 Phe Val Gln Ala Leu Arg Met Ala Pro Asp His Glu Lys Ala Cys Ile
 165 170 175
 55

- 90 -

Ala Cys Arg Asn Ala Lys Ala Leu Lys Ala Lys Lys Glu Asp Gly Asn
180 185 190

5 Lys Ala Phe Lys Glu Gly Asn Tyr Lys Leu Ala Tyr Glu Leu Tyr Thr
195 200 205

Glu Ala Leu Gly Ile Asp Pro Asn Asn Ile Lys Thr Asn Ala Lys Leu
210 215 220

10 Tyr Cys Asn Arg Gly Thr Val Asn Ser Lys Leu Arg Lys Leu Asp Asp
225 230 235 240

Ala Ile Glu Asp Cys Thr Asn Ala Val Lys Leu Asp Asp Thr Tyr Ile
245 250 255

15 Lys Ala Tyr Leu Arg Arg Ala Gln Cys Tyr Met Asp Thr Glu Gln Tyr
260 265 270

Glu Glu Ala Val Arg Asp Tyr Glu Lys Val Tyr Gln Thr Glu Lys Thr
20 275 280 285

Lys Glu His Lys Gln Leu Leu Lys Asn Ala Gln Leu Lys Phe Arg Asn
290 295 300

25 Tyr Lys Phe Gln
305

(2) INFORMATION FOR SEQ ID NO:34:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 438 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Met Cys Pro Asn Asn Ala Ser Tyr Tyr Gly Asn Arg Ala Ala Thr Leu
1 5 10 15

45 Met Met Leu Gly Arg Phe Arg Glu Ala Leu Gly Asp Ala Gln Gln Ser
20 25 30

Val Arg Leu Asp Asp Ser Phe Val Arg Gly His Leu Arg Glu Gly Lys
50 35 40 45

Cys His Leu Ser Leu Gly Asn Ala Met Ala Ala Cys Arg Ser Phe Gln
50 55 60

55 Arg Ala Leu Glu Leu Asp His Lys Asn Ala Gln Ala Gln Gln Glu Phe

- 91 -

	65		70		75		80
	Lys	Asn	Ala	Asn	Ala	Val	Met
			85				90
5							95
	Phe	Glu	Lys	Arg	Asp	Phe	Arg
			100				105
							110
10	Leu	Glu	Phe	Ala	Pro	Ala	Cys
			115				120
							125
	Cys	Leu	Ala	Met	Leu	Gly	Arg
			130				135
							140
15	Asp	Ile	Leu	Arg	Met	Asp	Ser
			145				150
							155
							160
	Gly	Leu	Cys	Leu	Tyr	Tyr	Glu
							165
20							170
							175
	Phe	Val	Gln	Ala	Leu	Arg	Met
							180
							185
							190
25	Ala	Cys	Arg	Asn	Ala	Lys	Ala
							195
							200
							205
	Lys	Ala	Phe	Lys	Glu	Gly	Asn
							210
							215
							220
30	Glu	Ala	Leu	Gly	Ile	Asp	Pro
							225
							230
							235
	Tyr	Cys	Asn	Arg	Gly	Thr	Val
							245
35							250
							255
	Ala	Ile	Glu	Asp	Cys	Thr	Asn
							260
							265
							270
40	Lys	Ala	Tyr	Leu	Arg	Arg	Ala
							275
							280
							285
	Glu	Glu	Ala	Val	Arg	Asp	Tyr
							290
							295
							300
45	Lys	Glu	His	Lys	Gln	Leu	Leu
							305
							310
							315
							320
	Ser	Lys	Arg	Lys	Asp	Tyr	Tyr
							325
							330
							335
50	Ser	Glu	Asp	Glu	Ile	Lys	Lys
							340
							345
							350
55	His	Pro	Asp	Arg	His	Ser	Gly
							355
							360
							365

- 92 -

Glu Lys Lys Phe Lys Glu Val Gly Glu Ala Phe Thr Ile Leu Ser Asp
 370 375 380
 5 Pro Lys Lys Lys Thr Arg Tyr Asp Ser Gly Gln Asp Leu Asp Glu Glu
 385 390 395 400
 Gly Met Asn Met Gly Asp Phe Asp Ala Asn Asn Ile Phe Lys Ala Phe
 405 410 415
 10 Phe Gly Gly Pro Gly Gly Phe Ser Phe Glu Ala Ser Gly Pro Gly Asn
 420 425 430
 Phe Tyr Phe Gln Phe Gly
 15 435

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
 20 (A) LENGTH: 245 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
 25 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Met Ala Glu Asp Leu Ser Ala Ala Thr Ser Tyr Thr Glu Asp Asp Phe
 1 5 10 15
 35 Tyr Cys Pro Val Cys Gln Glu Val Leu Lys Thr Pro Val Arg Thr Thr
 20 25 30
 Ala Cys Gln His Val Phe Cys Arg Lys Cys Phe Leu Thr Ala Met Arg
 35 40 45
 40 Glu Ser Gly Ala His Cys Pro Leu Cys Arg Gly Asn Val Thr Arg Arg
 50 55 60
 Glu Arg Ala Cys Pro Glu Arg Ala Leu Asp Leu Glu Asn Ile Met Arg
 45 65 70 75 80
 Lys Phe Ser Gly Ser Cys Arg Cys Cys Ala Lys Gln Ile Lys Phe Tyr
 85 90 95
 50 Arg Met Arg His His Tyr Lys Ser Cys Lys Lys Tyr Gln Asp Glu Tyr
 100 105 110
 Gly Val Ser Ser Ile Ile Pro Asn Phe Gln Ile Ser Gln Asp Ser Val
 115 120 125
 55

- 93 -

Gly Asn Ser Asn Arg Ser Glu Thr Ser Thr Ser Asp Asn Thr Glu Thr
 130 135 140
 Tyr Gln Glu Asn Thr Ser Ser Ser Gly His Pro Thr Phe Lys Cys Pro
 145 150 155 160
 Leu Cys Gln Glu Ser Asn Phe Thr Arg Gln Arg Leu Leu Asp His Cys
 165 170 175
 Asn Ser Asn His Leu Phe Gln Ile Val Pro Val Thr Cys Pro Ile Cys
 180 185 190
 Val Ser Leu Pro Trp Gly Asp Pro Ser Gln Ile Thr Arg Asn Phe Val
 195 200 205
 Ser His Leu Asn Gln Arg His Gln Phe Asp Tyr Gly Glu Phe Val Asn
 210 215 220
 Leu Gln Leu Asp Glu Glu Thr Gln Tyr Gln Thr Ala Val Glu Glu Phe
 225 230 235 240
 Phe Gln Val Asn Ile
 245
 (2) INFORMATION FOR SEQ ID NO:36:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 245 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (v) FRAGMENT TYPE: internal
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
 Met Ser Glu Glu Leu Ser Ala Ala Thr Ser Tyr Thr Glu Asp Asp Phe
 1 5 10 15
 Tyr Cys Pro Val Cys Gln Glu Val Leu Lys Thr Pro Val Arg Thr Ala
 20 25 30
 Ala Cys Gln His Val Phe Cys Arg Lys Cys Phe Leu Thr Ala Met Arg
 35 40 45
 Glu Ser Gly Ile His Cys Pro Leu Cys Arg Gly Ser Val Thr Arg Arg
 50 55 60
 Glu Arg Ala Cys Pro Glu Arg Ala Leu Asp Leu Glu Asn Ile Met Arg
 65 70 75 80
 Arg Phe Ser Gly Ser Cys Arg Cys Cys Ser Lys Lys Ile Lys Phe Tyr

- 94 -

	85	90	95
	Arg Met Arg His His Tyr Lys Ser Cys Lys Lys Tyr Gln Asp Glu Tyr		
	100	105	110
5	Gly Val Ser Ser Val Ile Pro Asn Phe Lys Ile Ser Gln Asp Ser Val		
	115	120	125
	Arg Ser Ser Asn Arg Ser Glu Thr Ser Ala Ser Asp Asn Thr Glu Thr		
10	130	135	140
	Tyr Gln Glu Asp Thr Ser Ser Ser Gly His Pro Thr Phe Lys Cys Pro		
	145	150	155
15	Leu Cys Gln Glu Ser Asn Phe Thr Arg Gln Arg Leu Leu Asp His Cys		
	165	170	175
	Asn Ser Asn His Leu Phe Gln Ile Val Pro Val Thr Cys Pro Ile Cys		
20	180	185	190
	Val Ser Leu Pro Trp Gly Asp Pro Ser Gln Ile Thr Arg Asn Phe Val		
	195	200	205
	Ser His Leu Asn Gln Arg His Gln Phe Asp Tyr Gly Glu Phe Val Asn		
25	210	215	220
	Leu Gln Leu Asp Glu Glu Thr Gln Tyr Gln Thr Ala Val Glu Glu Ser		
	225	230	235
30	Phe Gln Val Asn Met		
	245		

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

5

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence which encodes an *TI* polypeptide or a bioactive fragment thereof.
- 5 2. The nucleic acid molecule of claim 1, wherein the *TI* polypeptide or bioactive fragment thereof is a vertebrate *TI* polypeptide or a bioactive fragment thereof.
- 10 3. The nucleic acid molecule of claim 1, wherein the *TI* polypeptide comprises an amino acid sequence which is at least about 70% homologous to the amino acid sequence of SEQ ID NO:31, 32, 33, 34, 35, or 36 or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.
- 15 4. The nucleic acid molecule of claim 3, wherein the *TI* polypeptide comprises an amino acid sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO:31, 32, 33, 34, 35, or 36 or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.
- 20 5. The nucleic acid molecule of claim 4, wherein the *TI* polypeptide comprises the amino acid sequence of SEQ ID NO:31, 32, 33, 34, 35, or 36 or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.
- 25 6. The nucleic acid molecule of claim 1, comprising a nucleotide sequence which is at least about 70% homologous to the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, or 6 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.
- 30 7. The nucleic acid molecule of claim 6, comprising a nucleotide sequence which is at least about 80% homologous to the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, or 6 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.

- 97 -

8. The nucleic acid molecule of claim 1, which hybridizes to the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, or 6 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.

5

9. The nucleic acid molecule of claim 8, further comprising a label.

10. The nucleic acid molecule of claim 1, comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, or 6 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.

10

11. The nucleic acid molecule of claim 1, which is genomic DNA.

12. The nucleic acid molecule of claim 1, which is cDNA.

15

13. The nucleic acid molecule of claim 1, which is RNA.

14. An isolated nucleic acid molecule which is antisense to the nucleic acid molecule of claim 10.

20

15. An isolated nucleic acid molecule which is antisense to a coding region of the coding strand of the nucleic acid molecule of claim 10.

16. An isolated nucleic acid molecule which is antisense to a noncoding region of the coding strand of the nucleic acid molecule of claim 10.

25

17. A vector comprising the nucleic acid molecule of claim 1.

18. The vector of claim 17, which is an expression vector.

30

19. The vector of claim 18, which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:31, 32, 33, 34, 35, or 36 or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.

35

- 98 -

20. The vector of claim 18, which comprises the coding region of the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, or 6 or the coding region of the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.
- 5 21. A host cell containing the vector of claim 17.
22. A host cell containing the expression vector of claim 18.
- 10 23. A method for producing a *TI* polypeptide comprising culturing the host cell of claim 22 in an appropriate culture medium to produce a *TI* polypeptide.
24. The method of claim 23, further comprising isolating the *TI* polypeptide from the culture medium or host cell.
- 15 25. A nonhuman transgenic animal carrying the nucleic acid molecule of claim 1.
26. A nonhuman homologous recombinant animal which contains cells
20 having an altered form of the nucleic acid molecule of claim 1.
27. An isolated *TI* polypeptide or a bioactive fragment thereof encoded by the nucleotide sequence of the nucleic acid molecule of claim 1.
- 25 28. The polypeptide of claim 27, which comprises the amino acid sequence of SEQ ID NO:31, 32, 33, 34, 35, or 36 or the amino acid sequence encoded by the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98125, 98126, 98127, or 98128.
- 30 29. A composition comprising the polypeptide or bioactive fragment thereof of claim 27 and a pharmaceutically acceptable carrier.
30. A fusion polypeptide comprising the *TI* polypeptide of claim 27 and a second non-*TI* polypeptide.
- 35 31. An antibody which is specifically reactive with an epitope of the *TI* polypeptide of claim 27.

32. The antibody of claim 31, which is monoclonal.
33. Use of a nucleic acid encoding a *TI* polypeptide or a bioactive fragment thereof of claim 1 for the manufacture of a medicament for treating a weight disorder in a subject.
34. Use of a nucleic acid encoding a *TI* polypeptide or a bioactive fragment thereof of claim 1 for the manufacture of a medicament for treating diabetes in a subject.
35. Use of a *TI* polypeptide or a bioactive fragment thereof of claim 27 for the manufacture of a medicament for treating a weight disorder in a subject.
36. Use of a *TI* polypeptide or a bioactive fragment thereof of claim 27 for the manufacture of a medicament for treating diabetes in a subject.
37. Use of a *TI* modulator for the manufacture of a medicament for treating a disorder characterized by aberrant *TI* polypeptide bioactivity or *TI* nucleic acid expression in a subject.
38. The use of claim 37, wherein the *TI* modulator is a small molecule.
39. The use of claim 37, wherein the disorder is a weight disorder.
40. The use of claim 39, wherein the weight disorder is obesity.
41. The use of claim 39, wherein the weight disorder is cachexia.
42. The use of claim 39, wherein the weight disorder is anorexia nervosa.
43. The use of claim 37, wherein the disorder is diabetes.

- 100 -

44. A method for identifying a compound capable of treating a disorder characterized by aberrant *TI* polypeptide bioactivity or *TI* nucleic acid expression comprising assaying the ability of the compound to modulate the bioactivity of the *TI* polypeptide or the expression of *TI* nucleic acid thereby identifying a compound capable of treating a disorder characterized by aberrant *TI* polypeptide bioactivity or *TI* nucleic acid expression.

45. The method of claim 44, wherein the disorder is a weight disorder.

46. The method of claim 45, wherein the weight disorder is obesity.

47. The method of claim 44, wherein the disorder is diabetes.

48. A method for modulating a cell associated activity comprising contacting the cell with a *TI* modulator such that a cell associated activity is altered relative to a cell associated activity of the cell in the absence of the *TI* modulator.

49. The method of claim 48, wherein the *TI* modulator stimulates *TI* polypeptide bioactivity or *TI* nucleic acid expression.

50. The method of claim 49, wherein the *TI* modulator is an active *TI* polypeptide.

51. The method of claim 49, wherein the *TI* modulator is a nucleic acid encoding a *TI* polypeptide that has been introduced into the cell.

52. The method of claim 48, wherein the *TI* modulator inhibits *TI* polypeptide activity or *TI* nucleic acid expression.

53. The method of claim 52, wherein the *TI* modulator is an antisense *TI* nucleic acid molecule.

54. The method of claim 52, wherein the *TI* modulator is an antibody which is specifically reactive with an epitope of a *TI* polypeptide.

55. The method of claim 48, wherein the cell is present within a subject and the *TI* modulator is administered to the subject.

56. A method for determining if a subject is at risk for a disorder characterized by aberrant *TI* polypeptide bioactivity or *TI* nucleic acid expression comprising detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion, wherein the genetic lesion is characterized by an alteration affecting the integrity of a gene encoding a *TI* polypeptide or misexpression of the *TI* gene.

57. A method for identifying a compound which interacts with a *TI* polypeptide comprising contacting the *TI* polypeptide with the compound under conditions which allow binding of the compound to the *TI* polypeptide to form a complex; and detecting the formation of a complex of the *TI* polypeptide and the compound in which the ability of the compound to interact with the *TI* polypeptide is indicated by the presence of the compound in the complex.

58. A method for identifying a compound which modulates the interaction of an *TI* polypeptide with a target molecule comprising contacting, in the presence of the compound, the *TI* polypeptide and the target molecule under conditions which allow binding of the target molecule to the *TI* polypeptide to form a complex; and detecting the formation of a complex of the *TI* polypeptide and the target molecule in which the ability of the compound to modulate interaction between the *TI* polypeptide and the target molecule is indicated by an increase or a decrease in complex formation as compared to the amount of complex formed in the absence of the compound.

59. The method of claim 58, wherein the target molecule is a *tub* polypeptide or a portion thereof.

60. A method for detecting the presence of *TI* in a biological sample comprising contacting a biological sample with an agent capable of detecting *TI* polypeptide or mRNA such that the presence of *TI* is detected in the biological sample.

61. The method of claim 60, wherein the agent is a labeled or labelable nucleic acid probe capable of hybridizing to *TI* mRNA.

62. The method of claim 60, wherein the agent is a labeled or labelable antibody capable of specifically binding to a *TI* polypeptide.

- 102 -

63. A kit for detecting the presence of *TI* in a biological sample comprising a labeled or labelable agent capable of detecting a *TI* polypeptide or mRNA in a biological sample.

5 64. The kit of claim 63, wherein the agent is a nucleic acid probe capable of hybridizing to *TI* mRNA.

65. The kit of claim 63, wherein the agent is an antibody capable of specifically binding to a *TI* polypeptide.

10

FIG. 1A

N S A R A H S Q P W Q A A L V M E N E 19
 GG AAT TCG GCA CGA GCG CAC TCG CAG CCC TGG CAG GCG GCA CTG GTC ATG GAA AAC GAA 59

 L F C S G V L V H P Q W V L S A A H C F 39
 TTG TTC TCG GGC GTC CTG GTG CAT CCG CAG TGG GTG CTG TCA GCC GCA CAC TGT TTC 119

 Q K * V Q S S Y T I G L G L H S L E A D 59
 CAG AAG TGA GTG CAG AGC TCC TAC ACC ATC GGG CTG GGC CTG CAC AGT CTT GAG GCC GAC 179

 Q E P G S Q M V E A S L S V R H P E Y N 79
 CAA GAG CCA GGG AGC CAG ATG GTG GAG GCC AGC CTC TCC GTA CGG CAC CCA GAG TAC AAC 239

 R P L L A N D L M L I K L D E S V S E S 99
 AGA CCC TTG CTC GCT AAC GAC CTC ATG CTC ATC AAG TTG GAC GAA TCC GTG TCC GAG TCT 299

 D T I R S I S I A S Q C P T A G N S C L 119
 GAC ACC ATC CGG AGC ATC AGC ATT GCT TCG CAG TGC CCT ACC GCG GGG AAC TCT TGC CTC 359

 V S G W G L L A N G R M P T V L Q C V N 139
 GTT TCT GGC TGG GGT CTG CTG GCG AAC GGC AGA ATG CCT ACC GTG CTG CAG TGC GTG AAC 419

 V S V V S E E V C S K L Y D P L Y H P S 159
 GTG TCG GTG TCT TCT GAG GAG GTC TGC AGT AAG CTC TAT GAC CCG CTG TAC CAC CCC AGC 479

 M F C A G G G G G G G C A A G A G C A A G G C T C C T G C A A G G T G A C T C T G G G G G 539
 ATG TTC TGC GCC GGC GGA GGC CAA GAC GAC TCC TGC AAC GGT GAC TCT GGG GGG 539

 P L I C N G Y L Q G L V S F G K A P C G 199
 CCC CTG ATC TGC AAC GGC TAC TTG CAG GGC CTT GTG TCT TTC GGA AAA GCC CCG TGT GGC 599

FIG. 1B

Q V G V P G V Y T N L C K F T E W I E K 219
 CAA GTT GGC GTG CCA GGT GTC TAC ACC AAC CTC TGC AAA TTC ACT GAG TGG ATA GAG AAA 659
 T V P G Q L T L G T G N P *
 ACC GTA CCA GGC CAG TTA ACT CTG GGG ACT GGG AAC CCA TGA 233
 701
 AATTGACCCCAATATCTCTGCGGAGGAATTTCAGGAATATCTGTCCAGCCCCCTCCTCCCTCAGGCYCAGGAGTC 780
 CAGGCCCCCAGCCCCCTCCTCCCTCAAACCAAGGGTACAGATCCCCAGCCCCCTCCTCCCTCAGACCCAGGAGTCCAGACC 859
 CCCCAGCCCCCTCCTCCCTCAGACCCAGGAGTCCAGCCCCCTCCTCCCTCAGACCCAGGAGTCCAGACCCCCAGCCCCCTC 938
 CTCCCTCAGACCCAGGGTCCAGCCTCTCCTCCCTCAGACCCAGGAGTCCAGACCCCCAGCCCCCTCCTCCCTCAGACC 1017
 CAGGAGTCCAGCCCCCTCCTCCCTCAGACCCAGGAGTCCAGATCCCCCAGCCCCCTCCTCCCTCAGACCCAGGGTCCAGG 1096
 CCCCCAACCCCTCCTCCCTCAGACTCAGAGGTCCAAAGCCCCCAACCCCTCCTTCCCCCAGACCCAGAGTCCAGGTACCA 1175
 GCCCCCTCCTCCCTCAGACCCAGCGGTCCAATGCCACCTATCTCCTCTGTACANATTGCCNCCTTGTGGCACGTTGAC 1254
 CCAACCTTACCAGTTGGTTTTTCATTTTTTGTCCCTTTCCCTTAGATCCAGAAATAAAGTTTAAGRGRAGSGCCAAAAA 1333
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACVCGAGAANT 1387

FIG. 2A

CACACCAGTAGACCCACACAGCCACCGGTTGGCCCTGCCCGCCCGCCAGCTCGCTACAGACGACTCAGGGCGGAGG 79

GAAGTAGGTCGTTGGTCGGGAAACGAGGCTCAGGGGCCAGGCCCGCGGGAGCCGTTGCC 153

A A G D A D D E P R S G H S S S E G E C 23
GCC GCC GGG GAC GAC GAC GAG CCG CGC TCA GGC CAC TCG AGC TCG GAG GGC GAG TGC 213

A V A P E P L T D A E G L F S F A D F G 43
CGG GTG GCG CCG GAG CCG CTG ACT GAC GCT GAG GGC CTC TTC TCC TTC GCT GAC TTC GGG 273

S A L G G G A G L S G R A S G G A Q S 63
TCT GCG CTG GGC GGC GGC GGC CTC TCG GGC CGG TCC GGC GGC GGC CAG TCG 333

P L R Y L H V L W Q Q D A E P R D E L R 83
CCG CTG CGC TAC TTG CAC GTC CTG TGG CAG CAG GAT GCG GAG CCG CGC GAC GAG CTG CGC 393

C K I P A G R L R R A A R P H R R L G P 103
TGC AAG ATA CCC GCT GGC CCG CTG AGG CGC GCT GCC AGG CCC CAC CGG CTC GGC CCC 453

T G K E V H A L K R L R D S A N A N D V 123
ACG GGC AAG GAG GTG CAC GCT CTG AAG AGA CTG AGG GAC TCG GCC AAT GCC AAT GAT GTG 513

E T V Q Q L L E D G A D P C A A D D K G 143
GAA ACA GTG CAG CTG CTG GAA GAT GGC GCG GAT CCC TGT GCA GCT GAT GAC AAG GGC 573

R T A L H F A S C N G N D Q I V Q L L L 163
CGC ACA GCT CTA CAC TTT GCC TCA TGC AAT GGC AAT GAC CAG ATT GTG CAG CTG CTC CTG 633

FIG. 2B

D H G A D P N Q R D G L G N T P L H L A 183
 GAC CAT GGT GCT GAT CCT AAC CAG CGA GAT GGG CTG GGG AAC ACG CCA CTG CAC CTG GCG 693
 A C T N H V P V I T T L L R G G A R V D 203
 GCC TGC ACC AAC CAC GTT CCT GTC ATC ACC ACA CTG CTA CGA GGA GGG GCC CGT GTA GAT 753
 A L D R A G R T P L H L A K S K L N I L 223
 GCC CTG GAC CGA GGT GGT CGC ACA CCC CTG CAC CTG GCC AAG TCA AAG CTG AAT ATC CTG 813
 Q E G H A Q C L E A V R L E V K Q I I H 243
 CAG GAG GGC CAT GCC CAG TGC CTA GAG GCT GTG CGT CTG GAG GTG AAG CAG ATC ATC CAT 873
 M L R E Y L E R L G Q H E Q R E R L D D 263
 ATG CTG AGG GAG TAT CTG GAG CGC CTA GGG CAA CAT GAG CAG CGA GAA CGC CTG GAT GAC 933
 L C T R L Q M T S T K E Q V D E V T D L 283
 CTC TGC ACC CGC CTG CAG ATG ACC AGT ACC AAA GAG CAG GTG GAT GAA GTG ACT GAC CTC 993
 L A S F T S L S L Q M Q S M E K R * 301
 CTG GCC AGC TTC ACC CTC AGT CTG CAG ATG CAG AGC ATG GAG AAG AGG TAG 1047
 CAAGAGAGGCTCCCTGCTTCCCTGCCACTGCCACCCCTGCCCACTGCTGTCTCAGTACCAAGAAAGCCCAACATC 1126
 TGGGACTTGGAGCTGCACCTGTCTGGTGAGGACCTTGCCCTCACCCGCACATGCCGTGGGCAGAGATGCTCTCTCTCC 1205
 ACGGCCTCAGAGCCACTCCCGAGCCAGATTTCAGCATCTCTGTGGACAGGGACCACAGCTCCAGCTTCTTCCAGTTC 1284
 TCGCAGCACCAGACCGCTCTGCAGCTGCACTTCAGCTCCGAGACCTGCGCTATCTCAGCAGACCTCACTTGCCCCA 1363

FIG. 2C

TGGCCTTCAATGGCGCGCTCCAGGCCTCAGACCCCTTCTCTGTGTTCGGTCCCTGGCCATGGGCTTGTTCAGTCAGCAGGT 1442
GTGGGCTTAGGGCGGGCACCCCTGTGGCCAGGGGTACTGGTGAGGCCCTCAGTTGGTCCTGTGCCTCTCACCAGCACCTTA 1521
GACAGACACGTACCCAGACTTTCAAGGAGATACTGCAGTGAGTTCTCTGGTTGGAAGGGAGGGTTGGTGAGTCCCAG 1600
ACCTTAAAAATACAGGTTAAGAGGGACCCCAAGCAAAAAATTCCAACCCCTTTCCCTCCCAGTCATTGAAACACCCAAA 1679
ACTATTATACCGGAGGGTGTAATAGTTTGTGTGCCCCAGTTGTGGTAGGCCAGTAGTGGCCTCCCAAGATGCCCATGTCC 1758
TAATCCCAGGAACCTGTCAAAATTACCTTGTATGGCCAAAGGGGCTTTGCAGATGTAATGAAGTTAAGGATCTTTTCGCC 1837
AGGAAGATTATCCCAGCTTGTTCAGGAGGGCTTGATGTCTCACCCGGGTCTGTATACAGAGAGCAGGTGACGGGAG 1916
AGGAGGTTGGAGGTGTAGCGATGGAGCAGGAACCTGGAGTTGAGGAGGGCAGCTCAAGCCACAGAGTCCAGGCCACCTC 1995
AGAGCCAGGAATGCATCCTCCCACAGAGCCCTGGAAAGGCCCCAGCCCTGCTCCCACCTGGACTGGCTCAGTGAGGCTA 2074
ATTTTATAATTCTGGCTGATTTTAGAAGCTCTAAGGAATAAATTGTGTGTTTAAAGTCAAAAAAATAAAAAA 2153
ACTCGAG 2160

FIG. 3A

HAATTGGCAGAGAAAATGCTAGCTATTATGTAATCGAGCAGCCACCTTG	M	M	L	G	R	F	6
							71
R E A L G D A Q Q S V R L D D S F V R G							26
CGG GAA GCT CTT GGA GAT GCA CAA CAG TCA GTG AGG TTG GAT GAC AGT TTT GTC CGG GGA							131
H L R E G K C H L S L G N A M A A C R S							46
CAT CTA CGA GAG GGC AAG TGC CAC CTC TCT CTG GGG AAT GCC ATG GCA GCA TGT CGC AGC							191
F Q R A L E L D H K N A Q A Q Q E F K N							66
TTC CAG AGA GCC CTA GAA CTG GAT CAT AAA AAT GCT CAG GCA CAA GAG TTC AAG AAT							251
A N A V M E Y E K I A E T D F E K R D F							86
GCT AAT GCA GTC ATG GAA TAT GAG AAA ATA GCA GAA ACA GAT TTT GAG AAG CGA GAT TTT							311
R K V V F C M D R A L E F A P A C H R F							106
CGG AAG GTT GTT TTC TGC ATG GAC CGT GCC CTA GAA TTT GCC CCT GCC TGC CAT CGC TTC							371
K I L K A E C L A M L G R Y P E A Q S V							126
AAA ATC CTC AAG GCA GAA TGT TTA GCA ATG CTG GGT CGT TAT CCA GAA GCA CAG TCT GTG							431
A S D I L R M D S T N A D A L Y V R G L							146
GCT AGT GAC ATT CTA CGA ATG GAT TCC ACC AAT GCA GAT GCT CTG TAT GTA CGA GGT CTT							491
C L Y Y E D C I E K A V Q F F V Q A L R							166
TGC CTT TAT TAC GAA GAT TGT ATT GAG AAG GCA GTT CAG TTT TTC GTA CAG GCT CTC AGG							551

FIG.3B

```

M  A  P  D  H  E  K  A  C  I  A  C  R  N  A  K  A  L  K  A  186
ATG  GCT  CCT  GAC  CAC  GAG  AAG  GCC  TGC  ATT  GCC  TGC  AGA  AAT  GCC  AAA  GCA  CTC  AAA  GCA  611

K  K  E  D  G  N  K  A  F  K  E  G  N  Y  K  L  A  Y  E  L  206
AAG  AAA  GAA  GAT  GGG  AAT  AAA  GCA  TTT  AAG  GAA  GGA  AAT  TAC  AAA  CTA  GCA  TAT  GAA  CTG  671

Y  T  E  A  L  G  I  D  P  N  N  I  K  T  N  A  K  L  Y  C  226
TAC  ACA  GAA  GCC  CTG  GGG  ATA  GAC  CCC  AAC  AAT  ATA  AAA  ACA  AAT  GCT  AAA  CTC  TAC  TGT  731

N  R  G  T  V  N  S  K  L  R  K  L  D  D  A  I  E  D  C  T  246
AAT  CGG  GGT  ACG  GTT  AAT  TCC  AAG  CTT  AGG  AAA  CTA  GAT  GAT  GCA  ATA  GAA  GAC  TGC  ACA  791

N  A  V  K  L  D  D  T  Y  I  K  A  Y  L  R  R  A  Q  C  Y  266
AAT  GCA  GTG  AAG  CTT  GAT  GAC  ACT  TAC  ATA  AAA  GCC  TAC  TTG  AGA  AGA  GCT  CAG  TGT  TAC  851

M  D  T  E  Q  Y  E  E  A  V  R  D  Y  E  K  V  Y  Q  T  E  286
ATG  GAC  ACA  GAA  CAG  TAT  GAA  GAA  GCA  GTA  CGA  GAC  TAT  GAA  AAA  GTA  TAC  CAG  ACA  GAG  911

K  T  K  E  H  K  Q  L  L  K  N  A  Q  L  K  F  R  N  Y  K  306
AAA  ACA  AAA  GAA  CAC  AAA  CAG  CTC  CTA  AAA  AAT  GCG  CAA  CTT  AAG  TTT  AGA  AAT  TAC  AAG  971

F  Q  *
TTT  CAG  TAA  309
980

TAGCTGAACCTGTTCAAAATGTTAATAAGGTTTCGTTGCATGGTAGCATAAAAA
1049

```

FIG. 4A

M C P N N A S Y Y G N R A A T 15
 TCGAGATTACCCATAGAT ATG TGT CCT AAC AAT GCC AGC TAT TAC GGT AAT CGA GCG GCC ACA 64
 L M M L G R F R E A L G D A Q Q S V R L 35
 CTG ATG ATG CTT GGA CGG TTC CGG GAA GCT CTT GGA GAT GCG CAG CAG TCT GTG AGG TTG 124
 D D S F V R G H L R E G K C H L S L G N 55
 GAT GAC AGT TTT GTC CGG GGA CAC CTC CGA GAA GGC AAG TGC CAC CTC TCA CTT GGG AAT 184
 A M A A C R S F Q R A L E L D H K N A Q 75
 GCA ATG GCG GCA TGT CGT AGT TTC CAA AGA GCC CTA GAA CTG GAT CAT AAA AAT GCC CAG 244
 A Q Q E F K N A N A V M E Y E K I A E V 95
 GCA CAG CAG GAG TTC AAG AAC GCC AAT GCC GTC ATG GAG TAT GAG AAA ATA GCA GAA GTG 304
 D F E K R D F R K V V F C M D R A L E F 115
 GAT TTT GAA AAG CGA GAT TTC CGG AAG GTT GTT TTC TGC ATG GAC CGT GCC CTA GAA TTT 364
 A P A C H R F K I L K A E C L A M L G R 135
 GCC CCT GCC TGC CAT CGA TTC AAA ATT CTC AAA GCA GAA TGT TTA GCA ATG CTT GGT CGA 424
 Y P E A Q F V A S D I L R M D S T N A D 155
 TAC CCA GAA GCA CAG TTT GTG GCC AGT GAC ATT TTA CGA ATG GAT TCC ACC AAT GCT GAT 484
 A L Y V R G L C L Y Y E D C I E K A V Q 175
 GCT CTG TAT GTC CGG GGT CTT TGC CTT TAT TAC GAA GAT TGT ATT GAG AAG GCA GTG CAG 544
 F F V Q A L R M A P D H E K A C V A C R 195
 TTT TTT GTA CAG GCT CTC AGG ATG GCT CCT GCT GAC CAC GAG AAG GCT TGT GTC GCT TGT AGA 604

FIG. 4B

N A K A L K A K K E D G N K A F K E G N 215
 AAT GCC AAA GCC CTT AAA GCC AAG AAG GAA GAT GGG AAT AAA GCC TTT AAG GAA GGA AAT 664
 Y K L A Y E L Y T E A L G I D P N N I K 235
 TAC AAG CTA GCA TAT GAA CTG TAC ACA GAA GCC TTG GGG ATA GAT CCC AAC AAC ATA AAA 724
 T N A K L Y C N R G T V N S K L R Q L E 255
 ACA AAT GCT AAA CTC TAC TGT AAT CGG GGT ACG GTT AAT TCC AAG CTT AGG CAA CTG GAA 784
 D A I E D C T N A V K L D D T Y I K A Y 275
 GAT GCC ATA GAA GAC TGT ACA AAT GCG GTG AAG CTC GAT GAC ACT TAC ATC AAA GCC TAC 844
 L R R A Q C Y M D T E Q F E A V R D Y 295
 CTG AGA AGA GCT CAG TGT TAC ATG GAC ACA GAG CAG TTT GAA GAA GCC GTG CGG GAC TAT 904
 E K V Y Q T E K T K E H K Q L L K N A Q 315
 GAA AAA GTG TAT CAG ACG GAG AAA ACA AAA GAA CAC AAA CAG CTC CTT AAG AAT GCA CAG 964
 L E L K K S K R K D Y Y K I L G V D K N 335
 CTG GAA CTG AAG AAG AGC AAG AGG AAA GAT TAC TAC AAG ATC CTG GGA GTG GAC AAG AAT 1024
 A S E D E I K K A Y R K R A L M H H P D 355
 GCC TCT GAG GAC GAG ATC AAG AAA GCT TAC CGG AAA CGG GCC TTG ATG CAC CAT CCA GAT 1084
 R H S G A S A E V Q K E E E K K F K E V 375
 CGG CAC AGT GGG GCC AGT GCC GAA GTT CAG AAG GAG GAG AAG AAG TTT AAG GAA GTG 1144
 G E A F T I L S D P K K K T R Y D S G Q 395

FIG.4C

```

GGA GAG GCC TTT ACC ATC CTC TCT GAT CCC AAG AAA AAG ACT CGT TAT GAC AGT GGA CAG 1204
D L D E E G M N M G D F D A N N I F K A 415
GAC TTG GAT GAG GAG GGC ATG AAT ATG GGC GAT TTT GAT GCA AAC AAC ATC TTC AAG GCA 1264
F F G G P G G F S F E A S G P G N F Y F 435
TTC TTC GGT CCT GGC GGC TTC ACC TTT GAA GCA TCT GGC CCA GGG AAT TTC TAC TTT 1324
Q F G .
CAG TTT GGC TAA 439
TGAAGGCCAACTACTTAAACCCAGAAATGCAGACTTGCTTGGTTTAACCATGAGTGTGGACAGTTCACCTTCCTCCAT 1336
CATGTCCCTGTGTACTTATAGCACTNTCTGTTTCTCAGTCGGGTCGCCCTGTCTGTATGAGCGGTGAAGAAAGGGG 1415
CCAGTGCTGAGGACTAGGAGGGATGGAAGCCNCGGTAKACAGGGAAGCAGGCAGCTTGTGCAATTTTGTGTATTGT 1494
TTAAGCTTTTAAAGAAAGAAACAACTACTGTAAATTTTAAAGAAAGAAAGRATTAAAAAAGAAAGAAAGAAAGAA 1573
AAAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 1652
AAAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 1700

```

FIG. 5A

```

ACGAGCGGTACGGCCGGTAGGCTGTAGGCAGCGCAATGCCAAGACAGAGCTGCTGGCGCGCGGCGAATCTCCCT 79
GCACCATGAGCCTCGGCTCCGGCCCCCGTTAGGGCCGATAGCACACCGACGCCGCCCTCCATTGCCCCCGGGCCCTC 158
GGCTGCGAAGATAGCGGCGCGGACAGGAACCTCGAGGAAAGCGCTGGGCCGGTCTCTACGAACACGTGAAGGAAA 237
GCAGCTCCGTCCACAACGCCGCTTCGGGGCTCCTAGGGAGTCGGGCCCGGCCGCCACCGTCACCTCCGGCCGCTGCC 316
GCTGTGCCCATCGCCTTGTTTCCCCCATCCCCCGCC      M A E D L S A A T S Y 11
ATG GCC GAG GAC CTC TCT GCG GCC ACG TCC TAC 384
T E D D F Y C P V C Q E V L K T P V R T 31
ACC GAA GAT TTC TAC TGC CCC GTC TGT CAG GAG GTG CTC AAA ACG CCC GTG CGG ACC 444
T A C Q H V F C R K C F L T A M R E S G 51
ACG GCC TGT CAG CAC GTT TTC TGT AGA AAA TGT TTC CTG ACT GCA ATG AGG GAA AGC GGA 504
A H C P L C R G N V T R R E R A C P E R 71
GCA CAT TGT CCC CTA TGT CGT GGA AAT GTG ACT AGA AGA GAG AGA GCA TGT CCT GAA CGG 564
A L D L E N I M R K F S G S C R C A K 91
GCC TTA GAC CTT GAA AAT ATA ATG AGG AAG TTT TCT GGT AGC TGC AGA TGC TGT GCA AAA 624

```

FIG. 5B

Q I K F Y R M R H H Y K S C K K Y Q D E 111
 CAG ATT AAA TTC TAT CGC ATG AGA CAT CAT TAC AAA TCT TGT AAG AAG TAT CAG GAT GAA 684

 Y G V S S I I P N F Q I S Q D S V G N S 131
 TAT GGT GTT TCT TCT ATC ATT CCA AAC TTT CAG ATC TCT CAA GAT TCA GTA GGG AAC AGC 744

 N R S E T S T S D N T E T Y Q E N T S S 151
 AAT AGG AGT GAA ACA TCC ACA TCT GAT AAC ACA GAA ACT TAC CAA GAG AAT ACA AGT TCT 804

 S G H P T F K C P L C Q E S N F T R Q R 171
 TCT GGT CAT CCT ACT TTT AAG TGT CCC CTG TGT CAA GAA TCA AAT TTT ACC AGA CAG CGT 864

 L L D H C N S N H L F Q I V P V T C P I 191
 TTA CTG GAT CAC TGT AAC AGT AAT CAC CTA TTT CAG ATA GTT CCT GTG ACA TGT CCT ATT 924

 C V S L P W G D P S Q I T R N F V S H L 211
 TGT GTG TCT CTT CCT TGG GGA GAT CCT AGC CAG ATT ACC AGA AAT TTC GTT AGT CAT CTA 984

 N Q R H Q F D Y G E F V N L Q L D E E T 231
 AAT CAG AGA CAT CAA TTT GAT TAT GGA GAA TTT GTG AAT CTT CAG CTA GAT GAA GAA ACC 1044

 Q Y Q T A V E E F F Q V N I * 246
 CAA TAC CAA ACT GCT GTT GAA GAA TTT TTT CAA GTA AAC ATT TGA 1089

 AGGCTGTAGACATTTTTCATTTTGTACTGCAAGTCCCATCTTTAAGGGGAAATACATGAAGTCACCGTTACAGT 1168

 AACTTGATGTATATTAATAAAGTAATTCAGTCMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1247

 A 1248

FIG. 6A

```

AGTTCACCTACCACCACCTCGGCTCCTGCGCGCGCGCTCGCCTCTCCGCCACCCCTCGCC      M   S   E       3
GAA CTT TCG GCG GCC ACG TCC TAC ACG GAA GAT GAT TTC TAC TGC CCT GTC TGT CAG GAG      74
E   L   S   A   A   T   S   Y   T   E   D   D   F   Y   C   P   V   C   Q   E       23
V   L   K   T   P   V   R   T   A   A   C   Q   H   V   F   C   R   K   C   F       43
GTG CTC AAG ACG CCG GTG CCG ACC GCG GCC TGT CAG CAC GTT TTC TGT AGA AAA TGT TTC      134
L   T   A   M   R   E   S   G   I   H   C   P   L   C   R   G   S   V   T   R       63
CTG ACT GCA ATG AGA GAA AGT GGA ATA CAT TGT CCC CTA TGT CGT GGA AGT GTG ACT AGA      254
R   E   R   A   C   P   E   R   A   L   D   L   E   N   I   M   R   R   F   S       83
AGA GAA AGA GCA TGT CCG GAA CGG GCC TTA GAT CTT GAA AAT ATC ATG AGG AGG TTT TCT      314
G   S   C   R   C   C   S   K   I   K   F   Y   R   M   R   H   H   Y   K       103
GGT AGC TGC AGA TGC TGT TCA AAA AAG ATT AAA TTC TAT CGC ATG AGA CAT CAT TAC AAA      374
S   C   K   K   Y   Q   D   E   Y   G   V   S   S   V   I   P   N   F   K   I       123
TCT TGT AAG AAG TAT CAG GAT GAA TAT GGT GTT TCT TCT GTC ATT CCA AAC TTT AAG ATT      434
S   Q   D   S   V   R   S   S   N   R   S   E   T   S   A   S   D   N   T   E       143
TCT CAA GAT TCA GTA AGG AGC AGT AAT AGG AGT GAA ACA TCT GCA TCT GAT AAC ACA GAA      494
T   Y   Q   E   D   T   S   S   S   G   H   P   T   F   K   C   P   L   C   Q       163
ACT TAT CAA GAG GAT ACA AGT TCT TCT GGG CAT CCT ACC TTT AAG TGT CCC TTA TGT CAA      554
E   S   N   F   T   R   Q   R   L   L   D   H   C   N   S   N   H   L   F   Q       183
GAG TCA AAT TTC ACC AGA CAA CGT TTA TTG GAT CAC TGT AAT AGT AAC CAC CTA TTT CAG      614

```

FIG. 6B

I	V	P	V	T	C	P	I	C	V	S	L	P	W	G	D	P	S	Q	I	203
ATA	GTT	CCT	GTG	ACA	TGT	CCT	ATT	TGT	GTG	TCT	CCT	TGG	GGA	GAT	CCT	AGC	CAG	ATT	674	
T	R	N	F	V	S	H	L	N	Q	R	H	Q	F	D	Y	G	E	F	V	223
ACT	AGA	AAT	TTC	GTT	AGT	CAT	CTA	AAT	CAA	AGA	CAT	CAG	TTT	GAT	TAT	GGA	GAA	TTT	GTG	734
N	L	Q	L	D	E	E	T	Q	Y	Q	T	A	V	E	E	S	F	Q	V	243
AAT	CTT	CAG	CTA	GAT	GAG	GAA	ACC	CAA	TAT	CAA	ACT	GCT	GTG	GAA	GAG	TCT	TTT	CAA	GTA	794
N	M	*																		
AAC	ATG	TGA																		246
																				803
CAT	GTA	TAG	A	C	A	T	C	T	C	T	G	C	A	A	C	C	T	A	A	882
ATTT	GT	CT	GC	AT	TA	ATA	AAAA	ATA	AA	TTC	AG	CT	ACT	GT	ATT	AGG	TTT	TA	ATT	961
TAAT	ACC	AT	TCT	AG	AC	AG	TT	ACT	TT	TA	AC	AG	CA	TG	GA	AA	GG	GT	GT	1040
TTG	T	CT	TTT	T	CT	CT	TT	CA	T	CA	AT	T	T	CA	AT	T	T	CA	AT	1119
TAG	T	AC	AG	ATA	AC	AG	CA	AT	T	CT	GA	CG	AT	GT	GA	T	CT	TA	AA	1198
GAA	T	G	AA	AA	CT	T	G	AA	GT	GG	ATA	AT	CC	AA	AG	GA	TT	TT	TT	1277
CAAT	A	AG	AA	AG	TT	GT	AT	TT	AT	GT	AT	TT	TT	TT	TT	TT	TT	TT	TT	1356
GCAT	AT	GT	AC	AA	AT	GT	TT	CT	TT	TT	GT	CT	AT	TA	GA	AA	CA	AT	CA	1435

FIG. 6C

CAATCTAGGTTGAATAAATTTGTAGCCTAAATGTTATATACACAGTTCTTTGTAGTCAGTATTCTCACTGGGTGATG 1514
AAACTTTTCAGCCAGTGAATGATACATTCAATTAGTTTTTTTAAATAATCCAAAGTTGCAGATGTATGTGGATATGTACAT 1593
AGACTTTTGCATGTATATATACACATATATATCTTTTGGCTAGAGTTTGTACAGTTATGTATAGAAITTTCTATTAAAAAG 1672
TTTTTAATAATGGACAAGCAATATAGGATTGAAGTATTTATCTCCTTTGTTTAAAAATTTTGTATGTTACCAAGTTTTTAA 1751
AACAGTAAGCCAAATACTATGTGGTACAGTTGGCTGTTATTATACACCTGAAAAAATGTTAAATGGTGCTCACITTTGTTACGT 1830
TTGAAAATGATGCATAAAGTACGTTGGTGAGAGATTTTACCAGCTACTGTTTTCACATACATTTTAGTCAAAACAAAGTT 1909
TGTTCTTAATCTTTGGTATAAAGTGTGTAGAGAAAGGCCAAGTCACAAAGTAAAGGGTGAAGGGGGAATTTCTGACATTC 1988
CACACTAACATAACACTGTTATGCTTTCTTTTAAATAAATACTAACCGCAAAAGAAAAATCTCTGAAGTAGTTTGGCTGCTAAT 2067
ATATACATATATTGTAAAAAAGGTATATTTTGATTTTCTGGTAAATCTCG 2121

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/15627

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet. US CL : 435/4, 6, 320.1; 514/2, 44; 530/350; 536/23.5; 800/2 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/4, 6, 320.1; 514/2, 44; 530/350; 536/23.5; 800/2 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS; DIALOG DATABASES: MEDLINE, BIOSIS PREVIEWS, CA SEARCH, WORLD PATENT INDEX														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A	KLEYN ET AL. IDENTIFICATION AND CHARACTERIZATION OF THE MOUSE OBESITY GENE TUBBY: A MEMBER OF A NOVEL GENE FAMILY. CELL. 19 APRIL 1996, VOL. 85, PAGES 281-290. SEE ENTIRE ARTICLE.	1-65												
A	NOBEN-TRAUTH ET AL. A CANDIDATE GENE FOR THE MOUSE MUTATION TUBBY. NATURE. 11 APRIL 1996, VOL. 380, PAGES 534-538, SEE ENTIRE ARTICLE.	1-65												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*E* earlier document published on or after the international filing date</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*A* document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 30 SEPTEMBER 1997		Date of mailing of the international search report 17 OCT 1997												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer JOHNNY F. RAILEY II, PH.D. Telephone No. (703) 308-0196												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/15627

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C12N 1/21, 5/10, 15/12, 15/63; C12Q 1/00, 1/68; C07K 14/435, 14/47, 16/00; A61K 38/17, 48/00

THIS PAGE BLANK (USPTO)